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Summary 
 
Despite the interventional and pharmacological advances in treatment in ST elevation 
myocardial infarction in recent decades it continues to be a significant cause of morbidity 
and mortality in Scotland and around the world. The diagnosis and treatment of ST 
elevation myocardial infarction has been the subject of intense investigation and the focus 
of numerous randomised clinical trials over the past few decades. In an attempt to 
minimise adverse sequelae it is imperative that in patients with ST elevation myocardial 
infarction (STEMI) the immediate goal of therapy is to rapidly achieve patency of the 
epicardial infarct related artery (IRA) and consequently reperfusion of the affected 
myocardium.   
 
Thrombolysis achieves normal flow (TIMI grade 3) in the IRA in around 50% of patients 
compared to around 90% with primary PCI (pPCI). The successful restoration of 
epicardial coronary artery patency with TIMI grade 3 flow, however, does not necessarily 
translate into adequate tissue level perfusion. Inadequate tissue level perfusion in ST – 
elevation myocardial infarction in the presence of a patent epicardial artery is 
characterised by myocardial microvascular dysfunction. Evidence of microvascular 
obstruction (MVO) regardless of how it is assessed is associated with adverse clinical 
outcomes in this patient group. A series of consistent data has clearly shown that MVO 
has a strong negative impact on outcome.  
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The index of microvascular resistance is a marker of myocardial microvascular resistance 
which be validated in vitro and in vivo and has been shown to be independent of 
variations in haemodynamic state. By incorporating collateral flow IMR has been 
validated in the presence of an epicardial stenosis and therefore can be calculated prior 
and and following stenting. Calculation of IMR at the time of emergency PCI for STEMI 
could potentially provide a marker of microvascular and myocardial injury in the very 
early post infarct period when further potential interventions would be most beneficial to 
the patient. 
 
Cardiac MRI imaging is the current gold standard for assessment of left ventricular 
ejection fraction and infarct volumes. Using Gadolinium contrast agent CMR can 
characterise microvascular obstruction and calculate infarct volumes. This useful 
information is normally available at the time of emergency PCI.  
 
The principle aim of this thesis is to compare pressure wire derived markers of 
microvascular obstruction, principally IMR,  calculated at the time of emergency PCI for 
STEMI with evidence of microvascular and myocardial damage as assessed by ceCMR 
scanning at 2 days and 3 months post PCI. In particular I will look at whether IMR at the 
time of PCI for STEMI can be used as a predictor of myocardial damage on ceCMR. 
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I will also compare IMR the “traditional” indices currently used to assess microvascular 
perfusion and assess the impact that stenting itself has on the coronary microvasculature 
by comparing IMR prior and following PCI. 
 
CMR imaging is not commonly available in the early post infarct period. I will therefore 
also look at the safely, feasibility and clinical utility of ceCMR imaging in the 24 to 48 
hour period following PCI for STEMI. 
 
Patients who were undergoing emergency PCI for STEMI were recruited They 
underwent pressure wire assessment at the time of emergency PCI and had ceCMR scans 
at 2 days and 3 months following their myocardial infarction. A total of 77 patients were 
consented for the study between 04/01/2007 and 28/02/2008 and 69 patients had 
successful coronary physiological studies at the time of PCI. Two hundred patients in 
total underwent early ceCMR post STEMI over a longer time period. The funding for my 
study from the CSO Scotland allowed the evolved project to run for a further 18 months 
(and indeed still continues following further funding from the BHF) after I went back into 
clinical work therefore I was able to use extra patients whom underwent early CMR for 
that aspect of the thesis.  
 
In summary the findings of this thesis are: 
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 IMR is significantly higher in patients in whom there is evidence of MVO in 
ceCMR scanning at 48h but does not predict the amount of MVO present. 
 
  IMR is a strong independent predictor of LVEF, infarct volumes and LVESV on 
ceCMR imaging at 48h and 3 months. 
 
 IMR was an independent predictor of transmurality score on ceCMR 
 
 IMR does not alter significantly following stenting in emergency PCI indicating 
that stenting itself does not significantly alter the coronary microvasculature. 
 
 IMR correlates closely with the “traditional” markers of myocardial damage and 
myocardial infarction in ST – elevation myocardial infarction. 
 
 Anatomical site if myocardial infarction and therapeutic interventions at the time 
of emergency PCI do not significantly influence coronary pressure wire derived 
markers of microvascular obstruction taken immediately post – procedure. 
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 There was a nearly exact relationship between the presence of “early” and “late” 
MVO assessed by ceCMR imaging 48h post STEMI 
 
 CMR in the early post infarct period is safe, feasible and provides useful 
diagnostic information 
 
This was the first study to directly compare IMR with ceCMR assessment of MVO and 
myocardial damage. I feel that my results complement the other work done in this field 
both in stable patients and in the STEMI population. I have shown that an elevated IMR 
is linked to microvascular and myocardial damage as revealed by ceCMR in the early 
post infarction period and at longer term follow up. Accordingly, I suggest measurement 
of IMR represents a new approach to risk assessment at the very earliest stage of acute 
MI management, and potentially, therefore enables triage of higher risk patients to more 
intensive therapy. 
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Chapter 1: Introduction 
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1.1Background 
 
Improvements in the primary prevention of coronary artery disease, predominantly 
through more rigorous diagnosis and aggressive control of classical cardiac risk factors, 
have led to a decline in premature coronary heart disease in the Western world
1
. Despite 
this acute myocardial infarction (AMI) remains a significant problem at a local and 
national level as well as on a global scale.  
 
In one Scottish study looking at patients presenting to their general practitioner with 
angina as a first manifestation of potential ischaemic heart disease the investigators found 
that of these 1785 patients, within the five years’ follow-up, 152 (8.5%) patients 
underwent coronary artery bypass grafting, 108 (6.1%) underwent
 
percutaneous coronary 
angioplasty, 116 (6.5%) had
 
an acute myocardial infarction, 84 (4.8%) died from 
ischaemic
 
heart disease, and 175 (9.8%) died from any cause.
2
 In Scotland, although the 
age-standardised mortality rates following AMI have fallen between 1994 and 2004 
(from 223 to 140 per 100 000), cardiovascular morbidity and mortality remain high.
3
 
 
In the United Kingdom, based on incidence rates of AMI of 600 per 100 000 in men and 
200 per 100 000 in women under the age of 70 years, an estimated 123 000 persons aged 
75 or less will suffer an AMI per year. 
3
These data are thought to be a under-
representation given the relative young age of the patients involved.
4
 The combined 
expense of direct treatment, loss of earnings by the workforce, and informal caring for 
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these patients is estimated at over £7.9 billion per annum to the United Kingdom 
economy. 
1
 
 
Coronary heart disease (CHD)
 
caused about 1 of every 5 deaths
 
in the United States in 
2005.
 
CHD mortality in 2005 was 445
 
687. Current estimates in America state that each 
year, an estimated 785
 
000 people will suffer a first AMI, and about 470
 
000 will have a 
recurrent attack.
 
It is estimated that an additional
 
195 000 silent first myocardial
 
infarctions occur each year. In addition, in 2005 1
 
in 8 death certificates (292 214 deaths) 
in the United
 
States
 
mentioned heart failure.
5
 
 
The detrimental effect of heart failure after presenting with AMI is well established.
6-8
 In 
an analysis of the VALsartan In Acute myocardial iNfarcTion study (VALIANT) of 
11 040  post-MI patients deemed to be stable (no major non-fatal cardiovascular events or 
deaths within 45 days of randomization and without a prior history of HF), 1139 (10.3%) 
developed HF during the median 25-month follow-up at a rate of 3.4% per year.
9
 United 
Kingdom data from a large, single centre that followed up AMI patients who had a first 
or recurrent myocardial infarction in 1998 reported that 63% developed heart failure over 
the subsequent 6 years. This group also reported 84% of those who died during follow-up 
first developed HF.
10
 
 
 A North American study which looked at population-based cohort of 7,733 patients ≥65 
years of age hospitalized for a first MI between 1994 and 2000 in Alberta, Canada found 
that 2,831 (37%) MI patients were diagnosed with new HF and 1,024 (13%) died. Among 
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hospital survivors who did not have HF during their index hospitalization (n = 4,291), an 
additional 3,040 patients (71%) developed HF by 5 years, 64% of which occurred in the 
first year.
11, 12
 
 
The diagnosis and treatment of ST elevation myocardial infarction has been the subject of 
intense investigation and the focus of numerous randomised clinical trials over the past 
few decades. In an attempt to minimise adverse sequelae it is imperative that in patients 
with ST elevation myocardial infarction (STEMI) the immediate goal of therapy is to 
rapidly achieve patency of the epicardial infarct related artery (IRA) and consequently 
reperfusion of the affected myocardium.   
 
Thrombolysis achieves normal flow (TIMI grade 3) in the IRA in around 50% of patients 
compared to around 90% with primary PCI (pPCI). A meta-analysis of 23 randomised 
controlled trials has shown that primary PCI (pPCI) is superior to intravenous 
thrombolytic therapy for the prevention of death, stroke and reinfarction
13
. Evidence also 
states that in cases of failure to reperfuse following intravenous thrombolysis rescue 
percutaneous coronary intervention is the treatment of choice
14
 The successful restoration 
of epicardial coronary artery patency with TIMI grade 3 flow, however, does not 
necessarily translate into adequate tissue level perfusion.  
 
Inadequate tissue level perfusion in ST – elevation myocardial infarction in the presence 
of a patent epicardial artery is characterised by myocardial microvascular dysfunction. 
Evidence of microvascular obstruction (MVO) regardless of how it is assessed is 
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associated with adverse clinical outcomes. A series of consistent data has clearly shown 
that MVO has a strong negative impact on outcome. 
15-21
 Indeed, patients with no-reflow 
exhibit a higher prevalence of: 1) early post-infarction complications (arrhythmias, 
pericardial effusion, cardiac tamponade, early congestive heart failure); 2) left ventricular 
impairment; 3) late repeat hospital stays for heart failure; and 4) mortality.
22
 
 
 As a consequence attention in recent years has shifted from merely achieving epicardial 
artery patency towards the status of the coronary microvasculature. Restoration of 
epicardial vessel patency does not mean complete perfusion recovery and perfusion of the 
microvasculature is an additional prerequisite for optimal recovery.  However, there is 
not, as yet, a defined gold – standard for assessment of microvascular dysfunction in the 
cardiac catheterisation laboratory when intervention to minimise microvascular damage 
would be potentially of maximal benefit to the patient. Advances in the early 
identification of these patients and the pathophysiology of MVO in ST – elevation 
myocardial infarction could aid the development of preventative and therapeutic 
strategies.
23
  
 
Hence, this thesis will concentrate on novel methods for early assessment of MVO using 
a coronary pressure wire at the time of emergency PCI for STEMI using contrast enhance 
cardiac magnetic resonance imaging (ceCMR) as the gold standard for assessment of left 
ventricular function and microvascular obstruction. 
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1.2Pathophysiology of microvascular obstruction in myocardial 
infarction 
 
1.2.1Background 
 
Myocardial microvascular obstruction was first described as no – reflow phenomenon in 
1974
24
. In relation to this the working hypothesis is that ST elevation myocardial 
infarction is primarily an epicardial arterial event, with acute thrombus formation on the 
background of local atherosclerotic plaque rupture. This results in occlusion of the culprit 
vessel with subsequent downstream hypoxic myocardial damage and cell death. 
25
 The 
most prominent hypothesis is that coronary microvasculature damage is as a result of this 
acute insult secondary to mechanical and functional obstruction and reperfusion injury. 
However primary microvascular dysfunction must also be considered in this patient 
population.
26
 
 
1.2.2Mechanical obstruction of the microcirculation 
 
Distal embolisation of atherosclerotic material has been recognised as an important factor 
in decreased myocardial perfusion in the setting of ST elevation myocardial infarction. 
This has been shown by the injection of microspheres to represent atherosclerotic debris 
in the experimental canine setting 
27
 and was first noted in autopsy of 25 cases of sudden 
death due to acute coronary thrombosis. Falk noted that in 73% of cases there was 
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fragmentation of the proximal thrombus with peripheral embolisation causing micro-
embolic occlusion of the small intra-myocardial arterioles associated with 
microinfarcts.
28
 A further autopsy study confirmed this in patients who died within 30 
days of thrombolysis or balloon angioplasty for treatment of ST – elevation myocardial 
infarction.
29
 
 
Initial studies using a distal protection device confirmed a high number of patients in 
whom this was present and suggested improvement in surrogate markers of 
microvascular perfusion.
30
 Systematic evaluation of angiographic evidence reveals distal 
embolisation to be in the region of 15% although due to the visual nature of assessment 
this number is thought to be artificially low.
31
 In this same study, distal embolisation also 
carried an increased risk of poor clinical outcomes and was associated with an eight fold 
increase in 5 – year mortality. On the basis of these findings downstream embolisation of 
thrombus and plaque material is thought to be the major contributor to the mechanical 
element of microvascular obstruction in reperfused myocardial infarction. Hence, it was 
hypothesized the distal protection devices that prevent embolisation during primary PCI 
may improve distal perfusion.  
 
This concept however has not been proven in the numerous randomised controlled trials 
which remained inconclusive despite capture of atheromatous material. The 
DEDICATION study further confirmed that the routine use of distal protection by a 
filterwire system during primary PCI did not seem to improve microvascular perfusion, 
limit infarct size, or reduce the occurrence of MACE.
32-34
 A significant amount of distal 
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embolisation may occur prior to any medical or therapeutic intervention limiting the 
therapeutic benefits of distal protection devices. Therefore, although the presence of 
distal coronary embolisation is well documented its ultimate function and clinical 
significant remains to be further determined. 
 
1.2.3 Functional obstruction of the microcirculation 
 
Distal embolisation of plaque material must not be taken in isolation and it must be 
remembered that these substances are potentially vasoactive and therefore not 
biologically inert. These bioactive materials have the potential to increase the functional 
impairment of the coronary circulation. Experimental models support the hypothesis that 
microcirculatory vasoconstriction plays a part.  
 
The vasoconstricting peptide endothelin-1 is expressed in active plaque as a tissue factor 
which is shown to cause a significant reduction in coronary blood flow when released 
into the coronary circulation.
26
Moreover, ischaemia itself is known to reduce the 
bioavailability of nitric oxide further contributing to the dysfunction of the coronary 
microcirculation. However the extent to which these elements influence outcome in ST – 
elevation myocardial infarction is currently uncertain. 
 
1.2.4 Reperfusion injury 
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This is a controversial issue from a clinical standpoint if not an experimental one. This is 
defined as myocardial injury caused by the restoration of coronary blood flow after an 
ischaemic episode and can occur regardless of whether reperfusion is by medical or 
mechanical means. The coronary microcirculation is thought to be infiltrated by 
neutrophils and platelets at the time of reperfusion.
35, 36
 
 
A number of pathophysiological mechanisms have been postulated with the major focus 
being on the central role of the microcirculation. 
37
 Histological studies have confirmed 
platelet as well as leukocyte accumulation and activation in the myocardial 
microcirculation, leading to vasoconstriction, thrombosis as well as the release of oxygen 
free radicals, proteases and pro-inflammatory mediators that can lead directly to tissue 
and endothelial damage. Neutrophils also form aggregates with platelets that plug 
capillaries, thus mechanically blocking flow.
38
 
 
 Increase in oxidative stress mediates a reduction in nitric oxide bioavailability as well as 
activation of the endogenous endothelin and the local renin-angiotensin system. At the 
time of myocardial reperfusion there is an increase in intracellular calcium and this 
induces cardiomyocyte death by causing hypercontracture of the heart cells and 
mitochondrial PTP opening. Consequently myocyte death is observed as is interstitial 
oedema and further leukocyte adherence. 
26, 36
 
 
The majority of the work relating to reperfusion injury is done in experimental models 
following acute occlusion of a previously normal epicardial artery. The disappointing 
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attempts to convert successful studies in animal experimental models into the clinical 
setting, has raised the question of the suitability of these animal models as representation 
of acute myocardial infarction in humans.  
 
1.2.5Pre-existing dysfunction of the myocardial microcirculation  
 
There is increasing evidence that pre-existing microvascular dysfunction may also part a 
part in outcomes following ST elevation myocardial infarction and in assessment of risk 
of myocardial infarction in patients with angiographically coronary arteries. Coronary 
flow reserve (CFR) is thought to be a marker of microvascular disease. One study that 
looked at 120 patients in whom the epicardial coronary vasculature was angiographically 
normal or mildly disease found that reduced coronary flow reserve was significantly 
associated with a poor long-term outcome.  Cardiovascular events occurred in seven 
(18%) patients in the lowest tertile of coronary flow reserve compared with four patients 
in the middle tertile (10%) and two patients in the upper tertile (5%).
39
 Hence there is 
evidence that myocardial microvascular obstruction could be a predictor of future 
coronary events in the absence of haemodynamically significant coronary artery disease. 
It is likely that in this setting this merely represents a marker of vascular disease which is 
yet to appear significant angiographically rather than an independent contributor towards 
risk of future vascular events. 
 
The impact of pre-existing diabetes mellitus on myocardial perfusion following primary 
angioplasty has also been investigated. One study found that despite similar high rates of 
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TIMI flow grade 3 after primary PCI in patients with and without diabetes, patients with 
diabetes are more likely to have abnormal myocardial perfusion as assessed by both 
incomplete ST segment resolution and reduced myocardial blush grade. Diminished 
microvascular perfusion in diabetics after primary PCI may contribute to adverse 
outcomes. 
40
  
 
A substudy of the EMERALD study confirmed this adverse prognosis in diabetic patients 
concluding that in patients with ST-segment elevation myocardial infarction undergoing 
primary PCI, diabetes is independently associated with decreased myocardial reperfusion, 
larger infarct, development of congestive heart failure, and decreased survival. In this 
study myocardial perfusion was again assessed using myocardial blush grade and ST 
segment resolution index and infarct size was assessed using technetium-99m single 
proton emission computed tomography measured between days 5 and 14 post 
reperfusion.
41
 
 
1.2.6 Summary 
The pathophysiology of myocardial microvascular obstruction in the setting of 
myocardial infarction is multi-factorial, comprising of mechanical obstruction, functional 
obstruction, reperfusion injury and the elements comprising this as well as pre-existing 
microvascular disease in specific patient groups. The exact pathological mechanisms 
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remain to be determined and this may in part be due to the heterogeneous nature of the 
pathophysiological process.  
 
 
Figure 1.1:  Mechanisms Responsible for No-Reflow Four interacting mechanisms (distal 
embolisation, ischemia-related injury, reperfusion related injury, and individual susceptibility to 
microvascular injury) are responsible for no-reflow phenomenon. The individual contribution of 
these mechanisms to the pathogenesis of no-reflow is likely to vary in different patients. 
 
 
 
 
1.3 Current tools for assessment of the coronary microcirculation 
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As previously stated when treating ST – elevation myocardial infarction with primary or 
rescue angioplasty restoration of normal epicardial blood flow (TIMI 3) flow does not 
guarantee sufficient microvascular perfusion or optimal outcomes due to a combination 
of the factors. These patients would need to be identified at the earliest possible 
opportunity in order to maximize the impact of any potential future target therapies. A 
variety of methods ranging from electrocardiographic criteria to magnetic resonance 
imaging and intracoronary pressure assessment can be used for this purpose. 
 
1.3.1 Electrocardiographic ST-segment resolution following reperfusion 
 
The measurement of the degree of resolution of ST segment elevation on the surface 12 
lead ECG has long been used to assess success or failure of reperfusion therapy. It is well 
established that early and complete resolution of ST segment deviation is a powerful 
predictor of infarct-related artery patency, preserved microvascular integrity and low 
mortality in patients with STEMI. When assessed 90 – 180 minutes after the 
administration of thrombolytic therapy, complete resolution of  ST segment elevation is 
associated with a very high (90 – 95%) probability of a patent infarct related artery, and 
around an 80% probability of TIMI (thrombolysis in myocardial infarction) grade 3 flow. 
42, 43
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In contrast, failure to completely resolve ST-segment elevation is not associated with a 
particularly high rate of occluded infarct related artery (around 50%). These patients are 
known to have an adverse prognosis 
44
 and a significant proportion of these patients are 
now known to have decreased microvascular perfusion.  
 
Studies using contrast echocardiography, myocardial blush grade and intracoronary 
pressure assessment among patients with normal epicardial blood flow following STEMI 
have shown inconstant results when comparing persistent ST segment to other markers of 
persisting microvascular dysfunction. 
45-49
 Several studies have failed to show an 
association between ST-segment resolution and extent of microvascular obstruction 
assessed by cardiac magnetic resonance imaging. Furthermore, other published data have 
failed to show a definitive link between ST-segment resolution and infarct size measured 
by single photon emission computed tomography imaging.
46, 50
 
 
The above has looked at ST-segment resolution index, however, there are now a variety 
of ways that the ECG can be assessed to provide further information about reperfusion. 
ST analysis may have a place as a surrogate marker of outcome in STEMI but the 
evidence shows that it cannot be used for accurate quantification of microvascular 
dysfunction. In addition, some patients with acute myocardial infarction have ECGs that 
cannot be interpreted such as left bundle branch block. Furthermore, if ST segment 
analysis is to be accepted as a surrogate measure of outcome in primary PCI studies a 
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consensus is needed about which measures to analyse, the optimal timing of ECG 
analysis and whether single ECGs or continuous ECG sampling is preferable.
51
 
 
1.3.2 TIMI myocardial blush grade 
 
TIMI myocardial blush grade (MBG) is a semi-quantitive angiographic index of 
microvascular damage after recanalization of the infarct related artery. 
52
 This index is 
graded form 1 to 3, one being what appears to be no apparent  myocardial perfusion and 
grade three being apparently normal myocardial perfusion in the context of TIMI grade 3 
flow in the epicardial artery. MBG is a strong angiographic predictor of mortality in 
patients with TIMI 3 flow after primary angioplasty. Enzymatic infarct size was found to 
be larger and left ventricular ejection fraction was found to be lower in patients with 
MBG 0 or 1 compared with MBG 2 or 3.   
53, 54
  
 
MGB has also been shown to have an association with other potential markers of 
microvascular dysfunction such as ST segment resolution index, TIMI frame counting 
and coronary pressure wire derived markers.
17, 47
 
 
However, MGB can be subjective and as such can be open to differing interpretation by 
different operators. Although MGB has been shown to be associated with enzymatic 
51 
 
markers of infarct size 
55
recent studies comparing MBG with more accurate markers of 
myocardial damage post myocardial infarction such as contrast echocardiography, 
cardiac MRI imaging and SPECT scanning have raised doubts about its ability to 
accurately predict myocardial perfusion.
16
  
 
In one study using SPECT scanning for assessment of myocardial viability in patients 
with TIMI 3 flow post angiography found that if MBG 0 and 1 were regarded as a sign of 
nonviable myocardium and MBG 2 and 3 were regarded as viable myocardium the 
sensitivity of MBG for the prediction of myocardial viability was 79%, specificity was 
40%, positive predictive value was 88% and negative predictive value was 27%. This 
showing that although sensitivity is fairly good specificity is very low
56
. 
 
Porto et al analysed the pathophysiological features underlying different blush grades 
using early CMR imaging and concluded that increased MBG was associated in a linear 
fashion with less microvascular obstruction on CMR imaging, concluding that the 
common practice of including MBG grades 2 and 3 into a single “patent 
microcirculation” category may not be justified.57 In addition, Fearon et al concluded that 
MBG did not correlate with 3 month echocardiographic wall motion score in patients 
treated with primary PCI in the context of STEMI.
47
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TIMI myocardial blush grade is therefore known to be a useful angiographic predictor of 
outcome in STEMI although given its semi-quantitative nature there can be intra-operator 
variability in its interpretation. While it can serve as a marker of microvascular disease it 
cannot be used for accurate assessment of microvascular dysfunction and myocardial 
viability. 
 
1.3.3 Corrected TIMI frame count 
 
The thrombolysis in myocardial infarction (TIMI) frame count (TFC) was developed as a 
simple objective, quantitative and reproducible method to assess coronary blood flow.
58
 
This method counts the number of cine-angiographic frames required for radio-opaque 
contrast to reach specified landmarks in each coronary artery. The TFC provides a more 
reproducible measurement of infarct-related artery blood flow than the TIMI flow grade. 
The TFC has also been shown to be associated with prognosis with one study finding that 
the corrected TIMI frame count (cTFC) three weeks after myocardial infarction was an 
independent predictor of five-year survival, but not 10-year survival in patients treated 
with thrombolysis for STEMI. 
59
 In the setting of percutaneous intervention for STEMI 
Handama et al found that lower cTFC of the infarct-related artery immediately after PCI 
was associated with greater functional recovery; and hence, cTFC could predict clinical 
and functional outcome in patients undergoing successful angioplasty.
60
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It has been postulated previously that in the setting of PCI for STEMI cTFC may be 
suitable to assess the degree of microvascular injury. However when Ohara et al 
investigated the relationship between cTFC and coronary blood flow velocity parameters 
(using a coronary Doppler wire) reflecting the degree of microvascular injury, in patients 
with acute myocardial infarction, they found that cTFC reflected epicardial coronary 
blood flow velocity but was not accurate to assess the degree of microvascular injury 
after primary coronary intervention. 
61
 
 
From a practical aspect these angiographic assessments can rely on performing very long 
acquisitions at high frame rates particularly if there is slow flow or no-flow and this 
generates technical problems for some catheter laboratory x-ray systems as well issues 
about radiation exposure. 
 
1.3.4 Assessment of microvascular integrity using myocardial contrast 
echocardiography  
 
Myocardial contrast echocardiography (MCE) is a technique that uses micro-bubbles 
during transthoracic echocardiography(TTE). These micro-bubbles (typically 2 to 6 µm 
in diameter) remain exclusively within the intravascular space, and their status within any 
myocardial territory can be used to assess the status of microvascular perfusion within 
that area.
62
 Micro-bubbles are biologically inert and purely act as tracer agents. They are 
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able to pass through an intact microcirculation. After bolus injection of micro-bubbles, 
contrast intensity seen within the myocardium reflects the concentration of bubbles. 
During a constant infusion of bubbles and resultant full saturation of the myocardium, the 
signal intensity represents the capillary blood volume. During high powered imaging, 
micro-bubbles are destroyed and the rate of replenishment can be measured.  Myocardial 
blood flow at tissue level can thus be determined from the product of capillary blood 
volume and rate of micro-bubble replenishment after destruction by high powered 
imaging. Decreases in myocardial blood flow are associated with a proportionate 
prolongation of replenishment time
63
.
64
  
 
Ito et al first described the significance of no reflow detected by intracoronary MCE 
despite apparently successful reperfusion therapy. In 39 patients with anterior STEMI 
treated with thrombolysis they found that patients demonstrating no-reflow had 
significantly reduced left ventricular ejection fraction and lower regional wall motion 
scores at 1 month follow-up.
65
 
 
MCE was compared with corrected TIMI frame count, myocardial blush grade and 
percentage ST segment resolution at 90 and 180 minutes to predict left ventricular 
function assessed by regional wall motion score index (WMSI) at one month. In the small 
study (n=15) MCE was found to be the best predictor of improvement in LV function 
with sensitivity and specificity of 88 and 74% respectively.
66
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Intracoronary MCE can be performed at the time of emergency PCI by injection of 
contrast agent into the coronary ostium. Myocardial perfusion can be graded semi – 
quantitavely using an MCE score index (MCESI) from averaging the scores in each of 
the American Heart Association 16 segment model for myocardial perfusion (0 = not 
visible, 1 = patchy, 2 homogeneous contrast effect)
16
. In a study of 124 patients when 
MCESI ≥ 1 is considered adequate reperfusion, those with evidence of MVO defined by 
MCESI = 0 had higher mean creatinine kinase, lower baseline ejection fraction on TTE 
and higher adverse remodeling at 6 month follow up. MCESI = 0 patients also showed 
worse survival in terms of cardiac death (p=<0.0001) and combined events (p<0.0001)
16
. 
 
The multicentre prospective cohort study AMICI (Acute Myocardial Infarction Contrast 
Imaging) evaluated the extent of microvascular damage assessed by MCE in comparison 
with tradition markers of microvascular damage in the prediction of LV remodeling after 
emergency PCI in ST elevation myocardial infarction. At multivariate analysis only TIMI 
grade < 3 flow and endocardial length of contrast defect (expressed as a percentage of 
endocardial length) were independently associated with adverse LV remodeling. Among 
patents with TIMI grade 3 flow endocardial length of contrast defect was the only 
independent variable associated with adverse LV remodeling. 
49
In this study MCE was 
performed 12-24 post PCI. 
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In the majority of studies MCE examination using intravenous contrast the first 
examination is performed between 12 – 24h flowing PCI. This could potentially result in 
a delay in identification of “at risk” patients. In addition some studies thus far in the field 
have concentrated on anterior myocardial infarction although not the case in the AMICI 
study. Inadequate echocardiographic image quality is another potential pitfall of this 
imaging modality especially in patients with inferior/posterior or apical myocardial 
infarction, patients with chronic lung disease or with a high body mass index (BMI). Of 
note, inadequate echocardiographic image quality was an exclusion from the AMICI 
study therefore it is not possible to tell how many patients were excluded on this basis.
21
  
 
Intracoronary MCE has been used to assess microvascular perfusion in the early post 
intervention period (5 – 60 minutes). One study evaluated this in 199 patients following 
PCI however was limited to anterior myocardial infarction
66
 The semi-quantitative 
mature of the indices used in these situations can also make interpretation open to 
observer variability and examinations require appropriate technical expertise especially in 
patients who are overweight.  
 
Despite the evidence for MCE in the diagnostic assessment of microvascular damage and 
prediction of LV remodeling in some circumstances, currently available contrast agents 
are not yet approved for myocardial perfusion, only for LV opacification. Thus, their use 
is limited to clinical studies and consequently restricted in the clinical area.  
57 
 
 
1.4 Cardiac magnetic resonance imaging following acute myocardial 
infarction 
1.4.1 Background 
 
European and American guidelines recommend that all patients who have suffered AMI 
should undergo a formal evaluation of LV function, ideally pre-discharge. The exact 
means of LV assessment is not stipulated in the American College of 
Cardiology/American Heart Association (ACC/AHA) guidelines, while the European 
Society of Cardiology (ESC) guidelines recommend that TTE should be performed in all 
patients; other modalities may be used if available.
67, 68
 
 
Unenhanced 2-dimensional (2-D) TTE is the most widely-used method of assessing LV 
function following AMI
69
. It is widely available and portable, but operator and acoustic 
window dependent. Even with a skilled operator and good acoustic windows a major 
limitation in LV function assessment in the post AMI period is the necessary geometrical 
assumptions required to produce volumes from two-dimensional echocardiography. 
70
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While subjective assessment of LVEF by an experienced operator is normally sufficient 
in clinical practice 
72
 there are potential pitfalls when accurate LV assessment is needed 
for research purposes. 
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ECG-gated myocardial perfusion tomography has been validated in the assessment of 
ventricular volumes. As with 2-D echocardiography, it is reasonably reliable in the 
normal heart but can be limited by low special and temporal resolution. 
73, 74
 The use of 
ionizing radiation limits the utility of nuclear techniques for serial follow up studies, 
especially in research.  
 
Cardiac magnetic resonance imaging (CMR) has many advantages in the assessment of 
ventricular mass and function and has rapidly become the reference standard against 
which other techniques are measured.
75
 CMR is non-invasive, uses no radiation, and has 
been shown to be safe early after AMI, although specific safety questionnaires must be 
completed prior to consenting to the investigation and entering the designated MRI 
scanning room. CMR scanning has also been shown to be safe in the early post infarct 
period.
76
  
 
CMR scanning affords not only the gold-standard means of assessment of LV volumes 
and ejection fraction, but also allows assessment of myocardial viability, perfusion and 
regional function. Without any geometric assumptions, excellent accuracy can be 
maintained in abnormally shaped hearts, for example after myocardial infarction, where 
other techniques could be prone to error.
77-82, 82-84
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Excellent reproducibility is essential for follow up studies of patients, and especially in 
research as the better the inter-study reproducibility the smaller the sample size needed to 
detect a true clinical difference between patient populations. CMR has been shown to 
have the best inter-study reproducibility of any imaging technique for both mass and 
volumes of the left and right ventricles and specifically it is considered superior to two 
dimensional echocardiography.
70, 85, 86
 
 
In summary, CMR is now considered the gold-standard means of measurement of LV 
mass, volumes and LVEF, particularly in patients with LVSD in whom the geometrical 
assumptions on which planar imaging techniques necessarily depend, fail to account for 
the changes that occur in LV morphology. Volumetric analysis is performed on CMR by 
dividing the LV into a stack of short-axis slices, which removes the need for any 
geometric assumption. In addition, the excellent spatial and temporal resolution afforded 
by CMR allows accurate delineation of endocardial and epicardial borders.  
 
1.4.2 Late gadolinium contrast enhancement CMR (ceCMR) 
 
Although several techniques CMR techniques can be used for the diagnosis of 
myocardial infarction, the most accurate and best validated is ceCMR. The technique 
involves inversion recovery imaging 5-10 minutes after administration of intravenous 
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gadolinium contrast agent. With appropriate settings the normal myocardium appears 
black or nulled, whereas the non-viable regions appears bright or hyper-enhanced.  
 
The exact mechanism of hyper-enhancement has not as yet been clearly elucidated but 
the postulated theory is based on 2 principles. Myocytes in normal myocardium are 
densely packed and tissue volume is predominantly intracellular, therefore the 
predominantly extra-cellular gadolinium contrast agent cannot cross the intact myocytes 
cellular membranes. Consequently gadolinium distribution is small and the volume is low 
in an area of normal myocardium. In AMI there is membrane rupture which allows 
gadolinium to diffuse into the damaged myocytes, resulting in increased gadolinium 
concentration, shortened T1 relaxation and subsequent hyper-enhancement. In the 
chronic setting, scar has replaced necrotic tissue and the interstitial space has expanded 
again leading to increased gadolinium concentration and hyper-enhancement.  
 
In animal models, numerous studies have shown an almost exact relationship between the 
size and shape of infarcted myocardium as assessed by ceCMR to that of 
histopathological examination. 
87-91
  
 
Studies in humans have shown that infarct size measured by ceCMR is closely associated 
with peak cardiac enzyme release and to measurements performed by positron emission 
tomography.
92-95
 Furthermore, ceCMR appears to be superior to single photon emission 
computed tomography (SPECT) in detecting sub-endocardial infarcts and infarcts in non-
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anterior locations.
96, 97
 In humans with ischaemic LVSD, the transmural extent of the 
delayed enhanced region on ceCMR correlates inversely with improvement in regional 
contractility following revascularisation.
94
 It should be stressed, however, that delayed 
enhancement on ceCMR is not a specific sign of infarction – it simply indicates that the 
normal fluid homeostasis within the abnormal segment has been disrupted. Delayed 
contrast enhancement has been reported in a variety of conditions including 
myopericarditis, hypertrophic and dilated cardiomyopathies, infiltrative cardiac disorders, 
cardiac neoplasia and in the transplanted heart. 
 
A recent multi-centre international study assessed the performance of ceCMR. In total, 
282 patients with acute and 284 with chronic first time MI were scanned in 26 centres. It 
concluded that when a dose of gadolinium of 0.2mmol/kg (the dose used in this study) or 
higher was used, when MI was identified, its location was correct in more than 97% of 
patients (the location of the hyper-enhancement matched the perfusion territory of the 
infarct related artery). Of note this study also looked at chronic MI a subset of patients on 
whom less data exists, and in whom infarcts are thought to be more difficult to detect 
given the shrinkage that can occur during healing. 
88
 
 
Therefore in summary, the data indicates that ceCMR is a well validated and robust 
technique, with an effectiveness that rivals (and many say surpasses) the current best 
available imaging techniques for the detection and assessment of MI. 
 
1.4.3 CMR for the assessment of MVO 
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In the 1990’s MRI hardware improvement and pulse sequence advances allowed 
development of first pass and delayed enhancement contrast sequences which resulted in 
accurate assessment of tissue perfusion and necrosis. Early AMI studies using these 
techniques, principally in non reperfused infarcts, observed the heterogeneous nature of 
infarcted tissue. In particular areas of hypo-enhancement on contrast imaging were 
thought to represent diminished tissue perfusion. These areas were therefore thought to 
represent “no-reflow” also known as MVO. Further work in reperfused infarcts also 
suggested a relationship between this phenomenon and MVO. 
 
Judd et al compared CMR findings with pathological assessment of infarcts in a two day 
old canine model. They correlated regional blood flow as assessed by microspheres in the 
hyper and hypoenhanced areas with pathological assessment of infarct using thioflavin-S 
staining. They found that hypoenhanced areas on CMR scanning had significantly 
reduced blood flow in comparison with remote areas and that the special location of these 
areas correlated closely with the pathological staining. These findings provided support 
for the concept that the hypo-enhanced core within the hyper-enhanced area following 
contrast injection represented MVO.
98
  
 
 In 1995 Lima et al reported two distinct infarct types in humans with reperfused 
myocardial infarctions, those with hypo-enhancement surrounded by hype-renhanced 
regions, and those with hyper-enhanced regions alone. By time intensity curve analysis 
the investigators found that these different areas of enhancement occurred secondary to 
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differences in wash in kinetics of gadolinium. The hypo-enhanced regions exhibited 
delayed contrast “wash-in” kinetics secondary to a delay and or absence of the contrast 
agent perfusing the affected tissue. These findings were consistent with what was 
postulated to be found in areas of microvascular damage. 
99
 
 
1.4.4 CMR methodology for assessment of MVO 
 
The literature reveals that there is, as yet, no standard approach to imaging microvascular 
obstruction using MRI. The most commonly used methods are first pass perfusion 
techniques, early MVO assessment (normally 2 minutes following gadolinium injection) 
and late MVO assessment also known as late gadolinium enhancement from images 
acquired more than 10 minutes after gadolinium administration. 
15, 100-102
 
 
In theory, first pass perfusion should allow the most accurate assessment of MVO size as 
it allows less time than the other methods for diffusion of the gadolinium contrast agent 
to diminish the size of the defect. However, conventional first pass perfusion imaging 
affords significantly less spatial resolution than the other methods and typically does not 
cover the whole heart using only 3 slices the cover the left ventricle. In addition since 
first pass perfusion functions by highlighting differences in relative perfusion between 
areas of myocardium anything which causes a perfusion defect, for example a scar caused 
by a chronic infarct, could be interpreted as an area of MVO. 
103
 
104
 
 
64 
 
A proportion of patients whom have a defect of first pass scanning do not have evidence 
of MVO on late gadolinium imaging. This ranges from 26% to 31%. It has been 
hypothesised that the reduction in the size of the hypo-enhanced area indicated that the 
edges of the perfusion defect were filled in over time by gadolinium through collateral 
flow or by slow diffusion. It was therefore suggested that MVO on late gadolinium 
images reflected the presence of extensive and severe myocardial damage. Perhaps 
unsurprisingly it is this method for assessment of MVO which is most strongly linked 
with prognosis. 
105, 106
 
 
Recently, high resolution first pass assessment has been shown to be potentially superior 
to early and late gadolinium enhancement and may in the future become the method of 
choice for assessment and quantification of MVO
104
 however at the time of our study 
these sequences were not available and given the higher temporal resolution, particularly 
with delayed gadolinium enhancement we concentrated of assessment of MVO using 
“early” and “late” gadolinium enhancement also known as early and persistent MVO.  
 
One study which compared first pass and persistent MVO found a good level of 
concordance between the two methods. 
107
 Furthermore this thesis will document the 
comparison of early and persistent assessment of MVO in my study population. 
 
There are few papers directly comparing ceCMR assessment of MVO with other imaging 
modalities. One study, comparing MRI with 
201 
T1 SPECT for assessment of infarct size, 
found that those with MVO as assessed by ceCMR had larger infarcts on 
201 
T1 SPECT 
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imaging. There was no direct comparison between the 2 modalities for assessment of 
MVO. 
108
 
 
There has been a direct comparison between ceCMR and contrast echocardiography in a 
reperfused dog infarct model using thioflavin-S staining as the gold standard. They found 
a good correlation between the 2 methods. The threshold for detecting MVO as defined 
by microsphere flow was lower for ceCMR ( <40% of remote regions) than for contrast 
echocardiography ( <60% of remote regions) suggesting that ceCMR may be less 
sensitive but more specific than echocardiography for the detection of MVO.
109
 
 
1.4.5 Clinical and prognostic implications of MVO as assessed by ceCMR 
 
The presence of persistent MVO on ceCMR imaging in reperfused STEMI treated by 
primary angioplasty has been shown to be a significant factor on detrimental LV 
remodeling and ejection fraction at 6 months post reperfusion. 
110
 
 
Wu et al analysed early MVO defined as early hypo-enhancement, in 44 AMI patients 
(eight patients with primary PCI, 20 patients with elective PCI >48h). In patients with 
MVO, more cardiovascular events occurred than in those without MVO and 
microvascular status predicted the occurrence of cardiovascular complications. The 
combined cardiovascular risk of death, re-infarction, congestive cardiac failure or stroke 
increased with infarct extent (30%, 43% and 71% respectively) for small, medium and 
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large infarcts. Even if the analysis was adjusted for infarct size the presence of early 
MVO remained a prognostic marker for post MI complications.
111
  
 
The first study to link persistent MVO to prognosis was published in the European Heart 
Journal in 2005 by Hombach et al. They found using Kaplan-Meier curves a significant 
event free survival for patients without persistent microvascular obstruction. At 100 days 
follow up, the difference in occurrence of major adverse cardiac events (MACE) between 
patients with and without MVO was 12.6% (95% confidence interval, 1.4% - 23.8%). 
Furthermore, they found that the presence of early MVO was a predictor for the 
occurrence of MACE.
15
 
 
The largest and most recent study linking persistent MVO with prognostic impact in 
reperfused AMI was published by Cochet et al.
106
 They looked at 190 patients whom 
underwent primary PCI for treatment of STEMI. They found that persistent MVO was 
relatively common, occurring in around 50% of reperfused infarcts, a finding in keeping 
with work from our own group. 
112
  In addition they compared MVO assessed by first 
pass and persistent MVO. They found that persistent MVO was associated with a 
dramatically higher risk of cardiovascular events, even when adjusted for major markers 
of prognosis after AMI. In addition their data suggested that the prognostic value of 
persistent MVO was superior to MVO determined by first pass images.  
 
Therefore to summarise, MVO assessment by late gadolinium is thought to represent 
potentially severe cases with persistent contrast filling defects. It is also known to be 
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common in reperfused AMI and is linked with prognosis more strongly than the other 
methods for assessment of MVO. For these reasons I have chosen to look at persistent 
MVO primarily in my work but will also record early MVO and therefore also allow 
comparison between the two methods. 
 
1.4.6 The optimal timing for CMR scanning following STEMI 
 
Animal studies have shown that MVO whether early or late as assessed by ceCMR can 
increase in size up to 48 hours.
113
 A further study in the canine model has shown that 
MVO remains essentially unchanged at 2 days and 9 days post infarct.
114
 However 
further work by Albert et al revealed that in 96 patients imaged on different days 
following AMI, MVO prevalence fell dramatically beyond 48 hours from the recorded 
time of infarction (with a decrease in prevalence of greater than 50% within the first 7 
days). 
107
Therefore as can be seen there is as yet no consensus on the optimal timing for 
imaging in this patient group. Given the evidence available my aim was to perform all 
ceCMR scans at around 48h following reperfusion. This could not be done exactly given 
the 24 hours nature of recruitment in the study. I also felt that given average stay in 
hospital following STEMI is gradually decreasing this methodology did not result in 
ceCMR scanning delaying the patients discharge or transfer back to their base hospital.   
 
Although important prognostic information can be gained from ceCMR scans performed 
after successful reperfusion this diagnostic tool is not available in the very early post 
infarct period for a variety of reasons, clinical, logistical and theoretical. The result is that 
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this useful information is not available at the time of emergency PCI when interventions 
in an “at risk” patient group would potentially be most beneficial. Therefore this thesis 
will look also at the feasibility, safety and clinical utility of ceCMR in the very early post 
infarct period. 
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1.5 Novel invasive markers for microvascular dysfunction using a 
coronary temperature/pressure wire at the time of emergency PCI 
 
1.5.1 Coronary microvascular resistance 
 
Resistance equals pressure gradient divided by flow. In the case of the coronary 
circulation, the mean aortic to distal coronary back pressure gradient divided by total 
sinus blood flow over time yields total coronary resistance (mmhg/ml/min). Under 
normal conditions the epicardial arteries which run over the surface of the heart do not 
create any significant resistance to blood flow. Even at high flow rates only a negligible 
pressure difference exists between the central aorta and the most distal part of the 
angiographically smooth epicardial artery.
115
  
 
Under normal physiological conditions, resistance is principally determined by 
vasomotor regulation of the arterioles with a diameter of less than 400 μm and flow is 
kept constant over a wide level of perfusion pressures by auto-regulation. The control 
mechanisms of auto-regulation are numerous and beyond the remit of this thesis. 
116-119
 
Therefore, under baseline conditions the knowledge of coronary resistance reflects basal 
metabolism, but when auto-regulation is exhausted, as in under pharmacological 
hyperaemia, minimal resistance can be calculated.  
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Thus, in order to evaluate the performance of the microvascular bed and quantify 
microvascular resistance the following conditions should ideally be met: (1) exclude the 
presence of obstructive epicardial coronary artery disease or determine the pressure distal 
to the stenosis, (2) quantify flow, (3) induce maximal vasodilation while recording 
pressure and flow, and (4) correct for coronary back pressure. 
120
 
 
The difficulties involved in accurate quantification of coronary flow in vitro have given 
rise to the use of thermodilution as a surrogate marker. According to thermodilution 
theory
121, 122
 flow equals V/Tmn where V represents the vascular volume between the 
injection site (the tip of the guiding catheter) and the location of the sensor, in the distal 
part of the RADI 
TM 
 coronary pressure/temperature wire, and Tmn is the mean time taken 
from a bolus of saline to travel from the sensor in the proximal shaft of the guidewire to 
the distal sensor. Given that these measurements are taken under conditions of 
pharmacological induced maximal hyperaemia V should remain static while Tmn 
becomes representative of flow. Upon these principles the first coronary 
pressure/temperature wire based assessment of the coronary microcirculation was 
developed drawing on the previous Doppler wire experience.
123
 
 
1.5.2 Thermodilution derived coronary flow reserve 
 
The validity of the thermodilution principle to demonstrate CFR on a commercially 
available guide-wire (PressureWire 3, Radi Medical Systems) was first validated in an 
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experimental dog model by De Bruyne et al in 2001
124
. In this in-vitro model, absolute 
flow was compared with the inverse mean transit time (1/Tmn) of a thermodilution curve 
obtained after a bolus of 3ml saline at room temperature. A very close correlation 
(r>0.95) was found between absolute flow and 1/Tmn. In the canine model a significant 
correlation was found between CFR, calculated from the ratio of hyperaemic to resting 
flow velocities using a Doppler flow wire, and the CFR derived from the ratio of resting 
to hyperaemic Tmn (r=0.76;p = <0.001) 
 
Therefore thermodilution derived CRF is calculated as follows
124
. Coronary flow reserve 
(CFR) is defined as the ratio of peak hyperaemic to resting flow (F). 
123
 
 
  1.  CFR = F at hyperaemia / F at rest 
 
Flow is the ratio of the volume (V) divided by Tmn. Thus, CFR can be expressed as 
follows. 
 
  2.  CFR = (V/Tmn) at hyperaemia / (V/Tmn) at rest 
 
Assuming the epicardial volume (V) remains unchanged, CFR can be calculated as 
follows. 
 
  3.  CFR = Tmn at rest / at hyperaemia 
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This was then validated in humans by comparison with what was at the time the current 
gold standard for invasive CFR calculation, the Doppler flow wire. In 103 coronary 
artery territories in 50 patients, in a variety of angiographically normal and stenotic 
vessels the correlation between the two methods was close (r = 0.80; P < 0.001).
125
 
 
However, rather than being simply a measure of microvascular resistance, CFR accounts 
for both epicardial and microvascular resistance. Fractional flow reserve (FFR) is derived 
from the ratio of distal coronary pressure (beyond the stenosis in question) to the pressure 
proximal to the stenosis (in most cases taken as the aortic pressure). FFR, therefore 
accounted for the contribution of the epicardial artery to the total coronary resistance. 
Initially when thermodilution derived CFR was validated it was thought that CFR and 
FFR could provide the clinician with complimentary data. 
115, 125, 126
 
 
Therefore, while FFR went onto everyday use in our catheter laboratories for the 
evaluation of epicardial stenoses
127
 the limitation of CFR to independently assess the 
coronary microvasculature limited its clinical utility. 
128
 Furthermore CFR is limited by 
its dependence on heart rate and blood pressure, thereby calling into question its 
reproducibility.
129, 130
 
 
1.5.3 The index of microcirculatory resistance 
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Fearon et al 
131
 postulated that the calculation of the microvascular resistance by dividing 
the distal coronary pressure by absolute coronary blood flow would provide an 
independent assessment of microcirculatory function. Their theory was that a novel index 
of microcirculatory resistance (IMR), defined as a distal coronary pressure divided by the 
inverse of the hyperaemic mean transit time (a correlate to absolute flow), measured 
simultaneously with a coronary pressure wire would independently evaluate 
microvascular resistance. Or put more simply IMR would equal distal coronary pressure 
multiplied by the hyperaemic mean transit time.  
    IMR = Pd. Tmn  
 
A fundamental assumption in the theory is that Tmn is inversely proportional to 
hyperaemic blood flow. Because 
    F = V/ Tmn 
Where flow (F) equals the ratio of epicardial vascular volume (V) and mean transit time 
(Tmn). Because true microvascular resistance (TMR) equals distal perfusion pressure 
divided by flow: 
    TMR = Pd/F 
And because the vascular volume (V) may be assumed to remain constant at maximal 
hyperaemia by combining equations 1 and 2, can be derived that TMR is proportional to 
the product of distal coronary pressure and Tmn: 
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    TMR = Pd.Tmn 
 
Because both distal pressure and flow would drop in the presence of an epicardial 
stenosis, IMR should remain unaffected.  The investigators validated IMR against true 
microvascular resistance (TMR) in an open chested porcine model using embolised 
microspheres for disruption of the microcirculation. They found that changes in IMR 
between various epicardial and microcirculatory conditions mirrored those of TMR, their 
gold standard reference for microvascular resistance. 
131
  
 
This work was further corroborated by Aarnoudse et al
132
 who not only added to the 
weight of evidence of the close relationship between inverse Tmn and absolute coronary 
flow but further validated IMR as an independent marker of microvascular resistance in 
an in vitro physiological model. They found a close correlation between inverse Tmn and 
absolute blood flow (R
2 
= 0.93) and IMR and TMR (R
2
 = 0.94)
132
 
 
1.5.4 IMR in the presence of an epicardial stenosis 
 
While the initial IMR (IMR = Pd.Tmn) validation had pointed to the fact that IMR was 
independent of an epicardial stenosis
131, 132
 some subsequent studies suggested that the 
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minimum achievable myocardial resistance actually increased with the severity of the 
epicardial arterial stenosis. 
133-135
 Those studies calculated microvascular resistance using 
a coronary pressure wire to calculate distal pressure and a Doppler flow wire to estimate 
coronary flow. Resistance was calculated by dividing pressure by coronary flow. Of note 
however, changes in collateral flow, which may occur with increasing severity of stenosis 
and which may affect the calculation of resistance, were not incorporated into the 
formula.   
 
By working on the basis that myocardial blood flow is the sum of antegrade coronary 
flow and collateral flow, with collateral flow increasing with the severity of an epicardial 
stenosis. As a result of collateral flow, the distal perfusion pressure will not reach zero 
but rather but will approach the coronary wedge pressure as the epicardial stenosis 
reaches total occlusion at maximal hyperaemia. Therefore, the increase in collateral flow 
results in an increase in myocardial flow that is reflected in the distal pressure 
measurement (the numerator in the equation of resistance) but not incorporated into the 
previous method for assessment of flow (the denominator in the equation of resistance) 
resulting in an overestimation of microvascular resistance. Once the epicardial stenosis is 
removed and collateral flow is thought to diminish minimal vascular resistance will 
appear to decrease.   
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By measuring collateral flow by measuring distal coronary wedge pressure and 
incorporating it into the calculation Fearon et al 
136
 found no change in the minimal 
microvascular resistance with an increasing epicardial stenosis. 
  IMR = [(Pa – Pv) x Tmn] x [(Pd – Pw)/(Pa – Pw)]136 
Where Pd, Pa, Pw and Pv are distal coronary pressure, aortic pressure, distal coronary 
wedge pressure and central venous pressure respectively.  
Assuming Pv is around 0 then, 
    IMR = Pa.Tmn x [(Pd – Pw)/(Pa – Pw)]136 
 
Concurrent work by Aarnoudse et al
137
 tested this hypothesis in humans. They performed 
a total of 90 measurements in 30 patients whom were scheduled to undergo PCI. They 
found that when coronary wedge pressure (Pw) was appropriately accounted for 
microvascular resistance did not change significantly with the severity of the epicardial 
stenosis. Therefore, not only concluding that IMR was safe and feasible in humans with 
commercially available equipment, but that IMR was a specific index of microvascular 
resistance when collateral flow was properly taken into account. 
137
 
 
More recently IMR incorporating coronary wedge pressure has been termed IMRtrue and 
IMR in the absence of an epicardial stenosis has been termed IMRapp.
138
 I will use this 
terminology when directly comparing the two prior to and post stenting in chapter 6. 
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1.5.5 The clinical utility of IMR 
 
In comparison with CFR, IMR had been shown to be a specific index for microvascular 
resistance whereas CFR took into account epicardial and microvascular resistance. 
However, one of the other limitations of CFR was that it was shown to vary with 
haemodynamic conditions thereby limiting its reproducibility
129
 and hence it’s clinical 
utility. 
 
Ng et al
130
 compared the reproducibility and haemodynamic dependence of IMR, CFR 
and FFR in humans under different haemodynamic conditions, including baseline, right 
ventricular pacing at 110 beats per minute, nitroprusside infusion, and dobutamine 
infusion. In comparison with CFR, IMR and FFR values remained similar throughout all 
haemodynamic conditions suggesting that IMR provided a reproducible interrogation of 
microcirculatory resistance, which was independent of haemodynamic changes, 
suggesting therefore, that IMR could be used across a patient population rather than 
between two time-points in one patient. 
 
1.5.6 IMR in STEMI 
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As the last decade progressed the significance of the microcirculation in the context of 
reperfused STEMI became more topical.
23, 139
  An editorial in the New England Journal 
of Medicine suggested the need for sensitive diagnostic techniques to evaluate the 
microcirculation in patients with acute myocardial infarction.
140
 
 
Fearon et al 
47
evaluated IMR in 29 patients undergoing primary PCI for STEMI. They 
compared IMR with other known markers of microvascular damage TIMI perfusion 
grade, TIMI frame count, CFR and ST – segment resolution index in there ability to 
predict peak creatinine kinase (CK) as a marker of infarct size and recovery in wall 
motion scoring (WMS) as assessed by echocardiography. On multivariate analysis IMR 
was the most significant predictor of peal CK and three month WMS. IMR was also the 
only significant predictor of recovery of left ventricular function on the basis of 
percentage change in WMS (R = 0.50, p = <0.01)
47
 
 
It had therefore been shown that IMR was a feasible and safe, specific assessment of the 
coronary microcirculation which could potentially be used as a marker for microvascular 
resistance at the time of STEMI. 
 
1.5.7 Pressure derived collateral flow index 
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Pressure derived collateral flow index (CFIp) can be quantified on a pressure wire. This 
can only de done in the setting of PCI as it requires knowledge of Pw. The ratio of Pw to 
Pa during balloon inflation is thought to represent CFIp.  
  CFIp = (Pw – Pv/Pa – Pv) 
In practice the measurement of Pv is not routinely taken and has been assumed to have 
been 0. 
141
 
 
CFIp is hypothesized to increase with collateral flow and has been shown in a prospective 
study to predict future ischaemic events after PCI in patients with stable angina and 
normal left ventricular function
142
. In the infarcted heart, however, CFIp is not thought to 
solely reflect collateral supply but is influenced by microvascular dysfunction. A higher 
CFIp has been linked to other surrogate markers of poor microvascular perfusion, being 
significantly higher when no reflow
143
 is seen by contrast echocardiography and being 
associated with poor ST segment resolution
144
. 
 
Previous work by our own group found that increased CFIp and Pw in the patient group 
TIMI grade 3 flow following rescue PCI for STEMI was associated with poor left 
ventricular function adding weight to the theory that raised CFIp and Pw in the setting of 
STEMI may reflect a dysfunctional microcirculation rather than good collateral 
protection.
141
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Sezer et al measured CFIp in patients whom underwent PCI a mean of 3.3 days following 
successful thrombolysis for STEMI. They found that raised CFIp was an independent 
predictor for left ventricular dilatation assessed one year following infarction by 
echocardiography.
45
 
 
CFIp is therefore postulated to be a surrogate marker of MVO in STEMI
23
 although as 
can be seen it does not have the physiological data behind it that IMR has. It does appear 
however, from the work done previously that it does have an effect of left ventricular 
function following rescue PCI
141
, successful thrombolysis
145
 and primary PCI
146
, further 
strengthening this argument. 
 
1.6 Aims of this thesis 
 
Microvascular dysfunction is a significant problem linked with increased morbidity and 
mortality despite patency of the infarct related artery in STEMI. Contrast enhanced CMR 
scanning in the post infarct period allows assessment of left ventricular injury, can 
determine and allows quantification of MVO and allows quantification of infarct 
volumes. Cardiac MRI is thought to be the current gold standard for assessment of these 
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measures following STEMI. This important prognostic information is not however 
available until around 48h following PCI.  
 
IMR has been validated in vitro and in stable patients as a quantitative marker of 
myocardial resistance. It can be calculated as the time of PCI using a commercially 
available guidewire and software. IMR has been shown in a small study to be more 
predictive of peak CK rise (a biochemical marker for infarct size) and left ventricular 
damage by echocardiography than traditional markers for MVO at the time of emergency 
PCI. 
 
The hypothesis that this thesis will test is whether pressure wire derived markers on 
microvascular dysfunction, principally IMR, measured at the time of emergency PCI for 
STEMI, are associated with MVO and can predict left ventricular damage and infarct 
volumes on subsequent ceCMR imaging. A full outline of the aims of this thesis are 
stated below 
The aims of this thesis are:  
 To assess the relationship between pressure wire derived markers microvascular 
resistance, principally IMR, and MVO assessed of ceCMR imaging at 48h post 
emergency PCI for STEMI. 
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 To assess the ability of pressure wire derived markers microvascular resistance, 
principally IMR, at the time of emergency PCI to predict LVEF, LVESV, 
LVEDV and infarct volumes on ceCMR imaging at 48h and 3 months. 
 To assess the relationship between pressure wire derived markers microvascular 
resistance and adverse ventricular remodeling 
 To assess the relationship between pressure wire derived markers microvascular 
resistance and transmurality score on ceCMR 
 To assess the influence of anatomical site of myocardial infarction and therapeutic 
interventions at the time of emergency PCI on coronary pressure wire derived 
indices of microvascular obstruction. 
 
 To assess the relationship between coronary pressure wire derived markers of 
microvascular obstruction and “traditional” indices of myocardial damage and 
microvascular obstruction in ST – elevation myocardial infarction, in particular, 
TIMI flow grade, ST-segment resolution index, corrected TIMI frame count, peak 
troponin I and time to reperfusion. 
 
 To assess the relationship between coronary pressure wire derived indices of 
microvascular dysfunction prior to and following stenting in emergency PCI for 
ST elevation myocardial infarction.  
 The relationship between IMR, CFIp and Pw at the time of emergency PCI 
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 To assess the correlation between early and late/persistent MVO assessed by 
ceCMR scanning 48 following STEMI 
 To assess the feasibility, safety and clinical utility of ceCMR in the early post 
infarct period 
 To assess the impact of IMR measured at the time of STEMI on clinical outcomes 
(in collaboration with other groups) See Appendix V 
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Chapter 2: Pharmacological options for 
inducing maximal hyperaemia during 
studies of coronary physiology 
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2.1 Introduction 
The coronary pressure wire is used for physiological assessment of the coronary 
vasculature increasingly frequently in clinical practice. Fractional flow reserve can now 
be used to assess lesion severity in a variety of anatomical situations. Increasingly the 
coronary pressure wire is being used to interrogate the coronary microvasculature. 
Coronary flow reserve (CFR) and Index of microcirculatory resistance (IMR) require 
hyperaemia to accurately assess thermodilution – derived mean transit times, and 
pressure derived collateral flow index (CFIp) is calculated from coronary wedge pressure 
and aortic pressure at hyperaemia. In addition coronary flow velocity as assessed by a 
coronary Doppler flow wire needs appropriate induction of hyperaemia. However, the 
majority of this article will however focus on hyperaemia induction for pressure wire 
studies. 
 
Significant clinical decisions are made as a result of fractional flow reserve readings 
therefore it is imperative that they are carried out correctly.  Maximal coronary 
hyperaemia is essential in producing accurate, reproducible measurements. This article 
focuses on the pharmacological agents that can be used for this purpose, discusses which 
agents can be used in specific situations, and briefly addresses the future of 
pharmacological stress in the catheter laboratory. 
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2.2 Fractional Flow Reserve 
Measurement of pressure derived fractional flow reserve (FFR) is a widely used 
technique in cardiac catheterisation laboratories to determine the functional significance 
of coronary artery stenoses
127
. FFR is defined as the ratio of the maximal blood flow 
achievable in a stenotic vessel to the theoretical maximal flow in the same vessel if no 
stenosis was present. In a normal coronary artery there should be no pressure gradient 
between the aorta and the distal artery resulting in a FFR value of 1. These simultaneous 
measurements can be made in a stenosed coronary artery using a pressure tipped 
coronary guide wire to record distal pressure and a guide catheter to record pressure in 
the aorta. Studies have shown that a FFR < 0.75 reliably identifies a stenosis with the 
potential to induce reversible myocardial ischaemia. A multicentre registry study has also 
shown that post stenting FFR is a strong independent predictor of outcome at six months, 
the higher the post stenting FFR the lower the event rate.
147
 Furthermore, in patients with 
multivessel disease FFR can be used as a reliable and lesion-specific index of stenosis 
severity.
127
 Pullback of the pressure wire can be used to determine which of two or more 
serial stenosis is more functionally significant, Due to the interaction of serial stenosis 
determination of the exact FFR of distal lesions requires knowledge the coronary pressure 
proximal to that particular lesion and not the aortic pressure that is used in routine clinical 
practice.  The FAME trial was a multicentre randomised study comparing FFR guided 
PCI with angiographically guided PCI in patients with multi-vessel disease and 
determined that an FFR guided strategy results in superior clinical outcomes.
127 
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The achievement of maximal hyperaemia is a prerequisite for the accurate determination 
of all pressure wire derived markers of lesion severity and microvascular resistance.  
 
The available pharmacological agents for inducing maximal coronary hyperaemia can be 
given by intracoronary injection (ic) or intravenous infusion (iv). The most commonly 
used agent in clinical practice is adenosine, both ic and iv and intracoronary papaverine. 
For the sake of completeness this article will also cover dobutamine, sodium 
nitroprusside and contrast media although these should not be viewed as routine, 
effective options for induction of hyperaemia for pressure wire studies.  
 
2.3 Adenosine 
Adenosine was identified in the myocardium in 1929. It is synthesised in the myocardium 
and interstitial adenosine concentration rises as a result of increased metabolic oxygen 
requirements and ischaemia.
148
 Exogenously administered adenosine causes profound 
microvascular dilatation mediated by an adenosine receptor (A2) on the cell membrane of 
resistance vessel myocytes. Therefore adenosine induces near-maximal coronary 
vasodilation primarily through activation of adenosine receptors in vascular smooth 
muscle and hyperaemia is independent of metabolic demand.
149
However the exact 
physiological role of adenosine in the regulation of coronary blood flow is as yet 
unknown. The pharmacological profiles of adenosine differ depending on the mode of 
administration.
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2.3.1 Intracoronary adenosine 
Intracoronary adenosine is an extremely safe agent to induce maximal hyperaemia.
150
 The 
peak effect occurs less than 10 seconds after administration but has a duration of action 
of less than 20 seconds. There have been numerous studies looking at the appropriate 
doses of intracoronary adenosine needed to achieve hyperaemia. Initial thinking that 
lower doses of the drug (15 – 20 micrograms in the right coronary artery and 18 – 24 
micrograms in the left system)
 151
 have been superseded in recent years by evidence that 
administration at these levels may result in an overestimation of FFR in a significant 
number of patients, specifically those with an FFR between 0.75 and 0.80, the so called 
“grey area”.  It has been shown that intracoronary doses of ic adenosine are safe at higher 
doses, with minimal side effects. While initial high doses of ic adenosine are not always 
necessary, incremental dose escalation is recommended in those with an intermediate 
FFR value of 0.75-0.80.
151
 Current thinking is that to achieve optimal hyperaemia 
patients should be administered an intracoronary dose of 40 micrograms into the right 
coronary artery and 60 micrograms into the left coronary. This should be increased in 20-
30mcg increments to a maximum of 150 micrograms if the FFR remains between 0.75 
and 0.80. 
150 
The main side effect associated with this method of administration is short lasting, 
transient atrio-ventricular block, which is understandably, most frequently noted after 
administration of the drug into the right coronary artery.  
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2.3.2 Practical considerations when using intracoronary adenosine 
Prior to administration of ic adenosine it is prudent to administer a standard dose if ic 
nitrate to decrease the possibility of arterial spasm influencing the FFR measurements. In 
order to achieve maximal drug delivery to the coronary artery and to obtain accurate 
measurements of the aortic pressure it is essential to use a guide catheter without side 
holes and to ensure co-axial engagement. For all pressure wire studies it is important not 
to use a guide catheter that is too large for the ostuim of the artery as this may cause 
pressure damping to occur. This can be recognised by the presence of a ventricularised 
aortic pressure tracing. 
 
The more specific limitations encountered when using ic adenosine relate to both its rapid 
onset of peak effect and the short duration of peak hyperaemia. It is not possible to make 
a pull back curve to assess the potential severity of serial stenosis in the same epicardial 
artery. Given the short time scale involved in taking these measurements it is important 
that the readings are measured on a beat to beat basis rather than from a mean, which is 
the default setting in some analysers. Mean readings are likely to result in an 
underestimation of the maximum gradient. A further point to ensure an accurate FFR 
measurement is that the interruption in aortic pressure (Pa) recorded from the guide 
catheter should be as short as possible after the ic injection. A significant delay may 
result in the period of peak hyperaemia being over by the time aortic pressure is read. The 
use of an ic bolus of adenosine does however allow repeated measurements to be made 
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over a short period provided enough time is taken between readings for the effects of the 
previous dose to have waned. 
 
2.3.3 Intravenous adenosine 
In contrast with dosages used to achieve hyperaemia using ic adenosine there is 
widespread consensus regarding the appropriate dose of iv adenosine. When administered 
through the femoral vein or a large cubital vein the usual dose in clinical practice is 
140/micrograms/kg/min. 
 
This should achieve a peak effect in around 1 minute. Similarly 
the effect wears off approximately 1 minute after the infusion is stopped.  In the case of 
an intermediate FFR measurement of 0.75-0.80 the dose of the IV infusion can be safely 
increased to 180micrograms/kg/min.
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AV block is much less common with a continuous infusion of iv adenosine than with ic 
adenosine and is rarely seen in clinical practice. Adenosine can provoke 
bronchoconstriction so the main contraindication to iv adenosine is significant 
bronchoconstrictive lung disease such as asthma or chronic obstructive pulmonary 
disease. Intravenous adenosine is frequently accompanied by an unpleasant angina like 
sensation in the chest and throat which can be associated with dyspnoea.
149
 This sensation 
is harmless and does not indicate myocardial ischaemia. The patient should be suitably 
reassured prior to the procedure to prevent any undue alarm. This course of action should 
allow the vast majority of patients to tolerate the sensation. This feeling should pass 
quickly after ending the infusion. If the patient remains asymptomatic throughout the 
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administration of adenosine then the physician should question whether the drug us being 
appropriately delivered. Administration of the drug should also cause a decrease in blood 
pressure of around 10-20% and a similar increase in heart rate. These should also act as 
markers that the drug is being delivered effectively.   
 
2.3.4 Practical considerations when using an intravenous adenosine infusion 
General rules with regard to intravenous infusions should be followed to ensure the 
maximal amount of the pharmacological agent reaches the coronary vasculature. These 
include using a volume controlled infusion pump with sufficient capacity and ensuring 
the patients arm is extended if a brachial vein is used for the infusion. As with ic 
adenosine it is prudent to administer an ic dose of nitrate prior to commencing the 
infusion. One of the main advantages of using an IV infusion of adenosine is that it 
produces a steady state hyperaemia, which allows a pullback curve to be recorded. This 
allows physiological assessment of the entire coronary artery and assessment of serial 
stenoses and/or stent placements. Due to the short half-life of adenosine it is essential that 
venous return to the heart should not be interrupted by valvalsa-like manoeuvres. This 
can result in significant pressure signal fluctuations, which in turn can cause an 
overestimation of fractional flow reserve. The patient should therefore be instructed to 
breathe normally.  
 
92 
 
2.3.5 The effects of methylxanthines on adenosine 
It is postulated that caffeine can blunt the hyperaemic response by blocking the A2a 
receptors. Caffeine is a competitive inhibitor of adenosine at cellular level. There is not, 
as yet, definitive evidence that caffeine intake prior to a procedure which requires 
hyperaemia alters the fractional flow reserve. One small study (n=10) concluded that 
fractional flow reserve was not affected by an intravenous caffeine infusion at doses 
comparable to oral consumption. 
152
 Until further work is published in this area it is 
prudent to advise patients against caffeine ingestion for 24h prior to any procedure. 
Nahser et al looked at changes in coronary flow velocity measured by intracoronary 
Doppler catheter receiving 140 mcg/kg/ml of adenosine before and after an intravenous 
infusion of aminophylline. Although the numbers were again small (n=12), they found 
that the coronary haemodynamic effects of adenosine were attenuated by aminophylline 
concluding that the utility of myocardial imaging techniques using coronary vasodilation 
by adenosine as a prerequisite may be reduced in those patients treated with theophylline 
containing preparations.
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2.3.6 Adenosine 5’-triphosphate (ATP) 
ATP has a short half-life in plasma and is rapidly degraded into adenosine diphosphate, 
adenosine monophosphate, and adenosine. Although the effects of ATP are proposed to 
depend on its degradation to adenosine, neither direct stimulation of adenosine receptors 
by ATP nor an endothelium-dependent vasodilatory action of ATP via a P2-purinorecetor 
can be fully excluded.   
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Yamada et al reported that 50 mcg of ic ATP would induce the same amount of 
vasodilation as 10 mg of papaverine without any significant haemodynamic or 
electrocardiographic changes.
154
  
 
Perhaps the most comprehensive study looking at this pharmacological agent was by De 
Bruyne et al when comparing intracoronary and intravenous ATP with adenosine, 
papaverine and contrast medium. Their data indicated an equipotency of ATP and 
adenosine with no difference in their times of onset or duration of effect. They 
recommended the use of this agent at the same doses as that of adenosine. Increasing the 
intravenous infusion to greater than 140mcg/kg/min did not induce a further decline of 
the resistance index but induced a marked decline in systemic blood pressure in some 
patients.
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    2.4 Other vasodilator agents    
2.4.1 Sodium nitroprusside 
This pharmacological agent has been looked at primarily in respect to no reflow in the 
acute myocardial infarction setting rather than its ability to achieve hyperaemia capable 
of producing reproducible physiological measurements. Nitroprusside relaxes arterial and 
venous smooth muscle without effects on other types of smooth muscle or myocardial 
contractility. Although it is thought that its actions are in some way mediated through the 
sympathetic nervous system they are not dependent on any specific adrenergic receptor or 
ganglion. Therefore, unlike drugs acting through sympathetic blockade, regional 
distribution of blood is virtually unchanged by sodium nitroprusside. Nitroprusside 
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induces hyperaemia by its ability to preferentially vasodilate the coronary 
microcirculation.
156
Amit et al enrolled 98 patients into a randomized, double-blind, 
placebo controlled trial looking at whether intracoronary SNP injected into a coronary 
artery prior to percutaneous intervention affected vessel flow and myocardial perfusion. 
They found that selective intracoronary administration of a fixed dose of SNP failed to 
improve coronary flow and myocardial tissue reperfusion but improved clinical outcomes 
at 6 months.
157
 
 
Parham et al compared the hyperaemic and haemodynamic responses of intracoronary 
nitroprusside to intracoronary adenosine in patients during cardiac catheterisation with 
normal left anterior descending arteries. Using a Doppler wire time to peak and average 
peak velocity were similar with SNP and adenosine with the three doses of intracoronary 
SNP that were administered. (0.3, 0.6, and 0.9 microgrammes/kg). The duration of 
coronary hyperaemia is approximately 25 % greater with intracoronary SNP in 
comparison with adenosine. Significantly when used for coronary lesion assessment they 
found that intracoronary SNP produced identical FFR values to those obtained with 
adenosine.
158
 
 
The data, thus far, indicates that intracoronary administration of sodium nitroprusside is 
safe and effective for the induction of maximal coronary hyperaemia. It produces a 
slightly prolonged maximal hyperaemic effect, in comparison with adenosine, however 
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given the small body of evidence it is currently difficult to advocate its use in routine 
clinical practice as a viable alternative. 
 
2.4.2 Dobutamine 
Dobutamine is not commonly used as an agent to induce hyperaemia in the cardiac 
catheterisation laboratory but is used frequently as a stressor agent for SPECT and stress 
echocardiography. Dobutamine is a sympathomimetic amine that acts through alpha and 
beta adrenoceptors stimulating positive inotropic and chronotropic effects as well as 
enhancing myocardial blood flow principally through metabolic vasodilation.
159, 160
  
 
In keeping with the clinical environment in which dobutamine is used the literature 
contains very little about its potential use in the cardiac catheterisation laboratory during 
invasive pressure wire measurements. Meimoun P et al compared dobutamine and 
adenosine in assessment of transthoracic coronary flow velocity reserve. They found in 
the 47 patients they studied that dobutamine could be a good alternative to adenosine in 
this setting, particularly if the patient has a contraindication to adenosine
161
. Numerous 
other papers on the topic of dobutamine stress echocardiography exist, however, given 
the lack of evidence for the accuracy of dobutamine with regard to coronary pressure 
wire physiological assessment, its relatively long half-life and other possible alternatives 
to adenosine it is difficult to advocate its use in the catheterisation laboratory. 
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2.4.3 Papaverine 
Intracoronary papaverine induces maximal coronary vasodilation and has a short duration 
of action. Peak effect after administration is at 10-30 seconds and the duration of plateau 
is around 45-60 seconds. The recommended dosages for intracoronary papaverine are 12-
16mg in the right coronary artery and 16-20 mg in the left system.
155, 162
 Historically 
papaverine was the pharmacological agent of choice in the assessment of coronary flow 
reserve but has been superseded by adenosine because of concerns about complications. 
Specifically papaverine may induce Q-T prolongation which can lead to polymorphic 
ventricular tachycardia and ventricular fibrillation.
163
 Correcting hypokalaemia pre-
procedure and ensuring patients are not taking other drugs which cause Q-T prolongation 
(class I and III anti-arrhythmic drugs) can minimise the potential for this serious side 
effect. Pijls NHJ and De Bruyne B reported that in over 1000 patients whilst Q-T 
prolongation was common ventricular fibrillation occurred no more commonly than after 
contrast injection.
155 
However, several studies have demonstrated that ic papaverine 
induces a significant increase in coronary venous lactate in both canine models and in 
patients with normal coronary arteries and these results suggest that papaverine may 
produce myocardial ischaemia.
164, 165 
 
De Bruyne B et al compared intracoronary and intravenous adenosine 5’-triphosphate, 
adenosine, papaverine and contrast medium to assess fractional flow reserve and found 
that only intracoronary papaverine (20mg) and intravenous adenosine (140mcg/kg/h) 
induce complete, true steady state hyperaemia to enable a pressure pullback curve. They 
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stated that the latter was the easiest means for this, especially in cases with diffuse 
disease.
155 
 
Papaverine is essentially the only intracoronary injection, which can allow production of 
a pressure pullback curve although it is not ideal given the time constraints. Its half-life 
also means that the operator should wait five minutes between successive measurements 
using ic papaverine and should limit the number of doses to three in any one patient to 
reduce the risk of side effects. 
 
Over the years for both practical and safety issues intracoronary papaverine has been 
superseded by adenosine for the production of coronary hyperaemia in assessment of 
fractional flow reserve.  However papaverine still has a place in the cardiac 
catheterisation lab in those in whom adenosine is contra-indicated when appropriate 
precautions are taken. 
 
2.4.4 Radiographic Contrast media 
Both ionic and non-ionic radiographic contrast media cause vasodilation and associated 
increases in coronary blood flow when injected into the coronary arteries at the time of 
angiography.
166
 Hodgson and Williams compared ic papaverine to radiographic coronary 
flow reserve in patients with ischaemic heart disease and patients with normal coronary 
vasculature.  They concluded that papaverine was superior to contrast media because of 
the greater degree of hyperaemia and the ability to more accurately differentiate non-
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ischaemic from ischaemic vascular regions in individual patients.
167  
Radiographic 
contrast media does not therefore produce sufficient coronary vasodilation for accurate 
assessment of fractional flow reserve. 
 
2.5 The future of pharmacological stress 
Work in this field has concentrated on synthetic selective A2A receptor adenosine 
agonists. As well as stimulating the A2A receptor, adenosine itself also non-selectively 
activates A1, A2b and A3A receptor. Such nonselectivity is thought to contribute to the 
side effects that are seen during pharmacological stress testing (eg bronchospasm and A-
V block). Theoretically selective A2A adenosine receptor agonists would provide 
selective coronary vasodilation, rapid onset and termination of action and bolus 
administration as well as being tolerated in those in whom adenosine is currently thought 
to be contra-indicated.
168
 
 
Initial small studies looking at the selective A2A receptor agonist’s binodenoson and 
regadenoson have been reasonably encouraging in the field of nuclear myocardial 
perfusion imaging. Both showed a reproducibility of results in patients receiving 
clinically indicated adenosine single-photon emission computed tomography scans 
(SPECT) and both were noted to have a reduced subjective side effect profile at lower 
doses.
169, 170 
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On the basis of these and other studies three selective A2A receptor agonists, 
regadenoson, binodenoson and apadenoson are now in larger phase III clinical trials as 
pharmacological stress agents. Quite how these agents will be used in the future remains 
to be seen. The work so far has concentrated, predictably, on non-invasive nuclear 
perfusion imaging. Whether they can be useful in the cardiac catheterisation laboratory in 
the context of coronary pressure measurements will be decided in the future. 
 
2.6 Conclusions 
In conclusion, adenosine whether used intravenously or intracoronary is a safe and 
reliable method for the induction of coronary hyperaemia. The context in which the study 
is performed as well as operator preference should determine the route through which the 
drug is delivered. The authors believe this should be the first choice vasodilator to be 
used in coronary physiological assessment using a pressure wire. Intracoronary 
papaverine is a viable alternative in those in whom adenosine is contra-indicated.  
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Dosage tables 
 
Weight (lb) Weight (kg) Infusion  (ml/hr) 
99 45 378 
110 50 420 
121 55 462 
132 60 504 
143 65 546 
154 70 588 
165 75 630 
176 80 672 
187 85 714 
198 90 756 
209 95 798 
220 100 840 
231 105 882 
243 110 924 
254 115 966 
265 120 1008 
 
Table 2.1: Dosage table for IV adenosine at 140 micrograms/kg/min 
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Table 2.2: Dosage table for IV adenosine at 180 micrograms/kg/min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight (lb) Weight (kg) Infusion (ml/hr) 
99 45 486 
110 50 540 
121 55 594 
132 60 648 
143 65 702 
154 70 756 
165 75 810 
176 80 864 
187 85 918 
198 90 972 
209 95 1026 
220 100 1080 
231 105 1134 
243 110 1188 
254 115 1242 
265 120 1296 
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Chapter 3: Methods 
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3.1 Study overview and recruitment 
 
The principal techniques used for this thesis were intracoronary physiological assessment 
and contrast-enhanced cardiac magnetic resonance imaging (ceCMR). In this chapter the 
background, methods, apparatus and protocols for these techniques will be outlined. 
 
3.1.1 Inclusion and exclusion criteria  
 
Patients were prospectively enrolled when the following inclusion criteria were present: 
 Age  18 years with ECG and symptomatic evidence of acute STEMI and in 
whom emergency PCI was intended 
 Written informed consent. 
 
 Exclusion criteria were:  
 
 Standard contraindications to MRI: pacemakers; cochlear implants; some types of 
prosthetic heart valves, surgical prostheses, or vascular clips; metal intraocular 
foreign bodies 
 Contraindications to gadolinium: eGFR <30 mL/min/1.73m2; sickle cell anaemia; 
haemolytic anaemia  
 Contraindications to adenosine  
 Cardiogenic shock  
 Previous myocardial infarction  
 Pregnant.  
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3.1.2 Recruitment 
 
STEMI patients referred to our institution within 12 hours of symptom onset for primary 
PCI or after failed intravenous thrombolytic therapy for rescue PCI, or who underwent 
cardiac catheterization within 24 h of successful thrombolytic therapy  were considered 
for enrollment.  
 
During the time of the study the Western Infirmary in Glasgow was a tertiary referral 
centre for coronary intervention for the West of Scotland.  Patients were referred to the 
Western infirmary from other hospitals for emergency or urgent coronary angiography or 
referred to the cardiology department for assessment from the accident and emergency 
department. At the time of the study the hospital ran a 24h emergency percutaneous 
intervention (PCI) service for acute ST-elevation myocardial infarction (STEMI).  
 
Only consultant interventional cardiologists from the Western Infirmary took part in the 
study (KGO, MML, SDR, WSH, CB). The West of Scotland emergency PCI rota at this 
time was also staffed by consultant cardiologists from Glasgow Royal Infirmary and 
Stobhill Hospital who did not participate. Accordingly we did not recruit consecutive 
patients. Patients were screened and consented by myself or by the Consultant 
cardiologist on-call who was performing the PCI if I was not in the hospital. The 
consultants were fully aware of the study protocols and procedures and were involved in 
the development of the study. 
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3.1.3 Consent and ethics 
 
The research protocol was approved by the West Glasgow Ethics committee and 
informed consent was obtained from each patient. Given the time constraints involved in 
recruiting patients in the acute setting a shortened patient information sheet was used for 
initial consent prior to PCI. (Appendix I) Patients who agreed to enter the study were then 
asked to sign consent form one. A member of on-site staff not involved in the study was 
also asked to sign this consent form. (Appendix II) Following emergency PCI and before 
cardiac magnetic resonance imaging (CMR) patients were then given a longer, more 
detailed patient information sheet. (Appendix III)  If, after further consideration and 
discussion they agreed to continue in the study they were asked to sign consent form 2. 
(Appendix IV) 
 
3.1.4 Acute management of patients 
 
The trial did not interfere with routine patient management. Only patients in whom the 
decision for emergency coronary angiography had been made were considered for the 
study. If at the time of angiography the patient was deemed too unstable or had coronary 
artery disease not suitable for PCI by the operator the patient was excluded. The type and 
size of intracoronary balloons, type, size and number of stents and the use of 
thrombectomy catheters and glycoprotein 2b/3a inhibitors was at the discretion of the 
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primary operator. Vascular access route was also at the discretion of the primary operator 
although radial arterial access was the primary option of choice at our institution. 
 
Following emergency PCI patients were managed in the coronary care unit in the 
Western Infirmary. Length of stay and the prescription of standard medical secondary 
prevention including ACE inhibitors and β-blockers were entirely at the discretion of the 
admitting consultant and their team.  
 
If patients were deemed too unwell by myself or by the admitting consultant to tolerate a 
cardiac MRI scan or if was thought unsafe for the patient to leave the coronary care unit 
the patient was excluded from the study. 
 
Flow diagram of study (Figure 3.1) 
 
 
Patient admitted to or referred to WIG for emergency PCI 
 
 
Initial consent 
 
 
      Emergency PCI with pressure wire assessment  
         
 
 
  Re-consent 
 
 
                                               Contract-enhanced CMR at 24-48 hours 
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                                            Repeat Contrast-enhanced-CMR at 3 months 
 
 
               END OF TRIAL 
 
 
3.1.5 Index event and hospital admission 
 
After obtaining written, informed consent enrolled patients were assigned a unique study 
code number. They then underwent emergency PCI with physiological coronary pressure 
assessment. Thereafter they were re-consented and underwent ceCMR at 24-48h 
following re-perfusion.  
 
In addition to coronary angiography, pressure wire assessment and ceCMR the following 
were performed and recorded during the patient’s initial hospital admission: 
 
 Physical examination, including measurement of height, weight and resting 
haemodynamics prior to ceCMR scan 
 Retrieval and photocopying of diagnostic ECG (acute MI), post reperfusion 
ECG/90 minute ECG 
 Recording of baseline blood results on admission 
 12h troponin I 
 Patient demographics, past medical history, cardiac risk factors, admission and 
discharge medication 
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 Accurate recording of timings in the patient journey from onset of pain to 
reperfusion 
 
The above information and was recorded for each patient in the study on paper and 
electronically on a Microsoft Access database on a secure computer. 
 
3.1.6 Three month visit  
 
This consisted of a two hour visit to the Glasgow Cardiac MRI Unit at the Western 
Infirmary. 
 
Physical examination, including measurement of height, weight and resting 
haemodynamics prior to ceCMR scan 
 12 lead ECG recording 
 Contrast enhanced cardiac MRI scan with simultaneous electrocardiographic 
recording. 
 
 
 
 
 
 
109 
 
3.2 Invasive coronary physiological assessment protocols 
 
PCI was performed in line with current international guidelines. Glycoprotein IIb/IIIa 
inhibitors and thrombectomy catheters were used at the discretion of the primary 
operator. 
 
In this study, a commercially available 0.014-inch floppy pressure
 
guide wire 
(PressureWire-6, RADI Medical Systems) was used with
 
the appropriate software and 
interface (Radi-Analyzer, RADI Medical
 
Systems). This wire has a micro-sensor at a 
location
 
3 cm from the floppy tip, which enables simultaneous recording
 
of coronary 
pressure measurement as well as temperature
 
measurement at the location of that sensor, 
with an accuracy
 
of 0.02°C. The shaft of this wire, acting as an additional
 
electric 
resistance, can be used as a second thermistor, providing
 
the input signal at the coronary 
ostium of any fluid injection
 
with a temperature different from blood. All signals
 
can be 
displayed and recorded on the commercially available analyser for future off-line 
analysis. 
 
3.2.1 Pressure wire preparation 
 
In the majority of cases the coronary pressure/temperature sensitive guidewire was used 
as the primary guide-wire. The guide-wire was calibrated outside the body, equalised 
within the guide catheter, with the pressure sensor positioned at the ostium of the guide 
catheter, and then advanced into the distal segment of the culprit artery.  Meticulous 
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attention was taken to ensure appropriate catheter engagement and only guide catheters 
without side holes were used in the study. Patient details were entered into the analyser 
unit which allowed recording and storage of coronary physiological data. 
 
3.2.2 Hyperaemic agent used during pressure wire studies 
 
Adenosine induces near-maximal coronary vasodilation primarily through activation of 
adenosine receptors in vascular smooth muscle.
171
 In this study we used intravenous 
adenosine administered through an anti-cubital vein at a dose of 140/micrograms/kg/min 
via a volume controlled infusion pump. The patient was then assessed for a symptomatic 
and physiological response to adenosine. When this occurred the physiological 
measurements were taken. This route of adenosine administration was chosen to allow a 
hyperaemic “steady state” to occur allowing time to take the appropriate measurements. 
Prior to administration of the intravenous infusion we administered a bolus of 
intracoronary glyceryl tri-nitrate into the coronary artery to minimise the potential effects 
of arterial spasm on the readings. 
 
Outline and timings of pressure wire readings (Figure 3.2) 
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3.2.3 Measurement of coronary wedge pressure (Pw) 
 
This was measure by balloon inflation prior to stenting within the area of the stented 
segment. When the delivery balloon was inflated, occluding antegrade flow, mean 
pressure distal to the stenosis was recorded as the coronary wedge pressure (Pw) in 
millimetres of mercury (mmHg). Post stenting Pw was recorded with a short non-
compliant balloon inflated within the stented segment to occlude antegrade flow.  
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3.2.4 Measurement of pressure derived collateral flow index (CFIp) 
 
The pressure derived coronary collateral flow index (CFIp) can be obtained from the 
Mean Pw, mean aortic pressure (Pa), and mean central venous pressure (Pv): 
 
    CFIp = Pw - Pv/Pa - Pv 
 
Maximal hyperaemia and Pw were achieved as discussed previously. Distal coronary 
pressure (Pd) was obtained from the pressure wire and aortic pressure was recorded at the 
tip of the guide catheter using a fluid filled system. CFIp (units) was calculated from the 
ratio of mean Pw (Pd during balloon inflation and complete coronary occlusion) and 
mean Pa under conditions of maximal hyperaemia (CFIp = Pw/Pa). Pv was not routinely 
recorded. However, patients who were haemodynamically compromised and likely to 
have increased Pv (cardiogenic shock, right ventricular infarction) were excluded 
 
 
3.2.5 Measurement of the index of microcirculatory resistance (IMR)   
 
IMR is calculated as the product of simultaneously measured distal coronary pressure 
(Pd) and thermodilution-derived mean transit time (Tmn) of a bolus of Saline injected at 
room temperature into the coronary artery during maximal hyperaemia induced by 
continuous intravenous infusion of adenosine (140mcg/kg/min). The inverse of Tmn has 
been shown to correlate with absolute coronary blood flow. In the absence of any stenosis 
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in the epicardial artery IMR is equal to Pd x Tmn at maximal hyperaemia. When an 
epicardial stenosis is present accurate determination of IMR requires knowledge of 
coronary wedge pressure and can be represented by the following equation:  
    
   IMR=Pa.Tmn [(Pd-Pw)/(Pa-Pw)] 
 
where Pa represents the aortic pressure measured by the guiding catheter and Pw is the 
coronary wedge pressure measured by the pressure wire during balloon occlusion as 
described previously. 
 
3.2.6 Thermodilution derived mean transit times 
 
Thermodilution curves were generated prior to and following stenting in the infarct 
related artery. We used guide catheters without side holes to allow accurate delivery of a 
saline bolus into the coronary ostium. Care was also taken to flush the catheter with 
saline thereby removing contrast which could potentially interfere with the 
measurements. Thermodilution curves in the culprit coronary artery were obtained by
 
short manual injections of 3 ml of Saline at room temperature into the coronary ostium as 
described previously. Measurements were performed in triplicate at baseline and at 
hyperaemia. Care was taken not to advance
 
or pull back the wire during these 
measurements and meticulous attention was paid to guide catheter engagement.. 
Simultaneous measurement of mean Pa and Pd in combination with Pw as described 
previously allowed off-line calculation of IMR using both methods. 
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Figure 3.3 – Thermodilution curves at baseline and hyperaemia with simultaneous 
Pa and Pd measurement as represented on the RADI analyser screen 
 
 
 
3.3Assessment of angiographic Thrombolysis In Myocardial Infarction (TIMI) flow 
grade 
 
This was recorded by the primary operator prior to and following PCI and was based on 
the following visual analysis of the coronary vascular anatomy:  
 
0,  no perfusion, no antegrade flow beyond the point of occlusion; 
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1, penetration of the occlusion but no perfusion of the coronary bed distal to the 
obstruction;  
 
2, partial perfusion of the distal coronary bed;  
 
3, complete perfusion of the distal coronary bed. 
 
3.4 ceCMR Protocols 
 
CMR scanning was performed using a Siemens Sonata 1.5 Tesla (Erlangen, Germany) 
scanner using a six channel anterior chest coil and spinal coils within the gantry table, 
during breath-hold, and gated to the ECG. Each scan was performed by one of two 
experienced operators (RM, TS), both of whom are Advanced Life Support-qualified. 
RM was present throughout all scans thereby providing constant medical cover. Prior to 
entering the controlled zone, an MRI safety checklist was performed and signed by both 
patient and qualified MRI personnel. The importance of keeping as still as possible, and 
maintaining adequate breath-holds, was reinforced verbally prior to commencement of 
the scan. End-expiration is optimal for consistent breath-holding and was preferred. 
 
3.4.1 Preparation of patient for the scan 
 
The following steps were performed in all cases: 
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 Patient demographic details entered on scanner database 
 The power injector (Medrad Spectris, Volkach, Germany) for administration of 
the contrast agent (gadolinium diethylenetriaminepentaacetic acid, DTPA, GE 
Healthcare) was prepared. The Medrad injector contains two quick-fit syringes 
connected by a Y-tubed delivery set. Into syringe A, gadolinium-DTPA was 
drawn at a dose of 0.1mmol/kg. Syringe B contained 50ml 0.9% sodium chloride 
 Patient placed on table 
 Siemens active Brooker ECG electrodes placed on patient’s anterior chest wall, 
and position varied to obtain an optimal R wave 
 A 20G IV cannula was placed in a peripheral vein, and connected to the Medrad 
injector. 
 The six channel phased-array chest coil (Siemens CP body array flex) was applied 
and aligned 
 Patient, wearing ear protectors or headphones, enters scanner 
 Medrad power injector armed 
 
 
3.4.2 Clinical assessment prior to ceCMR scan 
 
As part of the larger study assessing safety and feasibility of CMR scanning following 
STEMI, each patient underwent an ECG to assess cardiac rhythm recorded, pulse and 
blood pressure taken and clinically assessed for evidence of heart failure and scored 
according to the Killip classification. 
172
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3.4.3 Left Ventricular structure and function 
 
All CMR scans commenced with a multi-slice breath-hold localiser. Each of the 
localisers described in this section used the same protocol: 
 
Protocol: Multi-slice single-shot breath-hold true fast imaging with steady-state 
precession (trueFISP) localiser with transverse, Sagittal and coronal slices. Settings: field 
of view = 360mm, field of view phase = 81.3%, slice thickness = 6mm, repetition time 
(TR) = 3.41ms, echo time (TE) = 1.71ms, flip angle = 60
o
, averages = 1, phase resolution 
= 80%, phase oversampling = 0% 
 
From these images, the best axial image depicting the LV and septum was selected 
(Figure 3.4 A). If no suitable image was produced by the initial localiser, a second axial 
localiser was performed using the coronal images until the closest match to Figure 3.4 A 
was obtained. This was used to plan 3 vertical long axis (VLA) parallel localisers along 
the long axis of the LV from the mid-point of the mitral valve to the apex. 
 
From the resulting VLA scan, 3 horizontal long axis (HLA) localisers were then planned, 
using the mid-point of the mitral valve and the LV apex to prescribe the orientation 
(Figure 3.4 B). This resulted in 3 HLA slices (Figure 3.4 C). Using the atrioventricular 
groove as a landmark, 3 short axis (SA) localiser slices were planned, with the most basal 
slice positioned in the atria to depict the left ventricular outflow (Figure 3.4 C). From the 
118 
 
resulting SA images, 3 long axis views can be prescribed – the 4-chamber, 2-chamber 
and left ventricular outflow tract (LVOT) views (Figure 3.4 D).  
 
3.4.4 Cinematographic (cine) imaging 
 
Having thus acquired 3 orthogonal long axis views, cine studies were acquired in each of 
these 3 orientations, as follows: 
Protocol: trueFISP breath-hold cine. Settings: field of view = 360mm, field of view phase 
= 81.3%, slice thickness = 8mm, TR = 47.4ms, TE = 1.58ms, flip angle = 60
o
, averages = 
1, measurements = 1, phase resolution = 65%, phase overSAmpling = 20%, segments = 
15. 
These images were used for visual analysis of structure and long axis function. 
 
3.4.5 Short axis cine stack 
 
Quantitative volumetric assessment of ventricular function requires that the LV be 
divided into a stack of short axis (SA) slices from base to apex. Measurements from each 
slice are then summed to provide overall ventricular mass and volumes, from which 
LVEF can be calculated. The SA stack was prescribed from the 4-chamber HLA cine 
already acquired. Using the end-diastolic image from this view, the cursor was positioned 
in an orientation across the mitral valve plane through the atrioventricular groove (as a 
marker of the most basal SA slice) as in Figure 3.4 E. The most basal slice that results is 
depicted in Figure 3.4 F. The slice position was then incremented by 10mm moving 
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towards the apex of the LV and repeated until the LV was completely covered; inter-slice 
gaps of 2 mm were used. A representation of the final SA cine stack is shown in Figure 
3.4 G. The Same protocol was used for all SA cine slices: 
 
Protocol: trueFISP breath-hold cine. Settings: field of view = 340mm, field of view phase 
= 81.3%, slice thickness = 8mm, interslice gap = 2mm, TR = 47.4ms, TE = 1.58ms, flip 
angle = 60
o
, averages = 1, measurements = 1, phase resolution = 65%, phase over 
sampling = 20%, segments = 15 
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Figure 3.4 Planning of cine CMR image acquisition. From transverse, Sagittal and 
coronal scout images, the best image of the LV and septum is selected (A) and then 
used to produce a vertical long-axis (VLA) localiser (B). Orientating the next scan 
through the apex and mid-point of the mitral valve (B – orientation line) creates a 
horizontal long-axis (HLA) localiser (C). Using the atrioventricular grooves as 
landmarks (C), a perpendicular plane to this HLA localiser is prescribed (D), based 
on which three orthogonal long-axis planes can be planned (2-chamber, 4-chamber 
and LV outflow tract views). Cine images are acquired for each of these three long-
axis orientations. Finally a short-axis cine stack is planned on the 4-chamber HLA 
cine image (E). A short-axis image is acquired of the base of the LV (F), from which 
slice position is advanced at 10mm intervals from base to apex, creating a short-axis 
cine stack (G). 
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3.5 Contrast imaging 
 
3.5.1 First-pass perfusion imaging 
 
The visualisation of first-pass myocardial perfusion following bolus contrast injection 
requires ultra-high speed MR imaging. A balanced single-shot turbo fast low angle-shot 
(FLASH) sequence with a saturation recovery pre-pulse before each slice was employed. 
This typically allowed 3 SA slices (copied from the cine SA stack) to be acquired per 
heart-beat. No breath-hold was required. The weight-adjusted dose of gadolinium-DTPA 
was delivered into a peripheral vein via the Medrad power injector at a constant rate of 
6ml/s, followed by 0.9% sodium chloride flush. The first-pass protocol was as follows: 
 
Protocol: first-pass single-shot turbo-FLASH sequence with Saturation recovery 
preparation, 3 slices per heartbeat. Non-breath-hold, controlled respiration. Settings: field 
of view = 340mm, field of view phase = 81.3%, slice thickness = 8mm, TR = 183ms, TE 
= 0.99ms, flip angle = 8
o
, averages = 1, measurements = 60, time to inversion (TI) = 
100ms 
 
3.5.2 Imaging of early microvascular obstruction 
 
At 2 to 5 minutes after contrast injection, images were acquired for the determination of 
“early” MVO. This required a single-shot steady-state free precession sequence with a 
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non-selective inversion pulse. No breath-hold was required. Typically three to five SA 
slices per heartbeat were acquired, copied from the SA cine stack. A single-shot sequence 
was acquired at each of four time-points: 2, 3, 4 and 5 minutes after contrast injection. 
The protocol for early MVO imaging was as follows: 
Protocol: ECG trigger, 100 lines field of view = 270 x 360, slice thickness = 8mm, 
interslice gap = 2mm, flip angle 30
o
, TE 1.2ms, TR 2.7ms, TI 200-350ms, bandwidth/ 
pixel = 980 Hz, matrix 256. 
 
3.5.3 Late gadolinium-enhancement imaging 
 
15 minutes after bolus contrast injection in all scans, ceCMR images were acquired. This 
utilised a contrast-sensitive segmented inversion recovery sequence to acquire a second 
stack of SA images (positions copied from the SA cine stack). Images were also acquired 
in three long axis views, with orientations copied from the cine 4-chamber, 2-chamber 
and LVOT views. Adequate breath-holding was essential for each acquisition. The 
protocol was as follows: 
 
Protocol: Breath-hold segmented re-phased Turbo-FLASH sequence with non-selective 
inversion pulse with non-slice selective inversion-recovery.  
 
Constant settings: field of view = 340mm, field of view phase = 81.3%, slice thickness = 
8mm, interslice gap = 2mm, TE = 4.3ms, flip angle = 30
o
, averages = 2, segments = 25, 
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phase resolution = 65%, trigger delay = 0, trigger pulse = 2 (but dependent to an extent 
on heart-rate: trigger on pulse 1 if bradycardic, or pulse >2 if tachycardic). 
 
Variable settings 
 
The acquisition window was set greater than RR-interval and TR just under to allow for 
diastolic imaging. TI was 220ms (for initial scan) and adjusted according to image quality 
by 10ms steps within the range 200-300ms to optimise image quality. The TI was often 
varied between image acquisitions, and if the quality of the preceding image was poor it 
was repeated until an image of adequate quality was obtained. Optimal TI and TR 
produced a diastolic image with black (nulled) myocardium and bright late enhancement 
area (Figure 3.5 A). If late MVO was present, it appeared as a dark hypoenhanced core 
within the bright hyperenhanced area (Figure 3.5 B). 
 
 
 
Figure 3.5  Mid-ventricular short-axis slices acquired using a contrast-sensitive 
segmented inversion recovery sequence 15 minutes after injection of gadolinium-
DTPA, from two separate patients admitted with anterior STEMI. (A) 
Subendocardial region of hyperenhancement affecting the anteroseptal wall of the 
LV, surrounded by normal (nulled, dark) myocardium; there is no MVO present. 
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(B) Full-thickness infarction of the anteroseptal wall of the LV reveals 
hyperenhancement throughout wall, from endocardium to epicardium, with a 
hypoenhanced core – this core represents (late) MVO. 
 
 
 
 
3.6 CMR analysis methodology 
 
 
3.6.1 LV volumes and ejection fraction 
 
 
Post-processing was performed using commercially-available Argus software (Siemens, 
Erlangen). The number of slices required to cover the LV in end-diastole and end-systole 
varied from scan to scan dependent on the long axis diameter of the LV. End-systole was 
chosen as the point where the total LV blood pool was smallest and end-diastole as the 
point where it was largest. The most basal LV slice at both end-systole and end-diastole 
was defined as that in which the blood pool was surrounded by 50% or more of 
ventricular myocardium; papillary muscles were excluded from the LV volumes and 
included in the LV mass. Manual digital planimetry was performed on endocardial and 
epicardial contours using the short axis cine images at both end diastole and end systole 
in random order by a single observer (RM) blinded to the pressure wire results. The scans 
were anonymised and randomised prior to analysis. Simple addition of the individual 
slice volumes in this stack of contiguous slices covering the entire LV allowed 
calculation of LVESV and LVEDV (ml), therefore allowing the calculation of LV 
ejection fraction (LVEF). LV myocardial mass (LVM) was estimated to be the mean of 
the total difference between the inner and outer circumferences of the LV myocardium in 
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end-diastole and end-systole, multiplied by the myocardial density (taken as 1.05 g/cm
3
). 
All CMR measurements were adjusted for total body surface area.  
 
3.6.2 “Early” Microvascular Obstruction 
 
“Early” MVO previously known as simply microvascular obstruction “MO” is the term 
used for assessment of MVO in the early stage following gadolinium-DTPA injection.  
Quantitative analysis of the size and extent of both the first-pass defect and early MVO 
can be imprecise as it requires multiple geometric assumptions due to the limited number 
of SA slices acquired during ultra-fast imaging. However although less evidence is 
available regarding this the mass of hypo-enhanced tissue could be calculated by 
multiplication of the volume following digital planimetry by the myocardial density 
factor (1.05g/cm
3
). Early MVO was also graded as present or absent. 
 
More recently literature comparing “early” MVO with “late” or persistent MVO has 
emerged suggesting that in contrast to early MVO, the presence and extent of late MVO 
is a strong independent predictor for the occurrence of death, non-fatal MI, myocardial 
reinfarction and congestive heart failure after STEMI.
106, 173
 
 
3.6.3 Late gadolinium enhancement, infarct volumes and late/ persistent MVO 
 
Analysis of the delayed enhancement images was also performed using Argus software 
(Siemens, Erlangen). Again the scans were anonymised and randomised and the 
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perimeter of the hyper-enhanced region on each SA slice was traced by a single observer 
(RM) blinded to the pressure wire results. Acute infarction was considered present only if 
LGE was confirmed on both the short and long axis acquisitions and corresponded with a 
wall motion abnormality on cine imaging. The myocardial mass of LGE (grams) was 
quantified by a semi-automatic detection method using a signal intensity threshold of >2 
SD above a remote reference region. Argus software also facilitated summation of the 
volume of enhanced tissue from each slice, producing a measure of infarct volume (ml). 
The mass of hyper-enhanced tissue could be calculated by multiplication of the volume 
by the myocardial density factor (1.05g/cm
3
).  
 
One major issue relevant to analysis of late hyper-enhanced images pertains to partial 
volume effect. The thickness of each slice is 8mm, but within this the pattern of late 
hyper-enhancement is not necessarily homogeneous. This irregularity can result in 
blurring of the infarct border. In some slices, towards the periphery of the hyper-
enhanced area, regions are occasionally seen wherein the brightness level is intermediate 
between normal (black, nulled) myocardium and bright, hyper-enhanced myocardium. 
There is a lack of universal consensus on whether (and how) to account for this partial 
volume effect in the quantitative measurement of late hyper-enhanced tissue.  In this 
study, in order to maintain consistency in our results, we decided to include everything 
that was hyper-enhanced, taking no account of partial volume effects.  
 
Late MVO was defined as an area of hypo - enhancement (black) within the area of 
hyper-enhanced (bright) infarcted tissue. The perimeter of the dark area within the hyper-
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enhanced was traced using digital planimetry on each short axis slice using the same 
method as described above for infarct volumes. In cases of doubt about the nature of the 
hypo-enhanced area on short axis slices, the long axis slices were used, to differentiate 
late MVO from partial volume effects. The mass of hypo-enhanced tissue could be 
calculated by multiplication of the volume by the myocardial density factor (1.05g/cm
3
). 
Evidence thus far has simply indicated that the presence of MVO is associated with 
adverse outcomes therefore
15
, as with early MVO the presence or absence of MVO was 
also recorded. The presence of MVO was recorded by two experienced and blinded 
observers (AP, RM). When there was disagreement between the two observers a third 
experienced observer (CB) had the final say. As stated above late or persistent MVO is 
now associated with adverse clinical outcomes and is becoming the method of choice for 
assessment of MVO in this patient group given that it also allows further characterisation 
of the infarct with the images being coincident late gadolinium images.
174
  
 
3.6.4 Site of myocardial infarction 
 
The anatomical location of the infarct was based on the AHA standardised 17-segment 
model.  Site of myocardial infarction was defined as anterior, inferior or lateral 
depending on the area in which the highest percent of infarcted tissue was visualised. The 
right ventricular insertion points were used as anatomical markers. 
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Figure 3.6: The 17 segment American Heart Association model for anatomical assessment of 
myocardial infarction in the ventricular short axis CMR images 
 
3.6.5 Transmural extent of myocardial infarction 
 
This was visually graded on a segmental basis of transmural extent of hyperenhanced 
tissue according to the following scheme: 0, no infarction; 1, 1% to 25% of LV wall 
thickness; 2, 26% to 50% of LV wall thickness; 3, 51% to 75% of LV wall thickness; and 
4, 76% to 100% of LV wall thickness. This number was them divided by the number of 
affected segments to give a mean, or transmurality score.
175, 176
 
 
3.6.6 Assessment of LV remodelling 
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LV remodelling is defined as the change in left ventricular end systolic volume, indexed 
to body surface area (LVESVI), over time.  An increase in LVESVI over time is termed 
adverse ventricular remodelling.
100
  
 
3.6.7 Timing of CMR scans 
 
Animal studies have shown that MVO whether early or late as assessed by CMR can 
increase in size up to 48 hours.
113
 A further study in the canine model has shown that 
MVO remains essentially unchanged at 2 days and 9 days post infarct.
114
 However 
further work by Albert et al revealed that in 96 patients imaged on different days 
following acute MI, MVO prevalence fell dramatically beyond 48 hours from the infarct 
(with a decrease in prevalence of greater than 50% within the first 7 days). 
174
 Therefore 
there is as yet no consensus on the optimal timing for imaging in this patient group. 
Given the evidence available our aim was to perform all ceCMR scans at around 48h 
following reperfusion. 
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3.7 Assessment of “traditional” indices of microvascular 
and myocardial damage 
 
3.7.1 Electrocardiographic assessment  
 
ST segment resolution (STR) was calculated as the percent resolution in the single lead 
with the maximum baseline ST segment elevation in the pre and post reperfusion ECGs.
43
 
If thrombolysis was achieved successful ECG and symptomatic reperfusion the 
diagnostic ECG and the 90 minute ECG were used. If rescue or primary PCI was needed 
the diagnostic and post catheter laboratory ECGs were used.  
 
3.7.2 Assessment by corrected Thrombolysis In Myocardial Infarction Frame Count 
(cTFC) 
 
Corrected TIMI frame count was calculated as the number of frames for dye to reach a 
standardised distal landmark in each angiographic territory. The first frame taken for the 
measurement was the frame in which dye touched both borders of the coronary artery in 
question and moved forward with at least 70% of the vessel lumen opacified. The 
standardised distal landmarks were taken as the first branch of the postero-lateral artery 
for the right coronary artery, the most distal branch of the obtuse marginal for the 
circumflex, and the distal bifurcation of the LAD. The number of frames from the first 
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frame to the last frame when the dye entered the standardised distal landmark was 
counted. 
 
A standard image acquisition speed of 30 frames per second was used. The correction 
factor used to account for the increased length of the LAD compared to the right and 
circumflex arteries was 1.7 thereby giving a “corrected TIMI frame count”.   
 
3.7.3 Biochemical assessment 
 
Troponin I concentration in cubital venous blood was measured 12 - 24 h post-MI using 
an automated analyser (Advia Centaur, Bayer Diagnostics). The limit of detection was 
<0.2 µg/L 
 
3.8 Statistical methods 
 
A sample size of 50 patients was calculated to have a power of (1-beta) 0.90 to detect a 
minimally significant correlation coefficient (R) of 0.45 between IMR and infarct size by 
ceCMR with a type 1 error rate of 0.05.  
 
Invasive markers of microvascular function (coronary wedge pressure, fractional 
coronary collateral supply and the index of microcirculatory resistance) were non-
normally distributed and are summarised with the median value and inter-quartile range 
(IQR). The Mann Whitney test was used to compare these data between patients with or 
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without MVO as revealed by ceCMR. An elevated IMR was defined as > than the median 
value.  
 
Log transformed invasive markers of microvascular function and other clinical features 
were compared to ceCMR outcomes using univariate regression analysis.  The variance 
in each model was expressed using the coefficient of determination, r
2
. The univariable 
predictors with a p value of less than 0.1 were entered into a multivariate model. Since 
our focus was to evaluate the predictive value of IMR compared to other clinical 
characteristics which were available at the time of primary PCI, only variables which 
were clinically available at that time, such as time-to-reperfusion but not troponin 
concentration, were included in the multivariable models.  A p value <0.05 was 
considered statistically significant. Statistical analyses were performed on MINITAB 14 
software and NCSS 2007. 
 
3.9 Funding of the study 
 
This work was funded by a project grant from the Chief Scientists Office Scotland 
(CZB/4/572). 
 
3.10 Sponsoring of the study 
 
The trial was sponsored by the North Glasgow University Hospitals NHS Trust. 
134 
 
 
 
 
Chapter 4: Demographics, admission 
data, angiographic 
and cardiac MRI results 
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4.1 Patient screening and recruitment 
 
A total of 77 patients were consented for the study between 04/01/2007 and 28/02/2008. 
Of these 8 patients were deemed not suitable for pressure wire study, in each case 
because no percutaneous coronary intervention was needed or possible. (3 patients with 
severe 3 vessel disease, 2 patients with small side branch occlusion only and 1 with 
calcified vessels unable to wire and 2 with no overt coronary artery disease). Therefore 
69 patients had successful coronary physiological studies at the time of PCI. Of these 12 
patients did not have cardiac MRI imaging. Five patients refused and did not give a 
reason, 4 were stated they were claustrophobic and 3 were deemed to be unstable due to 
runs of non-sustained ventricular tachycardia.  
 
This left 57 patients with successful physiological assessment and a baseline cardiac MRI 
scan. Of these, 47 had complete follow up scans. In addition a total of 47 patients had 
complete pre and post stenting physiological assessment.  
 
4.2 Demographics 
 
Of the 69 patients who underwent physiological assessment with pressure wire at the 
time of PCI, 60 (87%) were male and the mean (standard deviation [SD]) age was 58 
(10.6). The majority (97%) were of Caucasian origin. 
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Within the study population cardiovascular risk profile included hypertension in 20 
(29%), dyslipidaemia (defined as serum total cholesterol >5mmol/l and/or on lipid-
lowering therapy prior to admission) in 17 (25%), current smoking at the time of 
admission in 36 (52%) and a family history of premature coronary artery disease (defined 
a myocardial infarction in a first degree relative <60 years) in 10 (14%) of patients. Past 
medical history included myocardial infarction in 5 (7%), angina in 6 (9%), previous PCI 
in 4 (6%), cerebrovascular disease in 4 (6%), diabetes (type 2) in 4 (6%) and peripheral 
vascular disease in 1 patient.  No patients in the study had previously document left 
ventricular systolic dysfunction.  
 
4.2.1 Index event 
 
The reason for PCI in the study population (n=69) was primary PCI in 32 (46%) patients, 
rescue in 21 (31%) and prognostic (defined as PCI within 24 hours of successful 
reperfusion by thrombolysis) in 16 (23%). In total 37 patients received thrombolysis, with 
tenectaplase being used in every instance. 
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Figure 4.1: ECG defined site of MI. Anterior = 36, inferior = 29, posterior = 3, 
lateral = 1 (n=69). 
 
 
4.2.2 Admission blood results 
 
 
 
 Mean (Standard deviation) 
Haematology (n=69)  
             Haemoglobin (g/dl) 14.1 (1.4) 
             White cell count x 10
3
/µL 11.5 (2.8) 
             Platelets x 10
3
/µL 251 (82) 
Biochemistry  (n=69)  
             Sodium (mmol/l) 138 (2.8) 
             Potassium (mmol/l) 4.0 (0.4) 
             Urea (mmol/l) 5.4 (1.5) 
             Creatinine (mol/l) 92.4 (15.9) 
             Glucose (mg/dl) 7.2 (2.1) 
             C – Reactive Protein (mg/dl) 21.1 (24.1) 
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Table 4.1: Laboratory values on admission to hospital with index event 
 
 
 
4.2.3 Timescale of presentation and treatment 
 
The median [interquartile range] time from symptom onset to presentation was 120 [66 – 
240] minutes and the range within the study population was 0 minutes (for a patient who 
was already an inpatient) to 1620 minutes. The median [interquartile range] time from 
symptom onset to reperfusion by thrombolysis or PCI was 300 minutes [150 – 438] with 
the range being 30 minutes to 1740 minutes. 
 
4.2.4 Angiographic and PCI data 
 
The culprit artery as defined by the primary operator at the time of PCI was the left 
anterior descending (LAD) in 37 (54%) cases, the right coronary artery (RCA) in 28 
(40%) and the circumflex (Cx) in 4 (6%) of patients. 
Culprit artery 
*
  n (%) 
LAD 37 (54%) 
RCA 28 (40%) 
LCx 4 (6%) 
Stent type  n (%) 
Bare metal 45 (69%) 
Drug eluting 19 (28%) 
Balloon angioplasty 5 (7%) 
Stent data 
 
mean (SD)
†
 
Number of stents 1.4 (0.74) 
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Stent diameter (mm) 3.2 (0.45) 
Stent length (mm) 26.9 (16) 
Adjunctive therapy 
 
n (%) 
Aspirin (300mg) 69 (100%) 
Clopidogrel (300mg) 69(100%) 
  Glycoprotein 2b3a inhibitor 52(75%) 
Aspiration thrombectomy 31(45%) 
 
Table 4.2: Angiographic data for the study population. Data are presented as mean 
(SD) for continuous variables and number (%) for categorical variables. 
*
 Branch 
artery occlusions ie diagonal/obtuse marginal were categorised with the main 
epicardial artery. 
†
 n=64 
 
 
 
4.2.5 Medication on discharge 
 
 
The discharge medication of the study population is outlined in the table below. 
 
 
 n (%) 
Aspirin 69 (100%) 
Clopidogrel 69 (100%) 
Beta Blocker 58 (84%) 
ACE - Inhibitor 66 (96%) 
Statin 69 (100%) 
 
Table 4.3: Summary of standard cardiovascular secondary prevention medication at 
discharge from hospital in the study population. 
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4.3 Physiological assessment using pressure wire at the time of PCI 
 
The protocols and timings of these measurements are described in the chapter 3. All 
patients had measurements taken at the end of the procedure and 47 (69%) patients also 
had pre stenting measurements. In one patient the distal coronary wedge pressure tracing 
was unsuitable for analysis and was not included. As this patient was treated only with 
balloon angioplasty we did not feel it was appropriate to perform a further balloon 
inflation in an attempt to re-record the coronary wedge pressure. A summary of the 
pressure wire data is detailed below: 
 
 Pre-stenting (n=47) Post-stenting (n=69) 
Pw
*
 (mmHg) 21 (15–26.3) 23 (16.3-30) 
Mean transit time 
at rest (s) 
0.95 (0.63-1.60) 0.73 (0.45-1.22) 
Mean transit tine at 
hyperaemia (s) 
0.71 (0.47-1.02) 0.47 (0.33-0.70) 
FFR (units) 0.79 (0.73-0.86) 0.89 (0.79-0.94) 
CFR (units) 1.3 (1.11-1.45) 1.55 (1.31-1.72) 
CFIp
*
 (units) 0.25 (0.2-0.31) 0.27 (0.2-.0.34) 
IMR inc Pw
* 
(units) 36.55 (24.7-62.6) 32.0 (22.3-52.3) 
IMR (units) 41.3 (28.3-66.9) 34.8 (22.9-53.8) 
 
 
Table 4.4. A summary of pressure wire data pre and post stenting in the study 
population. All data are expressed as median (intra-quartile range). IMR inc Pw 
was calculated from the following equation “Pa.Tmn [(Pd-Pw)/(Pa-Pw)]” and IMR 
was calculated using Pd.Tmn as mentioned previously. 
*
 n=68. 
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4.4 CMR data and analysis 
 
 
4.4.1 Overview 
 
 
Of the study population 57(83%) patients in total consented for CMR imaging. Of these 
54 patients had complete scans as per protocol described in the methods section. 
Scanning was stopped early in 4 patients as these patients felt they were no longer able to 
tolerate the examination. Of these 4 patients, complete cine images were taken in all 
allowing analysis for LV volumes and ejection fraction. Gadolinium was administered in 
only one of these patients and “early MVO” images were taken prior to the patient 
requesting to finish the examination. 
 
In summary 57 had complete cine images, 54 had “early MVO” sequences taken and 53 
had “late gadolinium” sequences allowing assessment of infarct volume and “late MVO” 
 
All patients were invited back for the follow up scan at 3 months. Fifty (88% of the initial 
CMR group) attended. Of these one gentleman was under the influence of alcohol on 
attendance and was therefore excluded from the study on safety grounds. Forty nine 
patients (87% of the CMR group) underwent a further ceCMR examination, all 
completing cine sequences. Two patients did not receive gadolinium, one as a 
consequence of a deterioration in renal function post MI and one because they felt unable 
to continue with the scan. 
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The mean (SD) time from PCI to scan one was 34 (16.1) hours. The mean (SD) time 
between the baseline scan and the follow up scan was 91.3 (5.4) days.  The mean (SD) 
time for scan 1 was 41 (10.7) minutes and for scan 2 39.3 (9.4) minutes. Forty four 
patients were deemed to by Killip score 1 and the remaining 13 were Killip score 2 at the 
time of the initial CMR scan.  
 
4.4.2 Analysis of baseline and follow up ceCMR scans 
 
All scans were analysed as described in the chapter 3. The results are summarised in the 
table below 
 
 
CMR variables 2 days post-MI 3 months post-MI 
LV ejection fraction (%) 55.2 (11.9) 61.9 (10.8) 
LV end-diastolic volume (ml) 130 .5 (29.3) 147.1 (32.9) 
LV end-systolic volume (ml) 58.1 (21.0) 57.1 (24.4) 
LV mass (g) 133.1 (32.8) 136 (29.7) 
LV end-diastolic volume index (ml/m
2
) 68.2 (13.6) 74.3 (17.8) 
LV end-systolic volume index (ml/m
2
) 30.5 (10.8) 28.9 (12.4) 
LV infarct volume (ml)
 
23.1 (22.6) 12.1 (11.2) 
LV infarct mass (g) 24 .2 (23.7) 12.4 (11.7) 
143 
 
LV mass/infarct ratio (%) 17.3 (14.8) 9.16 (8.94) 
Transmurality score 2.25 (0.86) 1.89 (0.74) 
“Early” MVO;  n (%) 27 (50) - 
“Early” MVO volume (ml) 9.2 (7.4)  
“Early” MVO mass (g) 9.6  (7.8)  
LV mass/ “early” MVO ratio (%) 6.7  (4.9)  
“Late” MVO; n (%) 27 (51) - 
“Late” MVO volume (ml) 6.6 (7) - 
“Late” MVO mass (g) 6.8 (7.1) - 
LV mass/ “late” MVO ratio (%) 4.7 (4.5) - 
 
Table 4.5. Summary of CMR data at baseline and follow-up.  Data are expressed as 
mean (standard deviation). 
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4.5 The influence of anatomical site of myocardial infarction and 
therapeutic interventions at the time of emergency PCI on coronary 
pressure wire derived indices of microvascular obstruction. 
 
 
Following electrocardiographic analysis 32 infarcts were defined as inferior/posterior and 
37 as anterior/lateral at the time of presentation. Pressure wire data following PCI were 
grouped by these criteria and compared in the table below. 
 
 Inf/post STEMI Ant/lat STEMI P value 
Median IMR [IQR] 29.2 [22.7-52.6] 37.8 [26.4-54.6] 0.43 
Median CFIp [IQR] 0.30 [0.22-0.36] 0.26 [0.19-0.31]
* 
0.13 
Median Pw [IQR] 24.0 [17.0-30.8] 22.5 [16.0-26.8]
* 
0.47 
 
Table 4.6: Comparison of pressure wire data post PCI by ECG site of STEMI at 
presentation. Non-normal data compared using the Mann Whitney test. 
* 
(n=36) 
 
There was no significant difference in the pressure wire data post PCI by site of STEMI. 
 
4.6 A comparison of pressure wire data by primary operator’s choice of 
treatment at the time of emergency PCI. 
 
All patients in the study were loaded with 300 mg aspirin and 300mg of Clopidogrel prior 
to emergency PCI. It was the primary operator’s preference whether to use a glycoprotein 
2b3a inhibitor in the peri-procedural period, to use aspiration thrombectomy or to use 
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drug eluting stents at the time of PCI. These are compared in the table below. 
 
 n 
Median IMR 
[IQR] 
Median CFIp 
[IQR] 
Median Pw 
[IQR] 
GP2b3a 52 36.1 [23.4-54.2] 0.28 [0.2-0.33] 22 [16-30] 
No GP2b3a 17 34.1 [17.4-52.2] 0.28 [0.21-0.34] 24.5 [17.3-30.5] 
P value  0.46 0.99 0.61 
Aspiration 31 30.6 [23.1–41.5] 0.27 [0.19-0.34] 22 [16-30] 
No aspiration 38 37.3 [22.8-54.7] 0.29 [0.22-0.34]
* 
23 [16.5-29.5]
* 
P value  0.55 0.75 0.81 
DES 19 34.3 [20.1-47.8] 0.27 [0.23-0.35] 25 [20-32] 
BMS/POBA 50 35.2 [23.2 56.6] 0.28 [0.19-0.33]
† 
25 [20-32]
† 
P value  0.39 0.61 0.25 
 
Table 4.7: Comparison of physiological indices for microvascular dysfunction taken 
following PCI by primary operator’s therapeutic choices in the peri-procedural 
period. The Mann Whitney test was used for comparison of non-normal data. 
*(n=37) †(n=49)  
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4.7 Discussion - Demographics, admission data, angiographic and 
cardiac MRI results 
 
4.7.1 Demographics and patient characteristics 
 
 
In any study looking at STEMI it’s useful to put the patient population into the context of 
historical and contemporary work. The mean age of patients in this study was just under 
60 and the overwhelming majority were male, findings consistent with  contemporary 
AMI studies.
177
 Furthermore the demographics are in keeping with the Scottish STEMI 
population.
3
 The patient population is this study was therefore in keeping with the study 
population in wider international AMI studies as well as being representation of the 
STEMI population in a national basis. 
 
Although only a small number of previous studies have taken coronary physiological 
assessment using pressure wire in the AMI population, the patient population in this 
study is in keeping with these.
45
 In particular, Fearon et al reporting a mean age of 62 
and the majority of subjects male although the small numbers in this patient population 
contained a larger proportion of patients with hypertension and dyslipidaemia and a lower 
number of tobacco smokers. Broadly speaking the patient population is this study was 
similar to others in this field.
47
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Again small numbers of studies using the pressure wire at the time of STEMI had been 
done by the time of this work but again the proportion of successful physiological 
measurements was in keeping with previous work in this area.
47, 141
  
 
I am not aware, at this point, of any previous studies which have enrolled patients prior to 
emergency PCI and then re-consented the patients after physiological assessment but 
prior to CMR scanning. Given the clinical uncertainties within this patient group I feel 
that 57 patient undergoing baseline MRI scan is satisfactory from 69 whom had given 
initial consent. A successful follow up MRI scan rate of around 80% is also in keeping 
with previous MRI studies with the AMI population.
15
  
 
The study population were discharged from hospital with high levels of uptake of 
secondary preventative medications, with 100% on statin therapy, 84% on beta-blockers 
and 96% on ACE – inhibitors. Given that all of the study patients had underwent 
emergency PCI in the context of STEMI then anti-platelet therapy uptake of 100% on 
discharge is to be expected. 
 
The study population under investigation in this thesis therefore represents a very well-
treated cohort whose demographics, successful pressure wire and MRI scan rates are in 
keeping with previous studies within these fields. 
 
4.7.2 Pressure wire data in comparison with previous studies 
 
148 
 
There have been increasing numbers of studies published looking at pressure wire indices 
for microvascular dysfunction, principally IMR, in recent years and to a lesser extent 
CFIp.  
 
One study in which CFIp was performed in 28 patients a mean of 3.3 days following first 
acute myocardial infarction treated with thrombolysis the mean value was 0.17 
units.
145
Previous work performed by Balachandran et al in the West of Scotland found a 
mean CFIp of 0.25 units when perform during rescue PCI following failed thrombolysis. 
141
 The median value in my mixed (primary, rescue and prognostic) study was 0.27 units 
following PCI and 0.25 units prior to PCI. This is in keeping with the limited body of 
work in this area. CFIp in my study is higher than in the work by Sezer et al but this 
could be explained by the 3.3 day time lapse between thrombolysis and pressure wire 
study in the Turkish group’s study. 145 
 
There are more studies in the literature looking at IMR in acute myocardial infarction. 
Within these there are variations in the timing of the pressure wire studies in relation the 
emergency PCI. Furthermore some studies are limited to looking only at anterior 
myocardial infarctions. I have summarised these in the table below including my own 
data. 
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Authors Year 
Number of 
patients 
Site of MI Timing 
Median 
IMR 
Fearon et al
47
 2007 29 All At PCI 32 
Ito et al
137
 2009 40 All At PCI 26 
Sezer et al
178
 2010 35 All 
48h post 
PCI 
29 
Lim et al
179
 2009 40 
Anterior 
only 
At PCI 33 
McGeoch et 
al
180
 
2010 57 All At PCI 35 
Table 4.8: Comparison median IMR in this study with contemporary work in this 
field. 
 
The median IMR in my study was slightly higher than those in previous work in the field. 
It is not surprising that it is higher than the study by Sezer at al as you may expect IMR to 
decrease in the days following the acute event. I also included a significant proportion of 
patients whom had underwent rescue PCI and this increased the median IMR.  
 
Overall I feel that the invasive coronary physiological measurements in my study were 
similar the contemporary work in this field.  
 
4.7.3 CMR results in comparison with previous studies 
 
As discussed previously contrast enhanced CMR is a well validated and robust technique 
for assessment of left ventricular ejection fraction, MVO and infarct sizes following 
myocardial infarction. In order to improve the validity of my work it is however 
important that my study is not taken in isolation and that my CMR analysis was in 
keeping with contemporary CMR studies in this area. 
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One of the landmark studies linking CMR findings with prognosis following myocardial 
infarction was the work by Hombach et al
15
 published in 2005. They studied 110 patients 
a mean of 6.2 days after AMI. Infarct size was 12% of total LV muscle mass and MVO 
was detected in 47% of patients.  I think that these results are in keeping with my own 
work, infarct size of 17% and MVO in 51% of patients. I think that the differences 
between the two studies can be explained by the time differences between myocardial 
infarction and scanning.  
 
Infarct size shrank from 12% to 7.8% at follow up (mean 225 days) and no MVO was 
seen at follow up. Again this is similar to the decrease in infarct size in my study which 
fell to 9% at follow up, with no MVO found. In addition similar to my own work LVEF 
and LVEDV increased and LVESV decreased during follow up. 
 
A more recent study by Cochet et al published in 2009 which again looked at the 
prognostic significance of MVO following re-perfused myocardial infarction found the 
aforementioned present in 47% of patients.
106
 
 
Wu et al
181
 studied 122 patients whom underwent CMR scanning within 1 week of 
myocardial infarction and follow up at 3 months. Similar to this work the mean age was 
57 and 83% were male. In this patient population the mean infarct size was 22% of the 
LV mass and the mean ejection fraction was 41%. They found that follow up infarct size 
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decreased by 22%. They also noticed an increase in LVEF and LVEDV and a decrease in 
LVESV. 
  
It can therefore be seen that although natural variations will apply, the CMR analysis data 
for my study cohort is in keeping with contemporary work in this area. 
 
4.8 Conclusion 
 
The raw data on which this thesis is based, patient population, coronary physiological 
data and CMR analysis is in keeping with contemporary work in each of these areas. 
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Chapter 5: The relationship between 
coronary pressure wire derived indices of 
microvascular dysfunction at the time of 
emergency PCI with microvascular and 
myocardial damage on cardiac MRI 
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5.1 Introduction 
 
Emergency percutaneous coronary intervention (PCI) is the established treatment for ST 
elevation myocardial infarction (STEMI). Despite achieving normal epicardial artery 
flow in the majority of patients up to one third of patients do not achieve myocardial 
microvascular reperfusion.
26, 182
Microvascular dysfunction in this setting is associated 
with an adverse prognosis.
15, 16, 54
 However, there is no established method for evaluating 
the coronary microcirculation in STEMI patients in the cardiac catheterisation laboratory. 
 
The index of microcirculatory resistance (IMR) is a novel pressure/temperature tipped 
guide-wire based quantitative measure of coronary microvasculature function. IMR has 
been validated in animal models and tested in stable patients,
130, 131, 137
 and in a recent 
study of acute STEMI patients, IMR was a better predictor of left ventricular function 3 
months post-MI than current standard methods for evaluating the microcirculation.
47
 
 
Contrast enhanced cardiac magnetic resonance imaging (ceCMR) is the gold standard 
non-invasive technique for assessment of the coronary microcirculation.
183
Microvascular 
obstruction (MVO) on ceCMR following STEMI is associated with an adverse 
prognosis.
111, 184
 However, for safety reasons, ceCMR is generally not performed until 2 
or more days after hospital admission, limiting its clinical utility in the initial post-MI 
period.  
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In a broad range of STEMI patients, we aimed to determine whether IMR and other 
invasive physiological markers of microvascular dysfunction acquired immediately after 
stent deployment in emergency PCI for STEMI might predict the nature and severity of 
myocardial injury using ceCMR as the gold standard comparison. Specifically, we first 
hypothesized that an elevated IMR at the time of reperfusion would be associated with 
the nature of MI, as revealed by the occurrence of MVO on ceCMR. Secondly, we 
hypothesized that IMR would be independently predictive of the severity of MI, as 
subsequently revealed by infarct size and LV function on ceCMR during long term 
follow-up. 
 
5.2 Methods 
 
Patients who met the pre-specific criteria and gave informed consent were included. 
During emergency PCI, a coronary pressure/temperature sensitive guidewire was 
advanced into the culprit artery and baseline means transit times (Tmn) were obtained 
following bolus intra-coronary injection of 3 ml of saline. Tmn and distal coronary 
pressure (Pd) were obtained under conditions of peak hyperaemia achieved by 
intravenous adenosine infusion (140 mcg/kg/min). IMR was calculated as PdxTmn. 
Patients underwent baseline ceCMR 24-48h later and at 3 months follow up. Left 
ventricular dimensions were assessed using retro-gated (trueFISP) cinematographic 
breath-hold sequences and MVO was defined as a dark core of hypoenhancement within 
the area of hyperenhanced infarcted tissue using breath hold turboFLASH sequences 
following an intravenous bolus of gadolinium (0.1mmol/kg). 
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5.3 A comparison of patients with and without microvascular 
obstruction on contrast enhanced cardiac MRI 
 
5.3.1 Demographics, cardiac risk factors, admission information and angiographic 
variables 
 
As stated above there are two CMR sequences following gadolinium injection which can 
be used to elucidate the presence of microvascular obstruction. Fifty four patients had 
“early MVO” sequences taken and 53 had “late gadolinium” sequences allowing 
assessment of infarct volume and “late MVO”. Microvascular obstruction was noted on 
blinded analysis in 27 (51%) of 53 patients. This number is in keeping with previous MRI 
studies. There was no MVO noted on follow up CMR scanning. The breakdown of 
demographics and patient characteristics are noted in the table below.  
 
 
MVO present 
(n=27) 
MVO absent 
(n=26) 
Age (years[SD]) 56.9 (10.2) 58.6 (11.7) 
Male (%) 89 88 
Smoker (%) 56 46 
Hypertensive (%) 30 19 
Dyslipidaemia (%) 37 12 
Diabetes (%) 4 4 
Haemoglobin (g/dl)[SD] 13.9(1.7) 14.3(1.1) 
White cell count x 10
3
/µL 11.7 (2.4) 11.5(3.6) 
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Platelet count x 10
3
/µL 260.3 (107.3) 249.3(55.3) 
Troponin I ng/ml 79.1 (113.9) 26.1 (18.1) 
Time to reperfusion (h) 8.03 (6.8) 4.39 (3.3) 
Aspirin (%) 100 100 
Clopidogrel (%) 100 100 
GP2b3a inhibitor (%) 89 62 
Aspiration thrombectomy (%) 41 50 
Drug eluting stent use (%) 19 38 
 
Table 5.1: Comparison of demographic data, cardiac risk factors, admission blood 
results, time to reperfusion and peri-procedural therapy in each group. 
 
 
There was no significant difference in age and gender between the two groups. The MVO 
group contained significantly more patients with a history of dyslipidaemia and 
hypertension. Peak troponin I was significantly elevated in the patients with MVO vs 
those without MVO: 79.1 (113.9) vs 26.1(18.1); p=0.024.Time from symptom onset to 
reperfusion was also longer in those in whom MVO was present: 8.03 (6.8) vs 4.39(3.3); 
p=0.018. 
 
There were no significant differences in the peri-procedural therapy initiated in each 
group. 
 
5.4 A comparison of pressure wire data in patients with and without 
MVO on ceCMR 
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The median IMR (IQR) in patients with MVO was higher (38.1 (29.4 – 54.6) units) 
compared to in patients without MVO (26.9 (18.9 – 36.9) units; p = 0.003, Figure 5.1). 
The pressure-derived collateral flow index and distal coronary wedge pressure were 
similar in both groups.  The full results are outlined in the table below. 
 
 
MVO present 
(n=27) 
MVO absent 
(n=26) 
p value 
Median Pw (IQR) 25 (17-32) 21 (15.5-25) 0.14 
Median CFIp (IQR) 0.28 (0.2-0.35) 0.26 (0.19-0.34)* 0.41 
median IMR(IQR) 38.1 (29.4-54.6) 26.9 (18.9-36.9)* 0.003 
 
Table 5.2: Comparison of pressure wire data in the MVO present and MVO absent 
groups. * n=25 
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Figure 5.1: IMR box-plots dichotomised according to presence or absence of MVO 
 
5.5 Comparison “early” and “late” MVO volumes, mass and ratio 
 
Twenty five patients were noted to have both “early” and “late” MVO on blinded 
analysis. One patient was noted to have “early” MVO but did not have “late” gadolinium 
sequences taken due to claustrophobia. One patient was thought to have “early” MVO but 
no “late” MVO and two patients were thought to have “late” MVO but no “early” MVO. 
In these 25 patients the mean (SD) “early” MVO volume was 9.4 (7.6) ml, the mean (SD) 
mass was 9.8 (8.0) grams and the ration of MVO mass the left ventricular mass was 6.8% 
(4.9). The mean (SD) “late” MVO volume was 7.1 (7.1) ml, the mean (SD) mass was 7.4 
(7.5) grams and the ratio of MVO mass the left ventricular mass was 5.1% (4.7). The 
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correlation between calculation of MVO volumes, mass and ratio was very close as can 
be seen in the table and graph below. 
 
 R value P value 
MVO volume 0.96 <0.001 
MVO mass 0.96 <0.001 
MVO/LV mass ratio 0.95 <0.001 
  
Table 5.3: Correlations and P values of “early” and “late” MVO volumes, mass and 
ratio calculated using digital planimetry. (n=25) 
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Figure 5.2: Correlation of “early” MVO mass with “late” MVO mass. R=0.96; 
p=<0.001 
 
 
5.6 The relationship between pressure wire data and MVO volumes, 
mass and ratio on CMR scanning 
 
Given the very close correlation between the results for “early” and “late” MVO, I have 
compared the invasive physiological data taken following PCI with the “late” MVO data 
as only “late” MVO has been shown to be an adverse prognostic indicator.  
 
Twenty seven patients were found to have “late” MVO and the volumes, mass and ratio 
to left ventricular mass were calculated as described previously. The demographics of 
these patients are as described above. There was no correlation between the invasive 
pressure wire measurements and either MVO volumes, mass or ratio to left ventricular 
mass.  
 
5.7 The relationship between IMR and LVEF at baseline and follow up 
 
In univariable analyses, an elevated IMR was a negative predictor of left ventricular 
ejection fraction (p=<0.001) [figure 5.3] and a positive predictor of left ventricular end-
systolic volume index (LVESVI, p=0.035) at 2 days. IMR was the most significant 
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independent predictor of left ventricular ejection fraction at 2 days (<0.001) Full results 
of the multivariate analysis are shown in table 5.4. 
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Figure 5.3: Scatterplot of IMR (log transformed) against left ventricular ejection 
fraction at 2 days as assessed by ceCMR. In univariable analyses, an elevated IMR 
was a negative predictor of left ventricular ejection fraction (P=<0.001)  
 
IMR continued to be a univariate predictor of ejection fraction at 3 month (p = 0.007, 
Figure 5.4]. CFIp and Pw were not found to predict ejection fraction at 3 months. IMR 
was a significant predictor of ejection fraction a 3 months in the multivariate model (p = 
0.028). (see table 5.4) 
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Figure 5.4: Scatterplot of IMR (log transformed) and left ventricular ejection 
fraction at 3 months. Index of microcirculatory resistance continued to be a 
predictor of ejection fraction at 3 month (p = 0.007) 
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 Univariate R
2
 
(%) 
Univariate 
P value 
Multivariate 
P value 
Predictors of LVEF at day 2 
   
Cigarette smoking 5.4 0.08 0.37 
Diabetes 12.1 0.008 0.025 
IMR 29.1 <0.001 <0.001 
Time to reperfusion 9.5 0.02 0.096 
ST segment resolution > 70% 7.7 0.037 0.21 
Predictors of LVEF at 3 months 
   
    
Glycoprotein IIbIIIa inhibitor 10.8 0.02 0.031 
IMR 14.5 0.007 0.028 
Time to reperfusion 9.1 0.035 0.446 
ST segment resolution > 70% 12.3 0.013 0.175 
Culprit artery 16.8 0.003 0.039 
 
Table 5.4: Results of multivariable regression analyses for left ventricular ejection 
fraction measured by ceCMR performed 2 days and 3 months post-MI. 
 
The P values for the univariable models for LVEF measured by ceCMR at 2 days and 3 
months follow-up respectively were: age (P=0.23; P=0.97); male gender (P=0.23; 
P=0.34); cigarette smoking (P=0.08; P=0.37), dyslipidaemia (P=0.94; P=0.34), 
hypertension (P=0.63; P=0.56), diabetes (P=0.008; P=0.34), glycoprotein IIbIIIa inhibitor 
therapy (P=0.15; P=0.02), aspiration thrombectomy (P=0.31; P=0.22), IMR (P<0.001; 
P=0.007), CFIp (P=0.54; P=0.81), Pw (P=0.93; P=0.95), location of culprit artery 
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(P=0.19; P=0.003) time to reperfusion (P=0.02; P=0.035), ST-segment resolution > 70% 
(P=0.037; P=0.013), and cTFC (P=0.26;P=0.13). The strongest univariate predictors with 
a P value less the 0.1 were entered into the multivariate model to determine independent 
predictors. The rise in R
2
 value for each multivariate model including IMR as compared 
to all other variables was 37.1% to 50.8% at 2 days and 54.5% to 58% at 3 months. 
 
5.8 The relationship between IMR and infarct volumes at baseline and 
follow up 
 
In univariate analysis IMR is a predictor of infarct mass (R
2
=18.6%; P<0.001) at 2 days . 
The other physiological markers of microvascular dysfunction were not predictors of 
infarct size. In the multivariate model IMR was the most significant independent 
predictor of infarct size at 2 days (P = 0.01). Full results of the multivariate analysis are 
found below in table 5.5. At 3 months IMR remained an independent predictor of infarct 
volume on univariate analysis ( R
2
 = 15.6%; P = 0.006). Again CFIp and Pw were not 
predictors of infarct volumes. In the multivariate regression model IMR was again a 
significant predictor of infarct volumes however culprit artery (LAD) was the most 
significant predictor. (table 5.5) 
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 Univariate 
R
2 
(%) 
Univariate 
P value 
Multivariate 
P value 
Predictors of infarct volume at day 2  
   
Glycoprotein IIbIIIa inhibitor 5.3 0.09 0.29 
IMR 18.6 <0.001 0.01 
Time to reperfusion  11.1 0.016 0.32 
ST-segment resolution > 70% 14.7 0.005 0.06 
Culprit artery 14.2 0.006 0.03 
Predictors of infarct volume at 3 months 
   
Dyslipidaemia 9.1 0.04 0.112 
IMR 15.6 0.006 0.048 
ST-segment resolution > 70% 9.9 0.031 0.384 
Time to reperfusion 6.0 0.097 0.545 
Culprit artery 21.3 0.001 0.021 
 
Table 5.5: Results of multivariable regression analyses for myocardial infarct 
volume measured by ceCMR performed 2 days and 3 months post-MI. 
 
The P values for the univariable models for myocardial infarct volumes measured by 
ceCMR 2 days and 3 months post-MI, respectively, were: age (P=0.87; P=0.84); male 
gender (P=0.62; P=0.49); cigarette smoking (P=0.33; P=0.52), hypercholesterolaemia 
(P=0.18; P=0.04), hypertension (P=0.25; P=0.55), diabetes (P=0.77; P=0.52), 
glycoprotein IIbIIIa inhibitor therapy (P=0.09; P=0.11), aspiration thrombectomy 
(P=0.43; P=0.26), IMR (P<0.001; P=0.006), CFIp p=0.53, p=0.67), Pw (P=0.82; P=0.72), 
time to reperfusion (P=0.016 ; P=0.097), ST-resolution >70% (P=0.005; P=0.031), culprit 
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artery (P=0.006; P=0.001) and cTFC (P=0.19; P=0.23). The strongest univariate 
predictors with a P value less the 0.1 were entered into a multivariate model to determine 
independent predictors. The rise in R
2
 value for each multivariate model including IMR 
as compared to all other variables was 51.3% to 53.9% at 2 days and 40.7% to 45.1% at 3 
months. 
 
5.9 The relationship between IMR and LV Volumes at baseline and 
follow up 
 
In univariate regression analysis IMR was the strongest predictor of LVESVI in the 
ceCMR scan 2 days following myocardial infarction (R
2
 = 15.5%; p = 0.002) [see figure 
5.5]. Pw and CFIp were not predictors of LVESVI ( R
2
 = 1.3%; p = 0.4) ( R
2 
= 2.0% ; p = 
0.29) respectively. The 4 other most significant predictors of LVESVI on univariate 
analysis were entered into the multivariate model (see table 5.6). 
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Figure 5.5: Scatterplot of IMR (log transformed) against left ventricular end systolic 
volume indexed for body surface area on ceCMR at 2 days.  
 
In univariate regression analysis IMR was the strongest predictor of high LVESVI in the 
ceCMR scan 2 days following myocardial infarction (R
2
 = 15.5%; p = 0.002) 
 
 Univariate R
2 
(%) 
Univariate 
P value 
Multivariate 
P value 
LVESVI at day 2  
   
IMR 15.5 0.002 0.009 
Culprit artery 15.1 0.003 0.02 
ST segment resolution < 70% 9.8 0.01 0.12 
Time to reperfusion 4.5 0.11 0.78 
Hypertension 4.3 0.12 0.16 
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Table 5.6: Results of multivariable regression analyses for increased left ventricular 
end systolic volume index measured by ceCMR performed 2 days 
 
The following variables which did not reach significance when entered into the univariate 
model were not included in the multivariate model: age, gender, smoking, 
hypercholesterolaemia, diabetes, glycoprotein 2b3a use, aspiration thrombectomy at the 
time of PCI, CFIp, and Pw.  
 
Using the same variables as above the five most significant predictors of left ventricular 
end diastolic volume corrected for body surface area (LVEDVI) were age, 
hypercholesterolaemia, CFIp, Pw and culprit artery. None of these variables reached 
statistical significance on the multivariate model (see table 5.7). 
 
 
 
 Univariate R
2 
(%) 
Univariate 
P value 
Multivariate 
P value 
LVEDVI at day 2  
   
Age 5.7 0.07 0.12 
Hypercholesterolaemia 4.9 0.99 0.09 
CFIp 11.3 0.01 0.16 
Pw 5.9 0.07 0.81 
Culprit artery 8.6 0.03 0.09 
 
Table 5.7: Results of multivariable regression analyses for increased left ventricular 
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end diastolic volume index measured by ceCMR performed 2 days 
 
The only significant univariate predictors of increased LVESVI on follow up ceCMR 
were electrocardiographic ST segment resolution of less than 70% ( R
2
 = 14.4% ; p = 
0.007) and culprit artery location  ( R
2
 = 20.9% ; p = 0.001).  On entering the five most 
significant variables into the multivariate model the strongest predictor of LVESVI was 
culprit artery location (LAD). 
 
 Univariate R
2 
(%) 
Univariate 
P value 
Multivariate 
P value 
LVESVI at 3 months 
   
GP2b3a 6.3 0.08 0.009 
No aspiration thrombectomy 4.0 0.17 0.013 
IMR 6.8 0.07 0.49 
ST segment resolution < 70% 14.4 0.007 0.027 
Culprit artery 20.9 0.001 0.005 
 
Table 5.8: Results of multivariable regression analyses for increased left ventricular 
end systolic volume index measured by ceCMR performed at 3 months 
 
 
The following variables were also entered in the univariate model but were less 
significant predictors than those about hence not entered into the multivariate model ; 
age, gender, smoking, dyslipidaemia, hypertension, diabetes, CFIp, Pw and time to 
reperfusion.  
 
On univariate analysis for predictors of LVEDVI at 3 months of the variables stated 
above only the culprit artery was a predictor of increased volume ( R
2
 = 8.2%, P = 0.05). 
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On entering the four other most significant predictors of increased LVEDVI into the 
multivariate model none were significant (table 5.9) 
 
 Univariate R
2 
(%) 
Univariate 
P value 
Multivariate 
P value 
LVEDVI at 3 months 
   
Age 5.3 0.11 0.15 
Gender 2.4 0.28 0.14 
Diabetes 3.5 0.19 0.96 
ST segment resolution < 70% 7.3 0.06 0.2 
Culprit artery 8.2 0.05 0.12 
 
Table 5.9: Results of multivariable regression analyses for increased left ventricular 
end diastolic volume index measured by ceCMR performed at 3 months 
 
The following variables were entered into the univariate analysis model but were less 
statistically significant for increased LVEDVI than those above; smoking, dyslipidaemia, 
hypertension, CFIp, Pw, IMR and time to reperfusion. 
 
5.10 The relationship between IMR and infarct transmurality at 
baseline and follow up 
 
Fifty three patients had transmurality scores calculated as described in chapter 3. The 
mean (SD) value was 2.25 (0.86) with arrange of 0 to 3.9. Forty seven patients had 
transmuraity score calculated from the follow up CMR scans. The mean (SD) was 1.89 
(0.74) and the range was 0 – 3.3. On univariate analysis using the various variables 
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mentioned above as predictors for increased transmurality score at baseline the 
significant predictors were IMR (R
2
 = 26.7% ; p = < 0.001) [see figure 5.6], 
electrocardiographic ST segment resolution > 70% (R
2
 = 22.1% ; p = <0.001), time to 
reperfusion (R
2
 = 22.1% ; p = 0.004), use of GP2b3a inhibitor (R
2
 = 10.1% ; p = 0.02) 
and culprit artery (R
2
 = 7.5% ; p = 0.047).  
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Figure 5.6 : Scatterplot of IMR (log transformed) against transmurality score at 
baseline ceCMR imaging at 2 days. IMR was the most significant predictor of 
increased transmurality score at baseline (R
2
 = 26.7% ; p = < 0.001). 
 
The five most significant univariate predictors for increased transmurality score were 
entered in to the multivariate analysis model. IMR was again the most significant 
predictor of increased transmurality score at baseline (p = 0.001). Electrocardiographic 
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ST segment resolution index > 70% was also statistically significant (p = 0.006). The 
complete results are seen in table 5.10.  
 
 Univariate R
2 
(%) 
Univariate 
P value 
Multivariate 
P value 
Transmurality score at baseline 
   
GP 2b3a 10.1 0.02 0.08 
IMR 26.7 < 0.001 0.001 
Time to reperfusion 15.3 0.004 0.14 
STR > 70% 22.1 < 0.001 0.006 
Culprit artery 7.5 0.047 0.22 
 
Table 5.10: Results of univariate and multivariate regression predictive models for 
increased transmurality score at 2 days post myocardial infarction 
 
The following variables were entered into the univariate analysis model but were less 
significant than those above: age, male gender, cigarette smoking, dyslipidaemia, 
hypertension, diabetes, aspiration thrombectomy, CFIp, distal coronary wedge pressure, 
corrected TIMI frame count. 
 
On univariate analysis using the various variables described as predictors for increased 
transmurality score at baseline the significant predictors were IMR (R
2
 = 15.2% ; p = 
<0.009) [see figure 5.7], electrocardiographic ST segment resolution > 70% (R
2
 = 14.8% 
; p = 0.008), time to reperfusion (R
2
 = 21.7% ; p = 0.001), use of GP2b3a inhibitor (R
2
 = 
17.2% ; p = 0.004) and culprit artery (R
2
 = 5.8% ; p = 0.005).  
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Figure 5.7: Scatterplot of IMR (log transformed) against transmurality score at 
baseline ceCMR imaging at 3 months. IMR was a significant predictor of increased 
transmurality score at baseline (R
2
 = 15.2%; p = 0.004). 
 
In the multivariate model GP2b3a use was the most significant predictor of transmurality 
score at 3 months (p = 0.007). Electrocardiographic ST segment resolution > 70 % and 
increased IMR were also significant predictors (p = 0.008 and p = 0.01 respectively). See 
table 5.11 below. 
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 Univariate R
2 
(%) 
Univariate 
P value 
Multivariate 
P value 
Transmurality score at follow up 
   
GP 2b3a 17.2 0.004 0.007 
IMR 15.2 0.009 0.015 
Time to reperfusion 21.7 0.001 0.115 
STR > 70% 14.8 0.008 0.008 
Culprit artery 16.3 0.005 0.073 
 
Table 5.11: Results of univariate and multivariate regression predictive models for 
increased transmurality score at 2 months post myocardial infarction 
 
The following variables were entered into the univariate analysis model but were less 
significant than those above: age, male gender, cigarette smoking, dyslipidaemia, 
hypertension, diabetes, aspiration thrombectomy, CFIp, distal coronary wedge pressure, 
corrected TIMI frame count. 
 
5.11 The relationship between IMR and LV remodeling 
 
The mean LVESVI (SD) decreased from 30.5 (10.8) ml/m
2
 to 28.9 (12.4) ml/m
2
 during 
the three month follow up period in the larger patient group. Forty nine patients had 
complete ceCMR scans at baseline and follow up and pressure wire studies performed at 
the time of PCI. In these patients the mean left ventricular end systolic volume index 
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(SD) decreased from 31.0 (10.7) ml/m
2 
to 28.0 (12.4) ml/m
2
 over the three month follow 
up period.  
 
In the patient group with an IMR value greater than or equal to the median (35 units) the 
mean (SD) decrease in LVESVI was 3.04 (8.8) ml/m
2
 vs 1.2 (9.7) ml/m
2 
in those with an 
IMR of less than the median (p = 0.49). 
 
In the patient group with a CFIp value of greater than or equal to the median (0.28 units) 
the mean decrease in LVESVI was 3.83 (8.7) ml/m
2
 vs 0.4 (10.1) ml/m
2 
in those with 
CFIp less than the median (p = 0.2). 
 
In the patient group with a Pw of greater than or equal to the median (23 mmHg) the 
mean decrease in LVESVI was 0.31 (9.3) ml/m
2
 vs 4.13 (8.7) ml/m
2
 in those with Pw 
less than the median (p = 0.15). 
 
 
Δ LVESVI (SD) 
≥  median (ml/m2) 
Δ LVESVI (SD) 
< median (ml/m
2
) 
P value 
IMR - 3.04 (8.8) - 1.2 (9.7) 0.49 
CFIp - 3.83 (8.7) - 0.4 (10.1) 0.2 
Pw - 0.31 (9.3) - 4.13 (8.7) 0.15 
 
Table 5.12 : A comparison of Δ LVESVI defined by pressure wire data. There is no 
significant difference between the groups. 
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5.12 Discussion 
 
5.12.1The comparison of different cardiac MRI methods of MVO assessment in 
AMI 
 
Researchers have commonly used different CMR methods for assessment of MVO. I 
compared the presence and extent of “early” MVO with “late” MVO. MVO can also be 
assessed by gadolinium enhanced first pass perfusion sequences. The conventional 
sequence for this affords only about half of the spacial resolution of the other methods 
available at the time of my work. It typically does not cover the entire heart but transects 
the LV on three predefined perpendicular planes. For this reason I did not include this in 
this thesis, although since my work has finished, a higher resolution first pass sequence 
has been developed.
104
 
 
I found a very close correlation between “early” and “late” MVO. The fact that the LV 
mass/MVO ratio decreases between “early” and “late” MVO supports the suggestion that 
gadolinium passively diffuses into areas of microvascular damage over time following 
gadolinium injection and that the apparent size of MVO may decrease over a relatively 
short time period. However the differences between the two are minimal and indeed I 
think my work could help to refute the suggestion that localised areas of MVO may be 
missed by “late” MVO in comparison with “early”.  
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Given that the majority of the previous work linking prognosis with MVO has looked at 
“late” MVO15, 106 and given the minimal differences between the two groups in my own 
study I think my work supports the assessment that the most appropriate method for 
assessment of MVO at the time of this thesis was the “late” MVO method. Furthermore I 
feel this supports the use of this method in this thesis. 
 
5.12.2The relationship between pressure wire indices of microvascular obstruction 
and CMR data at baseline and follow-up 
 
Microcirculatory injury is a determinant of left ventricular function
16, 185
 and prognosis 
following acute MI.
15, 111
 While emergency PCI represents one of the first opportunities 
to evaluate and treat an acute MI patient the optimal method for evaluating the 
microcirculation in this setting is uncertain.
23
 
 
The key findings in this aspect of my thesis are as follows: 
 
Firstly, in a broad range of STEMI patients undergoing emergency PCI, an invasive 
measure of microvascular function, the IMR calculated immediately after PCI, was 
linked with the pathological nature of MI, since IMR was higher in patients with “late” 
MVO compared to those without “late” MVO, as revealed by ceCMR.  
 
Secondly, IMR independently predicted the severity of MI as revealed by infarct volume 
and left ventricular function 2 days and 3 months post-MI.  
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Thirdly, IMR, but not coronary wedge pressure or pressure derived collateral flow index, 
independently predicted infarct size 2 days and 3 months post MI. 
 
Fourthly, IMR, but not coronary wedge pressure or pressure derived collateral flow index 
independently predicted transmurality score at baseline and follow up. 
 
Finally, no pressure wire indices of microvascular injury were associated with adverse 
ventricular remodeling.  
 
As discussed previously IMR has been subject to preclinical and clinical validation, and 
these studies have demonstrated that IMR measurement is largely independent of 
variations in haemodynamic state.
130, 131, 137
 The seminal study by Fearon et al 
47
 
confirmed the IMR to be superior to other commonly used clinical markers of 
microvascular dysfunction for predicting left ventricular function assessed by 
echocardiography. 
 
This study is the first to compare invasively acquired measurements of microvascular 
injury using the coronary pressure wire with left ventricular function and MVO assessed 
by paired ceCMR studies obtained acutely and after longer-term follow-up.  
 
Contrast enhanced CMR is recognized as the current non-invasive gold standard for 
assessment of coronary microvascular damage and left ventricular function and 
179 
 
dimensions.
183
 A more recent study by Hirsch et al 
186
 quantified coronary blood flow 
characteristics using an intracoronary Doppler wire and related these findings to 
microvascular injury assessed by ceCMR. Twenty-seven anterior STEMI patients 
underwent repeat cardiac catheterization 4 - 8 days post primary PCI with ceCMR 
performed the preceding day. This study demonstrated that the extent of MVO was a 
multivariable predictor of abnormal coronary flow velocity characteristics, providing 
further functional evidence of the validity of ceCMR as a non-invasive tool to assess 
microcirculatory function. These observations complement those in the current study. 
 
My findings complement those of the other previously published studies in this field in a 
number of important ways. My study had a larger sample size and included patients with 
a broader range of acute MI types (e.g. non-anterior STEMI). The time to presentation 
from the onset of symptoms for patients in our study was less restricted than in previous 
studies which excluded patients with symptoms > 12 h. 
47, 141, 187
 
 
This work is also the first to compare the pressure wire indices of microvascular 
dysfunction with myocardial damage at two distinct time points using ceCMR as the gold 
standard reference point. That IMR remained a significant independent predictor of 
decreased ejection fraction and increased infarct volume out to 3 months follow up 
further adds weight to the validity of the measurement.  
 
This is the first study to compare pressure wire indices of microvascular damage with 
transmurality score assessed by ceCMR. Given that IMR is an independent predictor of 
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infarct volumes at baseline and follow up. Again I feel that the relationship of IMR, but 
not distal coronary wedge pressure or pressure derived collateral flow index, to 
transmurality score strengthens the case that IMR is a potential marker of subsequent 
myocardial injury which is available at the time of emergency PCI.  
 
The pressure wire indices of microvascular dysfunction showed no relationship with 
adverse ventricular remodeling as assessed by ceCMR. The study was however powered 
to assess a difference in each MVO group and to look principally at the relationship 
between the pressure wire indices of microvascular dysfunction with ejection fraction and 
infarct volumes at baseline and follow up. There is nothing in the published literature 
about the relationship of IMR with adverse ventricular remodeling. The majority of 
patients in this study as with the other published literature had an improvement in their 
left ventricular systolic volume index. Therefore, given the small numbers of patients 
whom developed adverse ventricular remodeling, it is perhaps predictable that there was 
no relationship. I feel that a much larger patient population would be needed to try and 
exhibit such a finding.  
 
Overall I think that these results extend the potential clinical relevance of IMR 
measurement to a larger group of patients with myocardial infarction and compliment the 
work that has gone before looking at IMR in the STEMI population. The median IMR in 
my study population was 35 units which is similar to that reported by Fearon et al 
(median IMR 32 units). My findings are consistent with and extend the results of these 
earlier studies and support the notion that standardized measurement of IMR may be 
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valid in clinical practice. Consequently, my results support the notion that invasive 
measures of microvascular function, specifically IMR, may be useful clinical tools to 
predict the initial severity of myocardial injury.   
 
Only a minority of patients had a history of hypertension or diabetes and patients with 
previous MI in the culprit artery territory were not included. Therefore, the microvascular 
dysfunction observed in our patients was most likely influenced by the effects of acute 
coronary thrombosis and reperfusion, rather than the effects of chronic microvascular 
disease related to pre-existing cardiac disease.  
 
5.13 Limitations 
 
There are also some important limitations in this aspect of the study. MVO is a dynamic 
phenomenon following coronary reperfusion and MVO which may be apparent on 
ceCMR initially may resolve by 48 h. In fact, MVO which is detectable 2 days post-MI is 
more correctly termed ‘persistent’ MVO. The dynamic nature of MVO may in part 
explain why elevated IMR values >35 may occur in some patients with no visible MVO 
on ceCMR scanning two days later.
188
 Serial ceCMR up to 48 h post-MI would be 
required to answer this question. The time point used to assess MVO by ceCMR is 
consistent with other studies in this subject and MVO measured at this time-point is an 
adverse prognostic marker .
15
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The study is limited by its small sample size, however IMR remains a significant 
predictor of myocardial damage. A larger sample size may have resulted in other 
predictors becoming significant. Larger studies will be needed to determine whether IMR 
can predict clinical outcomes (see Appendix V). 
 
5.14 Conclusions 
 
The IMR is a simple wire based technique that can provide a quantitative assessment of 
microvascular function at the time of emergency PCI. We have shown that an elevated 
IMR is linked to MVO as revealed by ceCMR. MVO independently predicts long term 
prognosis following myocardial infarction. Accordingly we suggest measurement of IMR 
represents a new approach to risk assessment at the very earliest stage of acute MI 
management, and potentially, therefore enables triage of higher risk patients to more 
intensive therapy. 
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Chapter 6: A comparison of Index of 
Microcirculatory resistance prior to and 
following stent implantation in emergency 
PCI for STEMI 
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6.1 Introduction 
 
Emergency percutaneous coronary intervention (PCI) is established as the treatment of 
choice in patients with ST segment elevation myocardial infarction (STEMI). Restoration 
of epicardial arterial flow and tissue level perfusion are the twin goals of this treatment. 
However despite achieving epicardial arterial patency in the majority of patients a 
significant proportion do not achieve complete myocardial reperfusion
26, 182
.  The 
coronary microvasculature has been recognised as an important determinant of 
myocardial perfusion in the setting of STEMI. A variety of pathophysiological factors are 
thought to contribute to coronary microvasculature injury,
25, 36
 including downstream 
microembolization of plaque material and thrombus at the time of balloon angioplasty or 
stenting, which if severe can lead to the phenomenon of no reflow. Autopsy studies have 
suggested that “clogging” of the microvasculature does occur during PCI as a result of 
downstream embolisation. 
29, 182
 
 
The status of the coronary microvasculature at the time of emergency PCI for STEMI can 
be assessed by measuring the index of microcirculatory resistance (IMR) using a pressure 
and temperature sensing coronary guidewire. IMR measured at the time of emergency 
PCI has been shown to be a predictor of the extent of subsequent myocardial damage.
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When coronary wedge pressure is included in the calculation of IMR, accounting for 
collateral flow, it has been shown to be independent of any residual epicardial stenosis 
137
. Accordingly any change in IMR pre and post stenting will reflect changes in 
microcirculatory resistance rather than any effect of stenting on the target epicardial 
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artery stenosis. For example, an increase in IMR post stenting could potentially result 
from downstream embolisation. We therefore investigated whether stent implantation at 
the time of emergency PCI for STEMI altered IMR and whether any changes in IMR pre 
and post stenting correlated with the extent of myocardial damage assessed using 
biomarkers and cardiac MRI. 
 
6.2 Methods 
 
The study population included patients with STEMI referred to our institution for either 
primary PCI or rescue PCI after failed thrombolytic therapy or convalescent PCI within 
24 h of successful thrombolytic therapy. Patients were prospectively enrolled when the 
following inclusion criteria were present: (1) age  18 years with electrocardiographic 
and symptomatic evidence of acute STEMI and in whom emergency stenting was 
intended, (2) written informed consent. Exclusion criteria were: (1) contraindications to 
adenosine, (2) cardiogenic shock. (3) Previous MI in the index territory (4) pregnancy. 
The research protocol was approved by the Institutional Review Board and informed 
consent was obtained from each patient. 
 
6.2.1 Physiological assessment 
 
PCI was performed in line with current international guidelines with glycoprotein IIb/IIIa 
inhibitors and aspiration thrombectomy used at the discretion of the primary operator. In 
the majority of cases the coronary pressure/temperature sensitive guidewire  was used as 
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the primary guide-wire. The guide-wire was calibrated outside the body, equalized within 
the guide catheter with the pressure sensor positioned at the ostium of the guide catheter, 
and then advanced into the distal third of the culprit artery. When indicated the guide-
wire was disconnected from the analyser to allow the delivery of the various catheter 
devices used during the PCI and wiped with a damp sterile swab before reconnection.  
 
After successful guide-wire passage into the infarct related artery beyond the 
stenosis/occlusion either balloon angioplasty or aspiration thrombectomy was performed 
as indicated. If the operating cardiologist did not think aspiration thrombectomy was 
indicated Pw was recorded during balloon pre-dilatation. If aspiration thrombectomy was 
performed Pw was recorded immediately following this by occlusive balloon inflation 
within the vessel at the site of proposed stenting. Immediately thereafter and before 
stenting thermodilution  derived mean transit times were recorded at hyperaemia as 
previously described 
131
. Adenosine 140 μg/kg/min was used to induce maximal 
hyperaemia via a large peripheral vein. Meticulous attention was paid to guide catheter 
engagement. Mean aortic pressure (Pa) and mean distal coronary pressure (Pd) were 
measured simultaneously during hyperaemia.  
 
Ten minutes following stent delivery thermodilution derived mean transit times were 
measured again, Pa and Pd were recorded and Pw was obtained following inflation of a 
non-compliant balloon within the stented segment. 
 
IMR was calculated using the following equations; 
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1. IMR true =Pa.Tmn [(Pd-Pw)/(Pa-Pw)] 137 
2. IMR app= Pd.Tmn 130 
 
6.2.3 CMR protocol 
 
As described in the chapter 3. 
 
6.2.3 CMR analysis 
 
Left ventricular mass, volume and function analyses were performed by a cardiologist 
experienced in CMR who was blinded to all clinical and pressure wire data. Results were 
obtained using Argus Dynamic Signal software (Siemens, Erlangen, Germany) as 
previously described.  
 
6.2.4 Angiographic analysis 
 
TIMI flow grade was recorded pre and post stenting and corrected TIMI frame count 
(cTFC) after stenting by an experienced independent observer(JL).  
 
6.2.5 Statistical analysis 
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Statistical analysis was performed on MINITAB 16 software. The IMR data was non-
normally distributed therefore is expressed as median [IQR] and was log transformed 
prior to statistical comparison. FFR, cTFC, TIMI flow grade, peak troponin I and LVEF 
were normally distributed and described as mean (standard deviation). The paired t test 
and the two sample t test were used to test for differences in the normally distributed 
data. A p value of less the 0.05 was taken as significant. 
 
6.3 Results 
 
6.3.1 Patient characteristics 
 
Forty seven patients were enrolled in this study and their demographics and clinical 
characteristics are presented in Table 6.1. Successful physiological measurements were 
made all patients.  
 
Variable  
Mean Age (SD) 58.7 (10.5) 
Male Gender 
* 
(%) 44 (88) 
Smoker 
*
(%) 28 (56) 
Hypertension 
* 
(%)
 
15 (30) 
Dyspilidaemia 
* 
(%)
 
14 (28) 
Diabetes 
* 
(%)
 
2 (4) 
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Table 6.1: Patient demographics. 
* 
n = 47 
 
The culprit artery was the right coronary in 17 cases, the left anterior descending in 26 
cases and the circumflex in 4 cases. The indications were primary PCI in 25 cases, rescue 
PCI in 12 cases and convalescent PCI (defined as PCI within 24h of successful 
thrombolytic therapy) in 10 cases. The median time from onset of pain to reperfusion (by 
stenting or thrombolysis) was 4.3 hours.  
 
All patents were preloaded with 300mg of Clopidogrel and aspirin. Aspiration 
thrombectomy was performed in 22 (46%) cases and glycoprotein 2b3a inhibitor was 
given in 31 (66%) cases. The mean number of stents implanted was 1.4 per patient. In 32 
cases bare metal stents were inserted, drug eluting stents in 15 cases. 
 
6.3.2 IMRtrue , IMRapp and TIMI flow grade pre and post stenting (table 6.2) 
 
There was a reduction in IMRapp following stenting (41.3[28.3-66.9] to 32.3[52.6]; p = 
0.02) but when collateral flow was accounted for (IMRtrue) there was no change (36.5 
[24.7 – 62.6] to 30.5 [22.4 – 51.5] ; p = 0.35). When collateral flow was accounted for 
only prior to stenting but not afterwards following the resolution of the epicardial arterial 
stenosis the change reduced further (36.5 [24.7 – 62.6] to 32.3[52.6] ; p = 0.82). 
 
However FFR improved significantly following stenting from 0.78 (0.14) to 0.91 (0.07); 
p = < 0.001, as did TIMI flow grade from 1.3 (1.2) to 2.8 (0.4); p <0.001.   
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 Pre stenting Post stenting P value 
IMR app 41.3 [28.8 – 52.6] 32.3 [22.8-52.6] 0.02 
IMR true 36.5 [24.7 – 62.6] 30.5 [22.4 – 51.5] 0.35 
IMR true/IMR app 36.5 [24.7 – 62.6] 32.3 [22.8 – 52.6] 0.82 
FFR 0.78 (0.14) 0.91 (0.07) >0.001 
TFG 1.3 (1.2) 2.8 (0.4) >0.001 
 
Table 6.2: The comparison of pressure wire data and TIMI flow grade before and 
after stenting. IMR is presented a median [IQR] and FFR and TFG mean (SD) 
 
 
6.3.3 Influence of adjunctive therapy on change in IMR 
 
There were no significant differences in IMR pre or post stenting in those who did 
(p=0.73) or did not receive GP2b3a inhibitors (p=0.11). Similarly there were no 
differences in IMR pre and post stenting in those who did (p = 0.83) or did not undergo 
aspiration thrombectomy (p=0.9).  
 
6.3.4 Influence of change in IMR on evidence of myocardial damage (Table 6.3) 
 
The IMR decreased in 24 patients and increased in 23 patients. Forty three patients 
underwent baseline CMR at 2 day and 37 had follow up scanning at 2 months. The LVEF 
at 2 days was significantly lower in those in whom IMR increased (p=0.001) but this 
difference had resolved by 2 months. There was a trend towards higher infarct volumes in 
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the group in which IMR increased both at baseline and at follow up but this did not meet 
statistical significance. Peak troponin I was significantly higher in those in whom IMR 
increased (p = 0.03) but there was no difference in ECG ST segment resolution index (p 
= 0.36) or cTFC (p = 0.23). 
 IMR increase IMR decrease P value 
LVEF at baseline (%) 49.5 (9.4) 60.9 (11.6) 0.001 
LVEF at 3 months (%) 58.9 (13.3) 62.4 (12.3) 0.41 
Infarct size at baseline (%) 22.6(17.4) 15 (13.4) 0.15 
Infarct size at 3 months (%) 13.7 (13) 9.4(10.2) 0.31 
Troponin I (units) 67 (65) 34.6(25) 0.03 
STR index (%) 63.6(36.6) 73.4(31.4) 0.23 
cTFC 20.1(12.4) 16.4(6.4) 0.23 
 
Table 6.3: The differences between indicators of myocardial damage grouped 
according to change in IMR following emergency PCI for STEMI. All values are 
mean (SD). 
 
 
6.3.5 The influence of angiographic no reflow in change in IMR 
 
 
I defined angiographic no reflow as a reduction in TIMI flow grade at any point during 
the emergency PCI procedure. This occurred in 11 cases altogether. The mean change in 
IMR in that group was 5.3 (29.4) and the change in those with no angiographic evidence 
of no-reflow was minus 2.6 (16.6). There was no significant difference between the two 
groups (p=0.46) 
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6.4 Discussion 
 
Myocardial microvascular obstruction was first described as no – reflow phenomenon in 
1974
24
 . Distal embolisation of atherosclerotic material has been recognised as an 
important factor in decreased myocardial perfusion in the setting of ST elevation 
myocardial infarction. This has been shown by the injection of microspheres to represent 
atherosclerotic debris in the experimental canine setting 
27
 and was first noted in autopsy 
of 25 cases of sudden death due to acute coronary thrombosis. Falk noted that in 73% of 
cases there was fragmentation of the proximal thrombus with peripheral embolisation 
causing micro-embolic occlusion of the small intra-myocardial arterioles associated with 
microinfarcts.
28
 A further autopsy study confirmed this in patients who died within 30 
days of thrombolysis or balloon angioplasty for treatment of ST – elevation myocardial 
infarction.
29
Initial studies using  distal protection devices confirmed high number of 
patients in whom this was present and suggested improvement in surrogate markers of 
microvascular perfusion.
30
 
 
Hence it was hypothesized, distal protection devices that prevent embolisation during 
primary PCI may improve distal perfusion and improve patient outcomes
140
. This concept 
however has not been proven in the numerous randomised controlled trials which 
remained inconclusive despite capture of atheromatous material and the DEDICATION 
study further confirmed that the routine use of distal protection by a filterwire system 
during primary PCI did not seem to improve microvascular perfusion, limit infarct size, 
or reduce the occurrence of MACCE.
32-34
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Our study is the first to compare invasive assessment of the coronary microvasculature at 
the beginning and end of an emergency PCI procedure, prior to and following mechanical 
reperfusion. This study therefore suggests that stenting itself does not have a detrimental 
effect on the coronary microvasculature despite a significant improvement in TIMI flow 
grade.  Given that the postulated detrimental effect of mechanical revascularisation in this 
patient population is caused by downstream embolisation 
30
 this may explain why 
previous studies looking at distal protection devices have not met their predefined 
endpoints. Furthermore, given that there is not a significant improvement in 
microvascular resistance following revascularisation of the epicardial artery despite a 
significant improvement in TIMI flow grade, we feel our study adds to the body of 
evidence that revascularisation alone is not sufficient to achieve optimal myocardial 
tissue level reperfusion following STEMI. 
140
  
 
Our findings are broadly in keeping with two recent studies, in stable patients, which 
have shown that when collateral flow is accounted for prior to PCI IMR does not change 
following stent implantation.
138, 189
 An interesting observation is that IMR was higher in 
our study reflecting the complex pathophysiological influences on the coronary 
microvasculature in the setting of STEMI as opposed to the stable setting.  
 
We have previously shown that IMR is a powerful independent predictor of myocardial 
damage assessed by CMR
180
. We have shown here that although a peri-procedural 
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increase in IMR is associated with a higher peak troponin I it is not associated with 
longer-term left ventricular damage as assessed by CMR.  
 
6.5 Limitations 
 
There are some important limitations in our study. Firstly the authors recognise that 
microvascular damage in this context is a complex pathophysiological process which is 
most likely a dynamic phenomenon around the peri-infarct period. Our study only looked 
at two time-points within this process. We are therefore only able to provide a “snapshot” 
rather than an overview of the status of the microvasculature, and therefore leave 
questions unanswered. However, given that coronary stenting is the cornerstone of our 
treatment of STEMI
13
 we feel that knowledge that this important intervention does not 
significant change the invasive indices of microvascular function is useful information. 
 
This study was powered to look for an overall change in IMR prior to and following stent 
implantation for emergency PCI. Although the sub group analysis such as angiographic 
evidence of no reflow indicates some interesting trends this aspect of the paper is limited 
by the small numbers involved in each sub-group. A larger patient population would be 
needed to be able to make definitive statements regarding the sub group analysis. 
 
We included 3 patient groups in our study. We found that the IMR was significantly 
lower in those who had PCI within 24h of successful thrombolytic therapy than in the 
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rescue or primary PCI groups. This may represent to time lapse between the acute event 
and the invasive physiological assessment. 
 
6.6 Conclusions 
 
Microvascular resistance does not change significantly following emergency stenting in 
patients with ST elevation myocardial infarction. This suggests that stent deployment 
itself does not significantly alter the status of the coronary microvasculature, and 
furthermore, that mechanical reperfusion of the infarct related epicardial artery does not 
achieve optimal treatment of the coronary microcirculation.  
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Chapter 7: The relationship between 
coronary pressure wire derived 
markers of microvascular obstruction 
and “traditional” indices of 
myocardial damage and 
microvascular obstruction in ST – 
elevation myocardial infarction 
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7.1 Background 
Independent interrogation of the coronary microvasculature is possible by the 
measurement of IMR. But, correlations between IMR and other more conventional and 
validated indices associated with microvascular and myocardial dysfunction following 
myocardial infarction is limited. We therefore investigated relationship between IMR and 
tradition indices of microvascular perfusion and myocardial injury in patients with re-
perfused STEMI treated with emergency PCI  
 
7.2 Methods 
Patients underwent comprehensive physiological assessment using a coronary 
pressure/temperature tipped guide-wire following emergency PCI for STEMI. IMR was 
calculated using Pd x Tmn, Pw was recorded and CFIp was calculated using Pw/Pa. 
Corrected TIMI frame count, TIMI flow grade and ST segment resolution index were 
calculated by a blinded observer(JL). Peak troponin I was recorded. 
 
 
7.3 Results 
 
7.3.1 A comparison of pressure wire data with TIMI flow grade prior to PCI 
 
TIMI flow 
grade 
n 
Median IMR 
[IQR] 
Median CFIp 
[IQR] 
Median Pw 
[IQR] 
0 28 37.6 [26.4-56] 0.27 [0.2-0.33] 23 [15.3-30.7] 
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1 20 36.3 [23.8-64.4] 0.26 [0.21-0.36] 21 [17-25.7] 
2 11 30.0 [15.3-49] 0.28 [0.16-0.34]
* 
25 [16.2-27.7]
* 
3 10 24.9 [17.7-34.8] 0.28 [0.19-0.35] 23 [16-33] 
 
Table 7.1. Pressure wire indices following PCI grouped by TIMI flow grade prior to 
PCI. 
* 
(n=10) Comparison between each group using the Mann Whitney test for 
comparison on non-normal data. 
 
IMR was significant lower in patients with TIMI 3 flow compared to those with TIMI 0 
flow (p=0.009) and those with TIMI 1 flow (p=0.04). There were no other significant 
differences between groups. There were no significant differences in CFIp or distal 
coronary wedge pressure according to TIMI flow grade. 
 
7.3.2 A comparison between the invasive physiological indices of MVO and 
corrected TIMI frame count immediately after emergency PCI 
 
Increased IMR correlated closely with cTFC, r = 0.36, p = 0.002. Both CFIp and Pw did 
not correlate with cTFC, r = -0.11, p = 0.37 and, r = -0.07, p = 0.56 respectively. 
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Figure 7.1: Scatterplot with regression of cTFC vs IMR.
* 
IMR was log transformed 
prior to analysis. 
 
7.3.3 A comparison of pressure wire data with ECG ST segment resolution index 
 
ST segment resolution (STR) was calculated as the percent resolution in the single lead 
with the maximum baseline ST segment elevation as described in the methods section. 
These data were divided into ST segment resolution of greater than or less than 70% as 
previously described. Electrocardiographic data was available for 69 patients.  The mean 
(SD) per cent STR was 68.8 (30.1) with 30 (43%) patients having an STR of less than 
70% and 39 (57%) having STR greater than 70% following reperfusion.  
 
These results are contained in table 7.2 below. 
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 STR < 70% STR > 70% P value 
Median IMR [IQR] 38.7 [30.1-55.5] 28 [20.1-43.4] 0.03 
Median CFIp [IQR] 0.26 [0.19-0.31] 0.28 [0.2-0.34] 0.51 
Median Pw [IQR] 22 [16.7-27] 24 [16-30.3] 0.56 
 
Table 7.2: Pressure wire data assessed by ST segment resolution index. The Mann 
Whitney test was used to compare non normal data. A p value of <0.05 was taken as 
significant. 
 
IMR was significantly lower in those with an ST segment resolution index of greater than 
70%. There were no significant differences in CFIp or Pw. 
 
7.3.4 Comparison between physiological assessment of MVO following PCI and 
peak troponin I 
 
In total 69 patients had their peak troponin I measured as described. The range was 1.39 
to 606 ng/ml and the median [IQR] was 33 [16.9-67.0]. Given the non-normal 
distribution of the data all was log transformed prior to comparison. Peak troponin I did 
not correlate with either distal coronary wedge pressure (r = 0.16;p = 0.2) of CFIp (r = 
0.09;p = 0.45). However IMR post procedure did correlate with TnI (r=0.46;p<0.001).  
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Figure7.2: Scatterplot of IMR vs peak troponin I (r=0.46;p<0.001) 
 
 
7.3.5 The influence on time to presentation and reperfusion on pressure wire data 
 
There were no significant correlations between IMR, CFIp and Pw and the time to 
presentation; r=0.14 p=0.26, r=0.09 p=0.49 and r=0.06 p=0.64 respectively. When total 
time from symptom onset to reperfusion (either by thrombolysis or PCI) was taken into 
account IMR, but not CFIp or Pw correlated significantly, r=0.25 p=0.039. 
 
7.3.6 A comparison of pressure wire data with method of AMI reperfusion 
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Median IMR (IQR) was 39.8 (30 -55) in those whom underwent rescue PCI, 35.5 (21-60) 
in those whom underwent primary PCI and 24.4 (17-35) in those in whom PCI was 
performed within 24 hours of successful reperfusion therapy (prognostic). There was a 
significant difference between the rescue and prognostic groups (p=0.009) and the 
primary and prognostic groups (p=0.04) 
 
Median CFIp [IQR] was 0.27 [0.20 – 0.33] in those whom underwent treatment for 
STEMI with rescue PCI, 0.27 [0.23 – 0.33] and 0.28 [0.18-0.34] in those in whom PCI 
was performed within 24 hours of successful reperfusion therapy (prognostic). There was 
no significant difference between the groups. 
 
Median Pw [IQR] was 23 [14.5-30] in those whom underwent rescue PCI, 22[17.5-30.2] 
in those whom had primary PCI and 25 [16.0-30] in those in whom PCI was performed 
within 24 hours of successful reperfusion therapy (prognostic). There was no significant 
difference between the groups. 
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Figure 7.3: Median IMR and Pw in each of the PCI groups 
 
 
 
Nature of PCI Median IMR (IQR) Infarct volume (SD) mls 
Primary 35.5 (21-60) 25 (24) 
Rescue 39.8 (30-55) 29 (24) 
Prognostic 24.4 (17-35) 13 (15) 
 
Table 7.3: median IMR and with mean infarct volumes at 48h by type of PCI 
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7.4 Discussion 
 
7.4.1 The relationship between IMR and other indices for microvascular damage 
available directly after emergency PCI 
 
Interrogation of the coronary microvasculature is possible by the measurement of 
IMR.
131, 137
 But, correlations between IMR and other more conventional and validated 
indices associated with microvascular damage in the context of STEMI is limited. In this 
aspect of my thesis I will discuss the relationship between IMR and the “traditionally” 
used indices of microvascular perfusion with patients with re-perfused STEMI treated 
with emergency PCI. 
 
Electrocardiographic ST segment resolution following reperfusion is known to be an 
indirect marker is microvascular perfusion and discussed is discussed previously in this 
work. In this thesis the median IMR was significantly higher in those who did not achieve 
ST resolution of 70%.  
 
There was a close correlation between IMR and CTFC post PCI and a close correlation 
between IMR and CFIp, and IMR and Pw following intervention.  
 
Fearon et al compared IMR, ST segment resolution, myocardial blush grade, cTFC and 
CFR in their ability to predict wall motion injury assessed echocardiographically in 29 
patients. They did not, however, directly compare these indices.
47
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Sezer at el compared IMR with Pw, CFIp, CFR, ST segment resolution and MBG in 42 
patients 48h following successful primary PCI.
190
  
 
My work in a larger group of patients found a close correlation between IMR, Pw and 
CFIp similar to Sezer et al. I believe, at the time of writing, that this is a largest study 
directly comparing IMR with these surrogate markers of microvascular damage following 
emergency PCI.  I believe that my work adds to that of Sezer et al by implying that the 
relationship between IMR and the surrogate markers for tissue perfusion indicate that the 
impairment of microvascular perfusion is most likely due to increased microvascular 
resistance or at least indicates that increased microvascular resistance following 
emergency PCI is one of the most important mechanisms in impairment of microvascular 
perfusion.  
 
I think this aspect of my thesis adds to the body of evidence that IMR could prove to be a 
valuable and robust modality in evaluating the coronary microcirculation following PCI.  
 
7.4.2 The relationship between IMR, time to reperfusion and method of reperfusion 
 
Meta-analysis has revealed that primary PCI is superior to thrombolysis in acute 
myocardial infarction.
13
 There has been a direct relationship between time to treatment 
with thrombolysis for STEMI and mortality.
191, 192
 It has been suggested that despite 
longer time to treatment seen generally with primary PCI, mortality is not as time 
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dependent as seen with thrombolysis.
193
 One suggestion is that thrombolysis is associated 
with slower and incomplete epicardial recanalisation in combination with downstream 
micro-embolisation of thrombotic and vasoactive material.
194
 
 
I therefore investigated the link between time to reperfusion and IMR and the differences 
in IMR depending on the method of reperfusion.  
 
There was a link between IMR and time to reperfusion but not with CFIp or distal 
coronary wedge pressure. Interestingly there was no link between time of symptom onset 
to time of presentation and IMR. Although the link between IMR and time to reperfusion 
is weakly significant (p = 0.039), animal models have shown that duration of coronary 
artery occlusion is directly related to infarct size
195
 therefore I feel it does further 
strengthen the link between IMR and extent of myocardial injury. 
 
Within my patient population the median IMR was higher in those whom underwent 
rescue PCI in comparison to primary PCI although this was not statistically significant. I 
think this is understandable, primarily given that by definition these patients have not re-
perfused electrocardiographically therefore have their coronary artery occluded for a 
longer period and therefore would be expected to have larger infarcts. This trend is 
confirmed by infarct volume analysis on the 48h CMR scanning. 
 
Both IMR and infarct volumes are significantly reduced in the patients whom underwent 
prognostic PCI within 24h of re-perfused STEMI with thrombolysis. The reduction in 
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IMR is most likely due to the time delay between electrocardiographic reperfusion and 
PCI. I accept this as a limitation within the study. 
 
Overall however I think this aspect of the thesis emphasizes the link between IMR and 
extent of myocardial injury. 
 
 
7.4.3 The relationship between pressure wire derived indices of microvascular 
damage and peak troponin I 
 
In my study I found a close correlation between peak troponin I and IMR. Elevated 
cardiac troponin in patients with ST elevation and non ST elevation myocardial infarction 
is associated with adverse outcomes, including a higher incidence of congestive heart 
failure, shock, and death. Large clinical trials have revealed the important prognostic role 
of troponin in this patient population. 
196-198
 The Global Utilisation of Streptokinase and 
Tissue Plasminogen Activator for Occluded Arteries (GUSTO) II reported that in patients 
with STEMI, there was a higher risk of 30-day mortality in groups of patients with a 
positive admission troponin T compared to those in whom it was negative ( 13.0% and 
4.7% respectively).
196
  This was confirmed in a GUSTO sub-study which enrolled over 
12000 patients. In this study elevated troponin T was associated with a worse early and 
long term prognosis. 
197
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The use of troponin has now become widespread in the diagnosis of myocardial 
infarction, its role as a biochemical marker of infarct size has also become well validated 
by using SPECT imaging 
199
 and more recently in a large study (n = 1237) correlating 
peak troponin T with scintigraphically determined myocardial infarct size in patients with 
STEMI undergoing contemporary primary percutaneous intervention
200
. 
 
Younger et al found that both 12 hour and 72 hour troponin I concentration correlated 
with infarct size as assessed by ceCMR (r = 0.56, p = 0.0003; r = 0.62, p<0.0001 
respectively). 
 
The close relationship between IMR and peak troponin I in my study therefore adds to 
the hypothesis that IMR is a robust marker of myocardial damage when measured 
directly after PCI. 
 
7.5 Conclusions 
 
IMR calculated following STEMI correlated closely with tradition angiographic, pressure 
wire and biochemical markers of microvascular and myocardial damage following 
STEMI. This adds to the growing body of evidence that IMR is a robust marker of 
myocardial damage following STEMI.  
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Chapter 8: Advances in cardiac imaging 
in STEMI survivors: diagnostic utility of 
cardiac magnetic resonance 
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8.1 Introduction 
Clinical guidelines recommend imaging of the heart for risk assessment after ST 
elevation myocardial infarction (STEMI)
68
, and cardiac imaging is required for the 
assessment of post MI complications including left ventricular dysfunction. 
Cardiac magnetic resonance imaging (CMR) is a powerful diagnostic method and 
provides prognostically relevant information
201
. In addition to being useful for 
quantifying heart function, volumes and viability after acute MI
85, 87, 202
, CMR can reveal 
myocardial injury characteristics, such as microvascular obstruction (MVO) and infarct 
size
15
. CMR within the first week post-MI is also safe but there is limited evidence on the 
safety and feasibility of the test in the heterogeneous group of patients who survive 
STEMI in the very early post infarct period.  
Contrast-enhanced CMR (ceCMR) provides diagnostic information which collectively 
cannot be provided by any other single imaging test. Although echocardiography is the 
standard of care for imaging post-MI it is limited by acoustic shadows and reveals little 
about extra-cardiac disease. Both forms of imaging should be performed and interpreted 
by trained individuals. Historically, CMR has generally not been feasible in STEMI 
patients because of logistical and cost issues, however it is becoming increasingly 
available in regional hospitals, including those which provide primary percutaneous 
coronary intervention (PCI). 
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In order to better understand the potential role of CMR for early risk assessment in 
STEMI, we prospectively studied the feasibility and diagnostic utility of CMR in a broad 
range of invasively managed STEMI patients treated in two different hospital settings. 
We included patients with angiographically incomplete myocardial reperfusion, heart 
failure, arrhythmia and those post thrombolysis. Furthermore we hypothesised that the 
utility of CMR might be enhanced by disclosure of clinically relevant cardiac findings in 
the early post infarct period as well as incidental non-cardiac findings
203
, provided these 
observations do not also trigger unnecessary tests or interventions. In addition we studied 
the clinical significance between early CMR findings and adverse cardiac events within 
30 days of discharge.  
 
8.2 Methods 
8.2.1 Patient population 
Two hundred patients with STEMI who underwent primary, rescue or convalescent PCI 
were referred for a CMR scan. Exclusion criteria were : lack of informed consent, lack 
scanner availability, standard contra-indications to MRI including an estimated 
glomerular filtration rate < 30 ml/min/1.73 m
2
 or on-going hemodynamic instability, 
defined as patients receiving support with intra-aortic balloon counter pulsation, 
temporary pacing wire or inotropic therapy. Patients with ventricular and supraventricular 
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arrhythmia were considered if the cardiac rhythm had been stable for > 6 hours. In all 
cases the scan was performed pre-discharge. The research was approved by the West of 
Scotland Ethics Committee and Clinical Governance office of the National Waiting 
Times Board. standard contra-indications to MRI including an estimated glomerular 
filtration rate < 30 ml/min/1.73 m
2
. 
STEMI was defined according to a history of symptoms consistent with acute myocardial 
ischemia and ST-segment elevation on the electrocardiogram (ECG) associated with a 
typical rise of troponin I (TnI) concentration
68
. Acute heart failure was diagnosed 
according to Killip class
172
. 
Acute MI management followed contemporary guidelines
68
. Aspiration thrombectomy, 
direct stenting, anti-thrombotic drugs and other therapies were administered according to 
local protocols. Pulse pressure was recorded at the beginning of the PCI. The 
Thrombolysis in Myocardial Infarction (TIMI) flow classification was used to grade 
culprit artery flow at initial angiography and at the end of the procedure
58
. 
8.2.2 Follow-up 
Patients were followed-up for 30 days from hospital discharge to detect early adverse 
events and assess for an association between cardiac events and early CMR findings. An 
adverse cardiac event was defined as death or an unplanned hospitalization for heart 
failure or an acute coronary syndrome (ACS) in line with contemporary criteria
 68
. The 
diagnosis was established based on a comprehensive review of hospital and general 
213 
 
practitioner records made by attending clinicians who were not members of the research 
team. 
8.2.3 CMR scans 
CMR was performed under medical supervision early after admission to the Coronary 
Care Unit in order to facilitate patient management as previously described.  
8.2.4 CMR image analysis and reporting 
All MR images were analyzed on a Siemens workstation by a trained cardiologist with at 
least 2 years MRI experience. Left ventricular (LV) dimensions, volumes and ejection 
fraction were quantified using computer assisted planimetry. A CMR report was written 
into the case notes immediately after the scan to facilitate early in-patient management. 
8.2.5 Incidental findings 
An incidental finding is a previously unknown medical problem which is unrelated to the 
condition being studied. In our study, we defined a clinically significant cardiac or non-
cardiac incidental finding as one which triggered a change in management (e.g. change in 
treatment) by the attending cardiologist. The field of view included the upper abdomen, 
including the liver, kidneys and spleen. We adopted a screening approach to the 
diagnostic evaluation of extra-cardiac disease based on the limitations of the scan being 
primary for assessment of the myocardium. 
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Our approach was motivated on a desire to detect clinically-significant pathology (e.g. a 
lung cancer) should ever it be present in the imaging field of view. The trade-off for this 
approach is the likelihood of reporting observations that are not clinically significant and 
the risk that such observations might trigger additional tests. Our approach to the 
interpretation of non-cardiac findings therefore involved a low threshold for a radiology 
consult and defined criteria for doing so. 
The presence of a lung nodule triggered a radiological consult. Isolated fibrotic change of 
lung parenchyma or pulmonary plaque was not considered as clinically significant. A 
liver mass > 2cm was taken as an indication for ultrasonography. Splenomegaly was 
defined as greater than 11 cm at its largest dimension and any renal mass was referred for 
a radiology consult due to the potential for renal cell carcinoma to present as an 
incidental finding at an early stage. Left ventricular thrombus was diagnosed based on 
endocardial cardiac mass which did not enhance with first pass or late gadolinium 
enhanced CMR.   
8.2.6 Biochemical assessment of infarct size 
Troponin I was measured (AxSYM; Abbott) as a biochemical measure of infarct size.  
A blood sample was routinely obtained 12 hours after hospital admission. 
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8.3 Statistical analysis 
Normality was confirmed or excluded using the Shapiro-Francia test. Mean (SD) 
values and medians (interquartile range) were calculated. All tests
 
were two-tailed. 
Between-group comparisons of normally distributed continuous data were undertaken 
using a Student’s t test. Between-group comparisons of non-normally distributed data 
were performed with a Mann Whitney test. A Fisher’s exact test was used to assess the 
difference in proportions.  The association between MRI findings and cardiovascular 
events was assessed with Log Rank test. P < 0.05 was taken as significant. The data were 
analyzed with SPSS (version 15.0). 
8.4 Results 
The mean age of the study population was 58±10 years with 78% being male. Primary 
PCI had been performed in 82% with the remainder undergoing rescue or convalescent 
PCI after thrombolysis. Killip class II – IV was present in 13% and 22% had prior 
hemodynamic instability (Table 8.1). 13 (6.5%) patients required electrical cardioversion 
for a ventricular arrhythmia. Of these, 10 (5%) were reperfusion arrhythmias that were 
treated in the catheter laboratory and 3 (1.5%) of these occurred in the coronary care unit. 
 All 
 
200 
≤ 24 h post-
admission 
128 (64%) 
> 24 h post-
admission 
72 (36%) 
P 
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Admission characteristics 
    
Age ± SD, years 58 ± 10 58 ± 10 58  ± 11 0.98 
Male gender, n (%) 157 (78) 104  (81) 53  (74) 0.21 
Previous MI, n (%) 11 (6) 5 (4) 6 (8) 0.21 
Diabetes, n (%) 10 (5) 7 (6) 3 (4) 1.00 
BMI ± SD, kg/m² 26 ± 4 27 ± 4 26 ± 4 0.60 
Killip class 
I 
II 
III 
IV 
 
174 (87) 
14 (7) 
11 (5.5) 
1 (0.5) 
 
112 (88) 
9 (7) 
7 (6) 
0 (0) 
 
62 (86) 
5 (7) 
4 (6) 
1 (1) 
 
Catheter laboratory characteristics 
    
Pain to balloon time ± SD, hours 5.4 ± 5.2 5.1 ± 5.0 5.8 ± 5.5  0.65 
TIMI grade post-PCI, n (%) 
                          0 
                          1 
                          2 
                          3 
 
1 (0.5) 
1 (0.5) 
15 (8) 
183 (91) 
 
0 (0) 
0 (0) 
8 (6) 
120 (94) 
 
1 (1) 
1 (1) 
7 (10) 
63 (88) 
 
0.21 
Hemodynamic instability prior to CMR, 
n (%) 
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Intra-aortic balloon therapy 
Non-sustained ventricular tachycardia  
Ventricular tachycardia 
Ventricular fibrillation 
BP< 90/60 mmHg 
1 (0.5) 
10 (5) 
7 (3.5) 
6 (3) 
13 (6) 
0 (0) 
5 (2.5) 
4 (2) 
3 (1.5) 
10 (8) 
1 (1.0) 
5 (2.5) 
3 (1.5) 
3 (1.5) 
3 (4) 
 
Laboratory characteristics  
Serum creatinine ± SD, mol/L 78 ± 29 76 ± 30 87 ± 19 0.42 
Troponin I ± SD, g/L 59 ± 65  59 ± 57 57 ± 77 0.83 
Drug therapy at time of MRI 
    
Glycoprotein IIbIIIa inhibitor, n (%)* 173 (85) 115 (90) 58 (76) 0.06 
Thrombolytic before CMR, n (%) 35 (18) 14 (11) 21 (29)  
I.V. diuretic before CMR, n (%) 20 (10) 12 (9) 8 (11) 0.72 
Other Imaging prior to CMR† 
    
CXR , n (%) 117 (58) 85 (66) 32 (44) 0.002 
Orbit X-Ray, n (%) 10 (5) 4 (3) 6 (8) 0.10 
Echocardiography, n (%)      45 (22) 19 (15) 26 (36)   0.001 
Table 8.I: Clinical characteristics 
MI: myocardial infarction; BMI: body mass index; LAD: left anterior descending artery; 
Cx: circumflex artery; RCA: right coronary artery; IABP: intra-aortic balloon pump; VT: 
ventricular tachycardia; VF: ventricular fibrillation; NSVT: non-sustained ventricular 
tachycardia; BP: blood pressure; TIMI grade: thrombolysis in myocardial infarction 
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grade; PCI: percutaneous coronary intervention;; CXR: chest X-ray; LVF: left ventricular 
failure Killip Class I: no heart failure; II: heart failure; III: severe heart failure; IV: 
cardiogenic shock. TIMI grade post-PCI: Grade 0: no perfusion; Grade 1: penetration 
without perfusion; Grade 2: partial perfusion; Grade 3: complete perfusion. 
 
* In patients who were being treated with intravenous glycoprotein IIbIIIa inhibitor 
therapy at the time of MRI, the infusion was stopped for the duration of the scan. 
† Imaging performed prior to CMR was prospectively documented in order to record new 
findings  
8.4.1 CMR scans 
The CMR scan was performed < 24 hours after hospital admission in 128 (64%) patients 
and the characteristics of patients who underwent very early CMR were similar to those 
imaged at a later time (Table 1). The remaining 72 patients (36%) were imaged between 
24 and 72 hours after admission. The median (inter quartile range) time from hospital 
admission to the CMR scan was 22 (16, 28) hours and the average (±SD) scan duration 
was 44 ± 10 min. Of the patients who had CMR within 24 hours of admission, 13 (10%) 
were scanned < 12 hours, 54 (42%) were scanned 13 - < 18 hours and 61 (48%) were 
scanned 18 - 24 hours after invasive management. 
CMR provided complete information on LV mass and function in 195 (98%) patients and 
no complications or adverse events occurred. Infarct size and MVO were measured in 
191 (96%) patients (Table 8.2). The CMR scan was stopped before a complete 
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assessment of LV function in 5 (2%) patients and in 4 (2%) other patients ceCMR was 
not tolerated. The reasons for an incomplete CMR examination were claustrophobia (8 
(4%) patients) and back pain (1 (0.5%) patient). Two (1%) patients had real time cine 
CMR because of heart rhythm irregularity. Fifteen patients (8%) had limited ability to 
breath-hold and information on infarct scar was facilitated in these patients using single 
shot LGE CMR. 
Chest radiography and echocardiography had been performed before CMR in 117 (58%) 
and 45 (22%) patients, respectively. 
8.4.2 Cardiac findings (Table 8.2) 
Impaired LV systolic function (LVEF < 55%) was common (61% of all patients). 
Fourteen (7%) patients had a severe reduction in LVEF (<55%), 35 (18%) patients had a 
moderate reduction in LVEF (35% - <45%) and 73 (60%) patients a mild reduction in 
LVEF (45 - < 55%). Ninety eight (50%) patients had an increased LV end-systolic 
volume index. 
CMR findings in patients imaged within 24 hr of hospital admission were similar to 
CMR findings in patients imaged later suggesting that patient selection for a very early 
CMR scan was not influenced by the severity of MI. Table 8.2. MRI scans and findings 
in 195 STEMI patients who underwent CMR early after hospital admission.* 
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MRI scan  All < 24 h post-
admission 
≥ 24 h post-
admission 
 
P 
Heart rate ± SD, min 73 ± 13 73 ± 13 73 ± 13 0.7 
Duration, ± SD, min 43.87 ± 10.22 43.63 ± 9.43  44.32 ± 11.58 0.77 
Scan completed, n (%) 191 (95.5) 122 (95.3) 69 (95.8) 1.00 
Complications 0 (0) 0 (0) 0 (0) - 
LVEF± SD, % 52 ± 11 51 ± 10 53 ± 12 0.34 
LVEDV ± SD, ml: Male  
                               Female 
160 ± 33 
126 ± 34 
159 ± 30 
131 ± 38  
167 ± 41 
115 ± 22 
0.44 
0.31 
Infarct size ± SD, % of LV 22.1 ± 14.8 23.4 ± 14.3 19.6 ± 15.5 0.10 
Microvascular obstruction ± SD, % of 
LV 
2.8 ± 3.7 3.1 ± 3.8 2.2 ± 3.3 0.07 
Table 8.2: CMR results 
* Of the 200 patients who had had a CMR scan, 195 had complete information on LV 
function. Four of these patients did not tolerate CMR after contrast administration. Real 
time cine and single shot delayed enhancement CMR were done in 2(1%) and 15(8%) 
patients, respectively. 
 
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end diastolic volume; 
LVESV: left ventricular end systolic volume; BSA: body surface area; infarct size and 
microvascular obstruction are recorded as a percentage of left ventricular myocardium 
 
For discrete variables χ2 test was used, except * (Fisher’s exact test). For continuous 
variables, 2-tailed independent samples T-test was used 
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Cine    T2 weighted CMR            Late gadolinium 
enhancement 
 
   
   
   
Figure 8.1. 
1: Transmural inferior myocardial infarction with haemorrhagic microvascular 
obstruction, (a) still image from retrospective cine; (b) T2-weighted CMR image; (c) 
LGE. 
2: Non-transmural MI in the left ventricular septum with transmural oedema and 
microvascular obstruction, (a) still image from retrospective  cine; (b) T2-weighted 
CMR image; (c) LGE. 
 
 
8.4.3 Incidental findings 
Incidental findings are described in Table 8.3. Six patients (3%) had a lung mass 
discovered which triggered respiratory investigations including chest computed 
a) 
b) 
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tomography. Three of these patients had a final diagnosis of lung cancer (2 patients had 
non-small cell lung cancer and 1 patient had an adenocarcinoma with ipsilateral 
metastases). The admission chest X-ray was normal in two of these patients and in the 
other patient the chest X-ray was independently read abnormal. The three other patients 
had benign lung disease. 
One 43 year old woman who did not smoke and had no prior history of coronary disease 
presented with an acute inferior STEMI. Coronary angiography revealed an occluded 
right coronary artery and otherwise angiographically normal coronary arteries. Following 
primary PCI, she underwent CMR directly without prior echocardiography in order to 
assess for a possible cardiac source of embolus. CMR revealed a patent foramen ovale 
and a valsalva manoeuvre supported a diagnosis of paradoxical embolus. There was no 
history of systemic illness and no other reason to suspect a non-cardiac source of 
embolus. The PFO was closed percutaneously the day after the CMR scan. One other 
patient had marked splenomegaly. This man was referred for a haematology consult and a 
new diagnosis of myeloproliferative disorder was established. Two patients had evidence 
of left ventricular thrombus revealed by CMR which had not been revealed by 
echocardiography.  
 
System Pathology Patients,  
n (%) 
Prognostic 
importance 
Management 
change 
 
Comment 
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Cardiac      
PFO^ 1 (0.5) Yes^ Yes Transcatheter closure  
LV thrombus 2 (1) Yes Yes Anti-coagulation 
Bicuspid aortic valve 1 (0.5) Yes Yes Referred to cardiology out-
patient clinic 
 Pleural effusion associated 
with pulmonary oedema 
15 (8) Yes Yes Intravenous furosemide was 
subsequently administered in the 
CCU in those not previously 
treated with iv diuretic 
Lung Pulmonary mass  3 (1.5) Yes Yes 2 confirmed as non-small cell 
lung cancer and 1 as lung 
adenocarcinoma with ipsilateral 
lung metastases 
Spleen Splenomegaly 1 (0.5) Yes Yes Myeloproliferative disorder 
Spine Vertebral crush fractures 1 (0.5) Yes Yes Referred for management of 
osteoporosis 
All  24 (12)   
 
 
Table 8.3: Incidental findings 
 
The following other abnormalities were observed which did not result in further tests or 
treatment: previous MI 14 (7%), cor triatriatum sinistrum 1 (0.5%), intra-myocardial 
lipomata 1 (0.5&), pulmonary fibrosis and/or plaque 5 (3%), hepatic cyst 3 (2%), splenic 
cyst 1(0.5%),  
 
The following other abnormalities were observed which resulted in abdominal ultrasound 
but no further treatment: liver haemangioma 3(2%), renal cyst 1 (0.5%),  
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^CMR revealed a patent foramen ovale and the aetiology of STEMI in this patient was 
paradoxical embolus. The PFO underwent percutaneous closure the day after the CMR 
scan. 
 
^^^ Pulmonary oedema was observed on T2 weighted HASTE CMR. In all of these 
patients, intravenous diuretic was administered in the coronary care unit afterward since 
pulmonary oedema was judged to be a complication of myocardial infarction. 
  
 
Figure 8.2  
1: Splenomegaly (arrow) in a patient with an undiagnosed low-grade 
hemoproliferative condition. The observation was revealed on T1 localiser imaging. 
2: HASTE MRI reveals a right upper lobe parenchymal lung tumour (arrow) with a 
second lesion in lower lobe (arrow). A diagnosis of metatstatic adeoncarcinoma was 
subsequently made.  
 
 
 
 
a) b) 
225 
 
 
8.4.4 CMR findings are associated with early rehospitalisation for heart failure or 
ACS 
Eight (4%) patients had an unplanned hospital readmission within 30 days of discharge 
because of heart failure (3 (1.5%) patients) or a confirmed ACS (5 (2.5%) patients), of 
whom 2 (1%) had acute stent thrombosis. All of the ACS patients had repeat angiography 
and 4 of these patients underwent PCI. Compared to patients who were not readmitted for 
heart failure or an ACS, the patients who were readmitted had a lower initial LV ejection 
fraction (40.3±11.5% vs. 52.1±10.6%; p=0.005) and higher initial LV end-diastolic 
volume index (50.5±16.7ml/kg/m
2
 vs. 37.5 ±12.7 ml/kg/m
2
; p=0.034) and infarct size 
(36.5±12.12% vs. 21.6±14.6%; p=0.006).  
8.5 Discussion 
We have described a series of 200 STEMI survivors who underwent early in-patient 
CMR. Our study describes one of the largest STEMI cohorts evaluated by CMR to-date.   
CMR was feasible, safe and informative in 98% of patients. In addition to providing 
prognostically important information, such as LV ejection fraction, infarct size and 
microvascular obstruction, CMR revealed clinically relevant incidental findings. 
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Our first aim was to evaluate the feasibility and safety of CMR in a broad range on 
STEMI survivors. Two thirds of the STEMI patients had a CMR scan within 24 hours of 
hospital admission and one fifth had a history of heart failure or hemodynamic instability. 
Ad hoc CMR was achieved by reserving the first CMR scan appointment each day for 
new admissions and by making use of the scanner when patients with elective 
appointments did not attend. CMR was performed under medical supervision and no 
complications occurred.  
Our findings extend those of Larose et al 
204
 who successfully scanned 102 patients < 12 
h post-STEMI in the Québec Heart Institute. All of their patients had undergone 
successful primary PCI (grade III TIMI flow at the end of the procedure) whereas our 
patients were higher risk. For example, in our cohort nearly one fifth of the patients had 
been initially treated with tenectaplase, some had sub-optimal catheter lab outcomes and 
patients with a history of hemodynamic instability (including one patient initially treated 
with an intra-aortic balloon pump) were included. Our findings indicate that CMR can be 
safely performed even in high risk patients supporting the potential utility of CMR in 
clinical practice. 
Finally, CMR revealed new observations of varying clinical significance. Some cardiac 
pathologies were obviously clinically significant (e.g. LV thrombus, patent foramen 
ovale associated with embolic right coronary occlusion). The LV thrombus had not been 
observed by prior echocardiography or left ventriculography. In one other patient, CMR 
revealed a PFO leading to a diagnosis of paradoxical embolus. This woman underwent 
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transcatheter closure of the PFO during the index admission. Similarly some extra-
cardiac pathologies (e.g. metastatic lung disease, splenomegaly Figure 8.2) were 
prognostically important. Chest radiography did not reveal the lung mass in two of the 3 
patients with lung cancer. Splenomegaly was observed in a patient who was subsequently 
diagnosed with a myeloproliferative disorder. Some observations had less certain clinical 
significance (e.g. pulmonary oedema) however the attending staff decided to administer 
diuretic, which we think is a pragmatic empirical decision commonly made in medicine. 
On the other hand, there were several observations which were not clinically significant, 
such as simple cysts. Simple cysts are common and even in the current study were all 
found confirmed by ultrasound as simple and did not alter management. MRI that 
includes gadolinium can characterize many of these cysts and avoid an unnecessary 
ultrasound.  
Overall, our approach to CMR was to screen for extra-cardiac findings using defined 
criteria and request a radiology opinion in selected cases as appropriate (e.g. for lung, and 
kidney masses). In this way, we sought to avoid unnecessary tests and improve diagnostic 
confidence. We accept that chest radiography and echocardiography and were not 
performed in all patients before CMR and so direct comparisons with other diagnostic 
methods is not possible. However, a formal comparative imaging study was not our aim. 
Consistent with findings by Weir et al 
203
,
 
we conclude that CMR has high diagnostic 
utility in STEMI survivors. 
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Usually, when a CMR is requested for an STEMI patient the scan is performed at least a 
few days after hospital admission in line with clinical guideline recommendations 
68
. 
Historically, CMR has been delayed in patients with recent MI because of safety 
concerns. However, STEMI patients managed invasively have a lower risk of post-MI 
complications than STEMI patients treated with thrombolysis alone. Based on our 
experience, CMR can be safely performed under medical supervision even within 12 h of 
hospital admission in stabilized patient, in line with observations from other groups 
76
  
 
In addition to providing LV ejection fraction and volumes in almost all of the patients, 
ceCMR was completed in 95% of patients delineating infarct burden and MVO. We did 
not perform a comparative study of CMR and echocardiography since the comparative 
strengths of each form of imaging are well described
 71
. Echocardiography can be 
performed at the bedside and is cheaper. Alternatively, CMR has higher diagnostic 
accuracy for assessment of LV ejection fraction and volumes
71
 and only CMR can 
provide information on prognostically-important infarct characteristics (infarct size, 
MVO) 
15, 87, 176
. 
 
The clinical utility of CMR is influenced by whether the test is feasible and if so, whether 
the diagnostic information from the scan leads to a change in management or provides 
new insights into prognosis (Table 8.3). CMR is an expensive diagnostic test and 
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therefore the health economic considerations of CMR post-MI are important. 
Increasingly, the emergency care of STEMI patients is centralised to ‘heart attack’ 
hospitals which provide primary PCI and coronary angiography for patients transferred 
after thrombolysis. These hospitals are usually resourced with advanced medical 
equipment such as MRI, meaning that the centralization of invasive cardiac services in 
hospitals potentially increases access of STEMI patients to CMR.  Even in this setting, in 
practical terms, although CMR may have the highest diagnostic accuracy for imaging 
post-MI
71
 it is unlikely to be feasible for all STEMI patients therefore its use should be 
selected to high risk subgroups in whom CMR is most likely to provide prognostically 
important information that could result in improved health outcomes. What we have 
shown is that CMR findings were associated with early readmission to hospital for a heart 
failure or recurrent ACS. We think this is because the diagnostic accuracy of CMR is 
high and the scans reveal the nature and severity of heart injury unlike echocardiography 
or chest radiography. Thus, our preliminary findings suggest that CMR may have a role 
for risk stratification. Should future studies demonstrate that CMR can identify patients at 
risk of early readmission to hospital then interventions could be tested to prevent these 
events. Going forward, we hypothesise that CMR will be most cost-effective in the 
following groups of STEMI survivors or scenarios 1) patients in whom echocardiography 
is limited (e.g. poor acoustic window), 2) availability of a future evidence-based therapy 
targeted at pathology which can be selectively revealed by MRI (e.g. MVO). Therefore, 
the cost-utility of CMR would likely increase if targeted to these patient groups.  
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8.6 Limitations 
About one third of all STEMI patients who were treated in our hospitals underwent 
CMR. When CMR was not performed it was usually for logistical reasons e.g. out-of-
office hours. Whenever an eligible patient agreed to have a scan, the MRI department 
was usually able to perform the scan ad hoc.  
CMR is not feasible in patients with some types of devices and foreign bodies meaning 
that around 5% of patients may be ineligible. Recent developments are helping to 
overcome some of these limitations. Firstly, technical developments with CMR mean that 
breath-holding is no longer mandatory and CMR can be performed in free-breathing 
patients including those with irregular heart rhythms. CMR compatible device leads are 
also now being used.  
Since rehospitalisations were uncommon we did not perform multivariable analyses for 
predictors of 30-day outcomes. 
8.7 Conclusions 
CMR is feasible and safe in the hours following emergency PCI in a broad range of 
patients following STEMI. It provides useful prognostic information in the early stages 
following revascularisation to potentially identify “high risk” patients and furthermore 
has potential to uncover clinically relevant extra-cardiac abnormalities.  
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Chapter 9 - Conclusions and clinical implications 
 
9.1 Postulated therapeutic interventions to minimize microvascular damage in 
STEMI 
 
Although the pathophysiological understanding of MVO has improved, mechanical and 
therapeutic interventions to prevent or minimize its impact have yet to be translated from 
the experimental level into hard clinical end-points.  
 
Distal protection devices effectively have been shown to effectively retrieve embolic 
debris during primary PCI but have not been shown to improve microvascular flow, 
reduce infarct size or improve event free survival. 
33
 
 
Although aspiration thrombectomy improves reperfusion on comparison with 
conventional PCI a significant number of patients continue to experience incomplete 
myocardial perfusion
205
 and indeed in my own study there was no difference in the IMR 
between each group with this operator dependent variable. 
 
Intra-aortic balloon pump counter pulsation reduced MVO in the experimental model but 
clinical studies using this intervention in the setting of STEMI have shown no 
improvement in LV ejection fraction or increased survival at follow up. 
206, 207
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Administration of intra-coronary verapamil after PCI decreased evidence of no-reflow
208
 
and glycoprotein IIb/IIIa inhibition has been shown to significantly improve 
microvascular flow in dog models and has increased the rate of ST segment resolution 
and CTFC in clinical trials.
209-211
 
 
Selective intracoronary administration of the microcirculatory vasodilator adenosine 
improved microvascular perfusion leading to improved regional ventricular function in 
the infarcted canine model. In the clinical setting, however, although infarct size was 
reduced, a three hour intravenous infusion of adenosine in re-perfused STEMI patients 
failed to show an improvement in outcome.
212
 
 
IMR recorded 48h after successful primary PCI has been used as a marker for increased 
myocardial microvascular perfusion following the administration of intracoronary 
streptokinase at the time of the procedure.
139
 The group which had the lower IMR 
following administration of the intracoronary thrombolytic were shown to have lower 
infarct volumes and higher ejection fractions at long term follow up. 
213
 
 
More recently Ito et al randomized patients whom underwent successful PCI to receive a 
bolus of intracoronary nicorandil, a vasodilator which acts both as a nitrate and on the K-
ATP channel, or a bolus of saline. There was a significant reduction in IMR following 
this in the nicorandil group, although interestingly this change was not seen it those 
whom had a low IMR at baseline.
214
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9.2Clinical implications for use of IMR in STEMI 
 
In summary, I found that IMR correlated with traditional markers for infarct size and 
myocardial damage. I found that IMR was significantly higher in those whom had 
evidence of MVO on ceCMR imaging. Increased was also a strong independent predictor 
of increased infarct volumes and low ejection fraction at baseline and follow up. The 
other postulated invasive markers of microvascular disease, CFIp and distal coronary 
wedge pressure did not correlate with myocardial damage by ceCMR. IMR can therefore 
provide an indicator of microvascular injury at the time of emergency PCI. This allows 
this at risk patient group immediately after the cornerstone of AMI treatment and could 
allow potential intervention to occur directly thereafter.  
 
It is known a significant proportion of patients who have TIMI 3 flow post PCI have 
evidence of microvascular damage. Significant microvascular obstruction post PCI is not, 
however, universal. This may in part explain why studies aimed as modifying 
microvascular damage post PCI that have recruited “all comers” have been successful on 
a theoretical basis but not in larger clinical studies. IMR has already been used at a 
marker of microvascular damage post PCI before and after therapeutic interventions. I 
think the future of IMR will be to identify the “at risk” population at the time of PCI. 
This will allow targeting of future therapies at the earliest opportunity. I think by 
targeting those who are known to have microvascular damage future studies will be more 
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likely to be beneficial. It is worth noting that in their recent study looking at Nicorandil 
Ito et al did not see any significant difference in the group who had a low baseline IMR, 
indicating that those with low levels of microvascular injury have the least to gain from 
intervention.  
 
 
The IMR is a simple wire based technique that can provide a quantitative assessment of 
microvascular function at the time of emergency PCI. I have shown that an elevated IMR 
is linked to microvascular and myocardial damage as revealed by ceCMR in the early 
post infarction period and at longer term follow up. Accordingly, I suggest measurement 
of IMR represents a new approach to risk assessment at the very earliest stage of acute 
MI management, and potentially, therefore enables triage of higher risk patients to more 
intensive therapy. 
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Appendix A 
 
Version 1.1 Oct 2006  Patient Information Sheet (1) 
 
 
You are being asked to take part in a clinical research study. It is important that you 
understand why you are being asked to take part and what it is involved for you. 
Participation in this trial in voluntary and it is entirely up to you whether you want to take 
part or not. 
 
Title of Project  
 
Correlation of invasive measurements for assessment of microvascular dysfunction with 
cardiac magnetic resonance imaging to predict those most at risk following acute 
myocardial infarction. 
 
What does this title mean and what is the purpose of the study? 
 
Heart attack (myocardial infarction) affects not only the large heart arteries but also the 
small heart arteries. We can see the large heart arteries at angiography. There is not 
currently a reliable way to measure damage to the hearts small blood vessels. There are 
new measurements which can be taken at the time of angioplasty which we now know 
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represent damage to the hearts small blood vessels. We plan to take these measurements 
during angioplasty. We will then perform a special heart scan, an MRI scan, which would 
allow us to look at the blood supply to the heart, to look at the amount of damage to the 
heart as a whole and at the amount of damage to the small blood vessels. Our aim is to 
identify patients with significant damage to the hearts small blood vessels at the time of 
angioplasty therefore allowing us to identify future patients with treatment to minimise 
damage at the earliest opportunity.   
 
What will happen to me if I take part? 
 
If you require an angioplasty (using balloons and stents to open the larger heart arteries) 
we will make measurements that represent damage to the hearts small blood vessels. This 
will add 10 minutes on to your procedure and does not pose any additional risk to you.  
 
Angioplasty involves placing tiny wires into the heart arteries that then allows us to 
inflate balloons and deploy stents (like tiny scaffolds) over the blockage restoring blood 
flow. We would use a wire with a special tip allowing us to make the measurements 
representing damage to the heart small blood vessels.  
 
In order to make these measurements accurately we will have to give you a drip of a drug 
called adenosine. This drug allows more blood to pass into the heart. Its main side effect 
is that it can cause tightness in the chest and can make you feel breathless. Although 
uncomfortable this senSAtion is harmless and does not indicate heart damage. It will pass 
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seconds after the drip is stopped.  Rarely adenosine can cause the heart to slow down but 
this again is only temporary and your heart rate will be monitored throughout the 
procedure.  
 
Adenosine can cause to become more breathless if you have asthma or COPD (smoking 
related lung disease). You will not be able to participate in the trial if you have either of 
these conditions. 
 
You will also receive a heart MRI scan during this hospital admission and in 3 months 
time. We will give you further information about this and the trial as a whole after your 
procedure when you are settled. At this point you can decide whether you wish to 
continue in the study. 
 
Thank you for taking the time to read this patient information sheet. 
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Appendix B 
 
Version 1.2 Oct 2006   CONSENT FORM (1) 
 
Title of project: 
 
Correlation of invasive measurements for assessment of microcirculatory dysfunction with 
cardiac magnetic resonance imaging to predict those most at risk following acute myocardial 
infarction. 
 
Name of researcher: Dr Ross McGeoch     Please initial box 
 
 
1. I confirm that I have read and understand patient information sheet (1) for the above 
study. I have had the opportunity to ask questions and I understand the information 
provided to me. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by responsible 
individuals from the research team or from regulatory authorities where it is relevant to 
my taking part in research. I give permission for these individuals to have access to my 
records. 
 
4. I agree to take part in the above study.       
.              
 
                                                                                                                                          
Name of patient         Date               Signature 
 
 
 
                
Name of Person taking consent        Date               Signature 
(if different from researcher)                                                                        
 
 
 
 
 Researcher                 Date               Signature 
 
I have witnessed the informed consent process and attest that the information contained in the patient 
information sheet was accordingly explained to the patient. I believe the explanation was understood 
and that consent to participate was freely given. 
 
 
 
Name of impartial witness            Date               Signature 
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Appendix C 
 
Version 1.3 Jan 2007                       Patient Information Sheet (2) 
 
 
You are being asked to take part in a clinical research study. Before you decide it is 
important for you to understand why the research is being done and what it will involve 
for you. Please take time to read the following carefully and discuss it with others if you 
wish. Please ask us if there is anything you are unclear about or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
Title of Project 
 
Correlation of invasive measurements for assessment of microvascular dysfunction with 
cardiac magnetic resonance imaging to predict those most at risk following acute 
myocardial infarction. 
 
What does the title mean and what is the purpose of the study? 
 
Treatment of heart attack (myocardial infarction) has traditionally concentrated on 
opening the large heart arteries, whether by “clot busting” medication or balloons and 
stents (angioplasty).  We now know that damage to the heart’s tiny blood vessels also 
occurs during heart attack and this can contribute to longer-term heart damage. We plan 
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to take measurements, which represent damage to the heart’s small blood vessels during 
treatment for heart attack with angioplasty. We will then perform a special heart scan, an 
MRI scan, which would allow us to look at the blood supply to the heart, to look at the 
amount of damage to the heart as a whole and at the amount of damage to the small blood 
vessels. We would also like to obtain a blood and urine sample at the time of each MRI 
scan in order to study some circulating cells and chemicals that may be involved in heart 
muscle and blood vessel repair. Our aim is to identify patients with significant damage to 
the hearts small blood vessels at the time of angioplasty therefore allowing us to identify 
future patients with treatment to minimise damage at the earliest opportunity.   
 
Why have I been chosen? 
 
You have had a heart attack and you require an emergency angiography procedure to 
look at the arteries that supply the heart.   
 
Do I have to take part? 
 
No, it is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and will be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at anytime, or a decision not to take part, will not affect 
the standard of care you receive. 
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What will happen to me if I take part? 
 
If you require an angioplasty (using balloons and stents to open the larger heart arteries) 
we will make measurements that represent damage to the hearts small blood vessels. This 
involves injecting dye into the heart arteries under x-ray guidance allowing us to identify 
if any blockages are present. Angioplasty involves placing a tiny wire into the relevant 
heart artery allowing us to inflate balloons and deploy stents (like small scaffolds) over 
the blocked area. We will use a pressure and temperature sensitive guidewire during the 
procedure rather than a normal wire. The measurements will take an additional 10 
minutes during the procedure and do not pose any additional risk to you. While these 
measurements are being taken a drug called adenosine is used to increase the blood flow 
through the heart arteries. 
 
You will have two heart MRI scans. One will occur within 48 hours of your heart attack 
during this current hospital admission and the other will be at around two months after 
your heart attack at a time that is convenient for you.   
 
The MRI scans last approximately one hour each. The scanner is basically tunnel shaped, 
like large “polo” mint, which is open at both ends. You are slid into the centre of the 
“polo” on an electric bed and the scans are taken. Some people find it a little enclosing 
but you can come out at any time. 
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Before you go into the scanner, you will be invited to provide a urine sample. Following 
this, two small plastic cannulas (similar to that used when putting in a drip) will be 
inserted into the veins in your arms by a doctor. We would like to draw about 40 
millilitres (about 3 tablespoonfuls) of blood from one of the plastic cannulas, and also ask 
you to provide a urine sample. We will examine some routine parameters, such as blood 
platelets, but also some new markers, known as endothelial progenitor cells, that may be 
involved in heart blood vessel repair. We will also measure some of the circulating 
growth factors (small chemicals in the blood) which stimulate the release of these cells. 
We will count the number of these cells in each blood sample, and also prepare DNA and 
RNA from these cells to examine whether the genetic make-up has any connection with 
heart muscle and blood vessel repair (as assessed by MRI). Small blood and urine 
samples will be stored in a freezer to be analysed at a later stage, particularly when new 
markers of heart disease will have been developed by us or by other scientists. 
 
Following this, the cannula will permit us to inject gadolinium dye during your MRI scan 
and also to administer a drug called adenosine. 
 
Gadolinium is a clear fluid like water. It is used in MRI scanning because it accumulates 
in abnormal tissue and “lights up” that area so the scanner can detect it. It is useful in 
telling us which parts of the heart are abnormal, if any. After a short while the gadolinium 
fades away and is removed from your body (within a few hours). 
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When you are in the scanner you will need to wear a pair of headphones. These are 
necessary because of the loud knocking noise that occurs when the pictures are being 
taken. The headphones allow you to listen to music of your choice (you may bring your 
own CD) and allow us to communicate with you throughout the scan. Whilst in the 
scanner, you will be given an emergency buzzer and can very quickly be taken out should 
you feel uncomfortable. During the scan you will be asked to hold your breath at times to 
improve the quality of the pictures. 
 
Women only: The effect of MRI scans on babies is unknown- for this reason, anyone 
who is pregnant or becomes pregnant during the study will be excluded. If you think you 
may be pregnant please inform the study doctor. 
 
What are the risks? 
 
There is no additional risk by taking these extra measurements during your angioplasty. 
The MRI scanner is very safe if you have no metal implants in your body.  
 
The dye used during the cardiac MRI scans is called gadolinium. It is generally harmless 
and will be washed out of your system by your kidneys. Side effects include mild 
headache and nausea. Rarely (less than 1 % of the time) low blood pressure and light-
headedness occurs. Very rarely (less than one in a thousand), patients are allergic to the 
contrast agent. 
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Senior doctors will be present during your angioplasty procedure and a senior doctor will 
be present during your cardiac MRI scans. 
 
The amount of blood and urine drawn does not place you at any risk. 
 
What are the potential benefits of taking part? 
 
You may not benefit directly from taking part in the study but the information that we get 
may help to improve treatment of patients in the future. You will be getting special scans 
of your heart that are not usually provided as part of routine care. This will provide 
additional information about your health, which could influence your future treatment. 
While the blood and urine results may be useful for clinical research purposes, we do not 
anticipate these results to be useful for the treatment of your condition. 
 
What if something goes wrong? 
 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then you 
have grounds for a legal action but you may have to pay for it. Regardless of this, if you 
wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal NHS complaints 
mechanisms will be available to you. 
Will my GP be informed? 
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If you agree we will inform your GP that you have agreed to take part in this study. 
 
Will my taking part in this study be kept confidential? 
 
All information that is collected about you during the course of the research will be kept 
strictly confidential. Any information about you that leaves the hospital will have your 
name and address removed so that you cannot be recognised from it. Your personal 
information will be kept on file and stored in a secure place at the BHF Glasgow 
Cardiovascular Research Centre and in the Department of Cardiology. All examinations 
(including urine and blood results and gene data) will be labelled with a code and not 
with any personal details so that all analyses will be carried out anonymously. All 
information which is collected about you during the course or the research will be kept 
strictly confidential. Any information about you which leaves the hospital or the Clinical 
Investigation Unit will have your name and address removed so that you cannot be 
recognised from it. 
 
What will happen to the results of the research study? 
 
When the results become available they will be submitted to medical journals where they 
will be considered for publication. The final results will also be submitted to national and 
international medical conferences where they will be considered for publication. At the 
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BHF Glasgow Cardiovascular Research Centre we will have events to inform the public 
about our ongoing research and about results from this and other studies. 
 
You will not be identified in any report or publication. 
If you would like a copy of the results, please ask your study doctor. 
 
Who is organising and funding the research? 
This study is organised by doctors from the Department of Cardiology, Western 
Infirmary and scientists from the BHF Glasgow Cardiovascular Research Centre at 
Glasgow University. The study is funded by charities and researchers will not receive any 
payment for conducting this study. 
 
Who has reviewed the study? 
The West Ethics committee of the North Glasgow University Hospitals NHS Trust has 
reviewed this study. 
 
Who can I contact for further information? 
 
Study doctor:  Dr Ross J McGeoch 
   Department of Cardiology 
Western Infirmary  0141-211-8527 
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Supervisor:  Dr K G Oldroyd 
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Appendix D 
Version 1.1 Aug 2006                  CONSENT FORM (2) 
 
Title of project: 
 
Correlation of invasive measurements for assessment of microcirculatory dysfunction with 
cardiac magnetic resonance imaging to predict those most at risk following acute myocardial 
infarction. 
 
Name of researcher: Dr Ross McGeoch     Please initial box 
 
 
1. I confirm that I have read and understand the information sheet for the above study and 
have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by responsible 
individuals from the research team or from regulatory authorities where it is relevant to 
my taking part in research. I give permission for these individuals to have access to my 
records. 
 
4. I agree to take part in the above study.       
 
.              
 
                                                                                                                                          
Name of patient         Date               Signature 
 
 
 
                
Name of Person taking consent        Date               Signature 
(if different from researcher)                                                                        
 
 
 
 
 Researcher                 Date               Signature 
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Appendix V 
 
Prognostic Value of the Index of Microcirculatory Resistance after 
Primary Percutaneous Coronary Intervention 
 
Authors: Andy S.C. Yong, Joshua Loh, Ross McGeoch, Maulik Shah, Michael Ho, 
David Daniels, Adrian Low, Keith Oldroyd, William F. Fearon 
 
Background: The Index of Microcirculatory Resistance (IMR) is an invasive, wire-based 
method for assessing microvascular function which can predict persistent left ventricular 
dysfunction after primary percutaneous coronary intervention (PCI) in patients with ST-
elevation myocardial infarction. The aim of this prospective multicenter study is to 
evaluate the ability of IMR to predict events in patients undergoing primary PCI. 
Methods: IMR was measured immediately after primary PCI in 253 patients from 3 
institutions using a pressure-temperature sensor wire. The primary end point was rate of 
death or rehospitalization for heart failure.  
Results: The mean IMR was 40.2 ± 32.4. Patients with IMR ≥40.2 had higher 1 year 
primary end point rates compared to patients with IMR <40.2 (17.1% vs. 6.6%, P = 
0.027). During a median follow-up period of 2.8 years, 34 patients (13.4%) suffered the 
primary end point and 11 patients (4.3%) died. Using Cox proportional hazards analysis, 
IMR ≥40.2 was associated with an increased risk of death or rehospitalization for heart 
failure (hazard ratio [HR] 2.08, P = 0.033) and death (HR 3.90, P = 0.03). Survival curves 
are shown below. In multivariate analysis, independent predictors of the primary end 
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point include IMR ≥40.2 (HR 2.50, P = 0.011), age (HR 1.04, P = 0.02) and diabetes (HR 
4.24, P <0.001).  
Conclusions:  An elevated IMR at the time of primary PCI predicts poor long term 
outcomes. Measurement of IMR may identify high risk patients who will benefit from 
novel therapy. 
 
 
 
